CHEBI ONTOLOGY - ANNOTATIONS |
|
The Chemical Entities of Biological Interest (ChEBI) ontology is downloaded weekly from EMBL-EBI at http://www.ebi.ac.uk/chebi/. The data is made available under the Creative Commons License (CC BY 3.0, http://creativecommons.org/licenses/by/3.0/). For more information see: Degtyarenko et al. (2008) ChEBI: a database and ontology for chemical entities of biological interest. Nucleic Acids Res. 36, D344–D350.
|
Term: | formamides |
|
Accession: | CHEBI:24079
|
browse the term
|
Definition: | Amides with the general formula R(1)R(2)NCHO (R(1) and R(2) can be H). |
|
|
|
G |
Neil1 |
nei-like DNA glycosylase 1 |
affects metabolic processing |
ISO |
NEIL1 protein affects the metabolism of 2,6-diamino-4-hydroxy-5-formamidopyrimidine |
CTD |
PMID:17389588 PMID:20067321 |
|
NCBI chr 8:61,817,258...61,824,023
Ensembl chr 8:61,817,258...61,823,102
|
|
G |
Ogg1 |
8-oxoguanine DNA glycosylase |
affects metabolic processing |
ISO |
OGG1 protein affects the metabolism of 2,6-diamino-4-hydroxy-5-formamidopyrimidine |
CTD |
PMID:20067321 |
|
NCBI chr 4:145,282,828...145,289,367
Ensembl chr 4:145,282,797...145,289,326
|
|
|
G |
Neil1 |
nei-like DNA glycosylase 1 |
affects metabolic processing |
ISO |
NEIL1 protein affects the metabolism of 4,6-diamino-5-N-formamidopyrimidine |
CTD |
PMID:17389588 |
|
NCBI chr 8:61,817,258...61,824,023
Ensembl chr 8:61,817,258...61,823,102
|
|
|
G |
Nat2 |
N-acetyltransferase 2 |
multiple interactions |
ISO |
[NAT2 protein results in increased metabolism of 1,7-dimethylxanthine] which results in increased chemical synthesis of 5-acetylamino-6-formylamino-3-methyluracil |
CTD |
PMID:19215233 |
|
NCBI chr16:23,960,709...23,991,570
Ensembl chr16:23,961,067...23,991,570
|
|
|
G |
Acox2 |
acyl-CoA oxidase 2 |
increases expression |
ISO |
Antimycin A results in increased expression of ACOX2 mRNA |
CTD |
PMID:19304788 |
|
NCBI chr15:18,449,304...18,481,472
Ensembl chr15:18,451,144...18,481,470
|
|
G |
Akr1b7 |
aldo-keto reductase family 1, member B7 |
increases expression |
ISO |
Antimycin A results in increased expression of AKR1B7 mRNA |
CTD |
PMID:19304788 |
|
NCBI chr 4:61,850,256...61,879,733
Ensembl chr 4:61,850,348...61,862,526
|
|
G |
Akt1 |
AKT serine/threonine kinase 1 |
multiple interactions decreases activity |
ISO |
Luteolin inhibits the reaction [Antimycin A results in decreased activity of AKT1 protein] |
CTD |
PMID:21466842 PMID:21782929 |
|
NCBI chr 6:137,218,398...137,239,970
Ensembl chr 6:137,218,376...137,236,258
|
|
G |
Aldh1l2 |
aldehyde dehydrogenase 1 family, member L2 |
increases expression |
ISO |
Antimycin A results in increased expression of ALDH1L2 mRNA |
CTD |
PMID:19304788 |
|
NCBI chr 7:26,375,866...26,425,838
Ensembl chr 7:26,375,866...26,425,108
|
|
G |
Angptl6 |
angiopoietin-like 6 |
increases expression |
ISO |
Antimycin A results in increased expression of ANGPTL6 mRNA |
CTD |
PMID:19304788 |
|
NCBI chr 8:21,895,523...21,902,002
Ensembl chr 8:21,895,524...21,901,829
|
|
G |
Atf3 |
activating transcription factor 3 |
increases expression |
ISO |
Antimycin A results in increased expression of ATF3 mRNA |
CTD |
PMID:19304788 |
|
NCBI chr13:109,817,892...109,849,632
Ensembl chr13:109,817,728...109,849,632
|
|
G |
Atg13 |
autophagy related 13 |
multiple interactions |
ISO |
Antimycin A promotes the reaction [ATG13 protein results in increased expression of ULK1 protein]; ATG13 protein promotes the reaction [Antimycin A results in increased expression of ULK1 protein] |
CTD |
PMID:27629431 |
|
NCBI chr 3:80,580,549...80,614,554
Ensembl chr 3:80,581,247...80,601,410
|
|
G |
Atp6v1h |
ATPase H+ transporting V1 subunit H |
multiple interactions |
ISO |
[PINK1 protein affects the susceptibility to [Trifluoperazine co-treated with Antimycin A co-treated with oligomycin A]] which affects the expression of ATP6V1H mRNA |
CTD |
PMID:28366621 |
|
NCBI chr 5:14,262,352...14,367,898
Ensembl chr 5:14,262,349...14,367,898
|
|
G |
Bax |
BCL2 associated X, apoptosis regulator |
multiple interactions increases expression |
ISO |
[FOXO1 protein co-treated with FOXO4 protein co-treated with FOXO3 protein] affects the reaction [Resveratrol inhibits the reaction [Antimycin A results in increased expression of BAX protein]]; Resveratrol inhibits the reaction [Antimycin A results in increased expression of BAX protein] |
CTD |
PMID:24040102 |
|
NCBI chr 1:101,451,801...101,457,207
Ensembl chr 1:101,451,802...101,457,207
|
|
G |
Bcl2 |
BCL2, apoptosis regulator |
decreases response to substance multiple interactions |
ISO |
BCL2 protein results in decreased susceptibility to Antimycin A PK 11195 inhibits the reaction [BCL2 protein results in decreased susceptibility to Antimycin A] |
CTD |
PMID:12730627 |
|
NCBI chr13:26,605,426...26,769,374
Ensembl chr13:26,605,426...26,769,374
|
|
G |
Bglap |
bone gamma-carboxyglutamate protein |
increases expression multiple interactions |
ISO |
Antimycin A results in increased expression of BGLAP protein sciadopitysin inhibits the reaction [Antimycin A results in increased expression of BGLAP protein] |
CTD |
PMID:23624148 |
|
NCBI chr 2:187,741,770...187,748,445
Ensembl chr 2:187,741,770...187,742,747
|
|
G |
Bnip3 |
BCL2 interacting protein 3 |
increases expression |
ISO |
Antimycin A results in increased expression of BNIP3 mRNA |
CTD |
PMID:19304788 |
|
NCBI chr 1:211,248,098...211,265,282
Ensembl chr 1:211,248,098...211,265,282
|
|
G |
Ca6 |
carbonic anhydrase 6 |
increases expression |
ISO |
Antimycin A results in increased expression of CAR6 mRNA |
CTD |
PMID:19304788 |
|
NCBI chr 5:167,226,246...167,244,786
Ensembl chr 5:167,226,246...167,244,786
|
|
G |
Casp1 |
caspase 1 |
increases activity |
ISO |
Antimycin A results in increased activity of CASP1 protein |
CTD |
PMID:30582969 |
|
NCBI chr 8:2,605,743...2,614,637
Ensembl chr 8:2,604,962...2,614,631
|
|
G |
Casp3 |
caspase 3 |
increases cleavage increases activity multiple interactions |
ISO EXP |
Antimycin A results in increased cleavage of CASP3 protein Antimycin A results in increased activity of CASP3 protein NAD inhibits the reaction [Antimycin A results in increased cleavage of CASP3 protein]; Niacinamide promotes the reaction [Antimycin A results in increased cleavage of CASP3 protein]; Resveratrol inhibits the reaction [Antimycin A results in increased cleavage of CASP3 protein]; splitomicin promotes the reaction [Antimycin A results in increased cleavage of CASP3 protein] |
CTD |
PMID:11078377 PMID:24040102 |
|
NCBI chr16:48,845,011...48,863,249
Ensembl chr16:48,845,012...48,863,204
|
|
G |
Ccl2 |
C-C motif chemokine ligand 2 |
decreases expression |
ISO |
Antimycin A results in decreased expression of CCL2 protein |
CTD |
PMID:20116850 |
|
NCBI chr10:69,412,065...69,413,863
Ensembl chr10:69,412,017...69,413,870
|
|
G |
Ccl3 |
C-C motif chemokine ligand 3 |
decreases expression |
ISO |
Antimycin A results in decreased expression of CCL3 protein |
CTD |
PMID:20116850 |
|
NCBI chr10:70,869,516...70,871,066
Ensembl chr10:70,869,513...70,871,066
|
|
G |
Ccl4 |
C-C motif chemokine ligand 4 |
decreases expression |
ISO |
Antimycin A results in decreased expression of CCL4 protein |
CTD |
PMID:20116850 |
|
NCBI chr10:70,870,926...70,886,357
Ensembl chr10:70,884,531...70,886,355
|
|
G |
Ccl5 |
C-C motif chemokine ligand 5 |
decreases expression |
ISO |
Antimycin A results in decreased expression of CCL5 protein |
CTD |
PMID:20116850 |
|
NCBI chr10:70,739,764...70,744,303
Ensembl chr10:70,739,800...70,744,315
|
|
G |
Ccna2 |
cyclin A2 |
decreases expression multiple interactions |
ISO |
Antimycin A results in decreased expression of CCNA2 mRNA; Antimycin A results in decreased expression of CCNA2 protein Antimycin A inhibits the reaction [ELAVL1 protein binds to CCNA2 3' UTR] |
CTD |
PMID:12730239 |
|
NCBI chr 2:123,274,727...123,282,266
Ensembl chr 2:123,275,881...123,282,214
|
|
G |
Ccnb1 |
cyclin B1 |
multiple interactions decreases expression |
ISO |
Antimycin A inhibits the reaction [ELAVL1 protein binds to CCNB1 3' UTR] Antimycin A results in decreased expression of CCNB1 mRNA; Antimycin A results in decreased expression of CCNB1 protein |
CTD |
PMID:12730239 |
|
NCBI chr 2:30,782,133...30,791,106
Ensembl chr 2:30,783,915...30,791,221
|
|
G |
Cd14 |
CD14 molecule |
increases expression |
ISO |
Antimycin A results in increased expression of CD14 mRNA |
CTD |
PMID:10491287 |
|
NCBI chr18:29,560,341...29,562,290
Ensembl chr18:29,560,365...29,562,153
|
|
G |
Cd34 |
CD34 molecule |
decreases expression |
ISO |
Antimycin A results in decreased expression of CD34 mRNA |
CTD |
PMID:19304788 |
|
NCBI chr13:113,691,842...113,711,259
Ensembl chr13:113,691,932...113,711,647
|
|
G |
Cd38 |
CD38 molecule |
increases expression |
ISO |
Antimycin A results in increased expression of CD38 mRNA |
CTD |
PMID:10491287 |
|
NCBI chr14:71,714,768...71,754,990
Ensembl chr14:71,715,269...71,754,672
|
|
G |
Cd68 |
Cd68 molecule |
increases expression |
ISO |
Antimycin A results in increased expression of CD68 mRNA |
CTD |
PMID:19304788 |
|
NCBI chr10:56,268,726...56,270,605
Ensembl chr10:56,268,720...56,270,640
|
|
G |
Chchd10 |
coiled-coil-helix-coiled-coil-helix domain containing 10 |
increases expression |
ISO |
Antimycin A results in increased expression of CHCHD10 mRNA |
CTD |
PMID:19304788 |
|
NCBI chr20:13,665,046...13,666,845
Ensembl chr20:13,665,031...13,667,333
|
|
G |
Col16a1 |
collagen type XVI alpha 1 chain |
decreases expression |
ISO |
Antimycin A results in decreased expression of COL16A1 mRNA |
CTD |
PMID:19304788 |
|
NCBI chr 5:148,257,030...148,311,645
Ensembl chr 5:148,257,642...148,311,645
|
|
G |
Cox6a2 |
cytochrome c oxidase subunit 6A2 |
increases expression |
ISO |
Antimycin A results in increased expression of COX6A2 mRNA |
CTD |
PMID:19304788 |
|
NCBI chr 1:199,624,037...199,626,255
Ensembl chr 1:199,624,037...199,624,783
|
|
G |
Cp |
ceruloplasmin |
increases degradation decreases expression |
ISO |
Antimycin A results in increased degradation of CP mRNA Antimycin A results in decreased expression of CP mRNA; Antimycin A results in decreased expression of CP protein |
CTD |
PMID:19019832 |
|
NCBI chr 2:104,744,249...104,803,034
Ensembl chr 2:104,744,461...104,799,853
|
|
G |
Creb1 |
cAMP responsive element binding protein 1 |
multiple interactions decreases phosphorylation |
ISO |
23-epi-26-deoxyactein inhibits the reaction [Antimycin A results in decreased phosphorylation of CREB1 protein]; acetovanillone inhibits the reaction [Antimycin A results in decreased phosphorylation of CREB1 protein] |
CTD |
PMID:21538410 PMID:22180388 |
|
NCBI chr 9:71,229,753...71,298,994
Ensembl chr 9:71,230,108...71,293,435
|
|
G |
Cth |
cystathionine gamma-lyase |
increases expression |
ISO |
Antimycin A results in increased expression of CTH mRNA |
CTD |
PMID:19304788 |
|
NCBI chr 2:264,266,959...264,293,040
Ensembl chr 2:264,266,984...264,293,046
|
|
G |
Cxcl3 |
C-X-C motif chemokine ligand 3 |
multiple interactions |
ISO |
Antimycin A inhibits the reaction [TNF protein results in increased expression of CXCL1 mRNA] |
CTD |
PMID:24316229 |
|
NCBI chr14:18,820,168...18,839,659
Ensembl chr14:18,820,168...18,839,595
|
|
G |
Cycs |
cytochrome c, somatic |
multiple interactions affects localization |
ISO |
glabridin inhibits the reaction [Antimycin A affects the localization of CYCS protein] |
CTD |
PMID:21621525 |
|
NCBI chr 4:80,331,226...80,333,326
Ensembl chr 4:80,331,227...80,333,326
|
|
G |
Ddit3 |
DNA-damage inducible transcript 3 |
increases expression |
EXP ISO |
Antimycin A results in increased expression of DDIT3 protein Antimycin A results in increased expression of DDIT3 mRNA |
CTD |
PMID:19304788 PMID:21337367 |
|
NCBI chr 7:70,578,564...70,585,074
Ensembl chr 7:70,580,198...70,585,084
|
|
G |
E2f7 |
E2F transcription factor 7 |
decreases expression |
ISO |
Antimycin A results in decreased expression of E2F7 mRNA |
CTD |
PMID:19304788 |
|
NCBI chr 7:53,275,659...53,318,261
Ensembl chr 7:53,275,676...53,316,481
|
|
G |
Elavl1 |
ELAV like RNA binding protein 1 |
multiple interactions decreases localization |
ISO |
Antimycin A inhibits the reaction [ELAVL1 protein binds to CCNA2 3' UTR]; Antimycin A inhibits the reaction [ELAVL1 protein binds to CCNB1 3' UTR] Antimycin A results in decreased localization of ELAVL1 protein |
CTD |
PMID:12730239 |
|
NCBI chr12:2,461,502...2,502,432
Ensembl chr12:2,461,502...2,502,432
|
|
G |
Entpd2 |
ectonucleoside triphosphate diphosphohydrolase 2 |
increases expression |
ISO |
Antimycin A results in increased expression of ENTPD2 mRNA |
CTD |
PMID:19304788 |
|
NCBI chr 3:2,617,795...2,623,818
Ensembl chr 3:2,617,805...2,623,445
|
|
G |
Epas1 |
endothelial PAS domain protein 1 |
multiple interactions |
EXP |
Antimycin A inhibits the reaction [Oxygen deficiency results in increased expression of EPAS1 protein] |
CTD |
PMID:18353899 |
|
NCBI chr 6:10,306,508...10,385,239
Ensembl chr 6:10,306,405...10,387,265
|
|
G |
Ero1a |
endoplasmic reticulum oxidoreductase 1 alpha |
increases expression |
ISO |
Antimycin A results in increased expression of ERO1A mRNA |
CTD |
PMID:19304788 |
|
NCBI chr15:19,619,947...19,655,381
Ensembl chr15:19,619,973...19,655,381
|
|
G |
Fas |
Fas cell surface death receptor |
decreases expression |
ISO |
Antimycin A results in decreased expression of FAS mRNA |
CTD |
PMID:8902626 |
|
NCBI chr 1:252,589,785...252,624,790
Ensembl chr 1:252,589,785...252,624,790
|
|
G |
Fgf1 |
fibroblast growth factor 1 |
decreases expression |
ISO |
Antimycin A results in decreased expression of FGF1 mRNA |
CTD |
PMID:19304788 |
|
NCBI chr18:32,273,830...32,359,831
Ensembl chr18:32,273,770...32,359,824
|
|
G |
Foxo1 |
forkhead box O1 |
multiple interactions decreases expression |
ISO |
[Antimycin A co-treated with Resveratrol] results in decreased acetylation of FOXO1 protein; [FOXO1 protein co-treated with FOXO4 protein co-treated with FOXO3 protein] affects the reaction [Resveratrol inhibits the reaction [Antimycin A results in increased expression of BAX protein]]; FOXO1 mutant form affects the reaction [[Antimycin A co-treated with Resveratrol] affects the expression of SOD2 mRNA]; FOXO1 mutant form affects the reaction [[Antimycin A co-treated with Resveratrol] affects the expression of SOD2 protein] Antimycin A results in decreased expression of FOXO1 protein |
CTD |
PMID:24040102 |
|
NCBI chr 2:141,451,234...141,527,016
Ensembl chr 2:141,451,234...141,527,016
|
|
G |
Foxo3 |
forkhead box O3 |
decreases expression multiple interactions |
ISO |
Antimycin A results in decreased expression of FOXO3 protein [FOXO1 protein co-treated with FOXO4 protein co-treated with FOXO3 protein] affects the reaction [Resveratrol inhibits the reaction [Antimycin A results in increased expression of BAX protein]]; FOXO3 mutant form affects the reaction [[Antimycin A co-treated with Resveratrol] affects the expression of SOD2 mRNA]; FOXO3 mutant form affects the reaction [[Antimycin A co-treated with Resveratrol] affects the expression of SOD2 protein] |
CTD |
PMID:24040102 |
|
NCBI chr20:46,428,078...46,519,156
Ensembl chr20:46,428,124...46,519,144
|
|
G |
Foxo4 |
forkhead box O4 |
multiple interactions decreases expression |
ISO |
[FOXO1 protein co-treated with FOXO4 protein co-treated with FOXO3 protein] affects the reaction [Resveratrol inhibits the reaction [Antimycin A results in increased expression of BAX protein]]; FOXO4 mutant form affects the reaction [[Antimycin A co-treated with Resveratrol] affects the expression of SOD2 mRNA]; FOXO4 mutant form affects the reaction [[Antimycin A co-treated with Resveratrol] affects the expression of SOD2 protein] Antimycin A results in decreased expression of FOXO4 protein |
CTD |
PMID:24040102 |
|
NCBI chr X:71,155,284...71,162,158
Ensembl chr X:71,155,601...71,162,158
|
|
G |
Gadd45a |
growth arrest and DNA-damage-inducible, alpha |
increases expression |
ISO |
Antimycin A results in increased expression of GADD45A mRNA |
CTD |
PMID:19304788 |
|
NCBI chr 4:97,782,512...97,784,814
Ensembl chr 4:97,782,512...97,784,842
|
|
G |
Gch1 |
GTP cyclohydrolase 1 |
increases expression |
ISO |
Antimycin A results in increased expression of GCH1 mRNA |
CTD |
PMID:19304788 |
|
NCBI chr15:23,935,011...23,968,971
Ensembl chr15:23,934,585...23,969,011
|
|
G |
Gsta2 |
glutathione S-transferase alpha 2 |
increases expression |
ISO |
Antimycin A results in increased expression of GSTA2 mRNA |
CTD |
PMID:19304788 |
|
NCBI chr 8:85,640,081...85,645,621
|
|
G |
Gsta5 |
glutathione S-transferase alpha 5 |
increases expression |
ISO |
Antimycin A results in increased expression of GSTA1 mRNA |
CTD |
PMID:19304788 |
|
NCBI chr 8:85,553,659...85,564,914
Ensembl chr 8:85,553,734...85,565,179
|
|
G |
Gsta6 |
glutathione S-transferase alpha 6 |
increases expression |
ISO |
Antimycin A results in increased expression of GSTA2 mRNA |
CTD |
PMID:19304788 |
|
NCBI chr 9:27,475,273...27,533,939
Ensembl chr 9:27,475,273...27,511,176
|
|
G |
Hif1a |
hypoxia inducible factor 1 subunit alpha |
affects expression |
EXP |
Antimycin A affects the expression of HIF1A protein |
CTD |
PMID:16034640 |
|
NCBI chr 6:96,810,868...96,856,303
Ensembl chr 6:96,810,907...96,856,052
|
|
G |
Hspa5 |
heat shock protein family A (Hsp70) member 5 |
increases expression |
EXP |
Antimycin A results in increased expression of HSPA5 protein |
CTD |
PMID:21337367 |
|
NCBI chr 3:13,838,304...13,842,763
Ensembl chr 3:13,838,304...13,842,762
|
|
G |
Htra1 |
HtrA serine peptidase 1 |
increases expression |
ISO |
Antimycin A results in increased expression of HTRA1 mRNA |
CTD |
PMID:19304788 |
|
NCBI chr 1:201,499,067...201,548,508
Ensembl chr 1:201,499,028...201,548,513
|
|
G |
Icam1 |
intercellular adhesion molecule 1 |
decreases expression multiple interactions |
ISO |
Antimycin A results in decreased expression of ICAM1 mRNA Antimycin A inhibits the reaction [N-caproylsphingosine results in increased expression of ICAM1 mRNA] |
CTD |
PMID:12952965 PMID:19304788 |
|
NCBI chr 8:22,035,287...22,047,049
Ensembl chr 8:22,035,256...22,047,059
|
|
G |
Il1b |
interleukin 1 beta |
multiple interactions |
ISO |
Acetylcysteine inhibits the reaction [[Antimycin A co-treated with IL1B protein] results in increased expression of CXCL8 protein]; Antimycin A promotes the reaction [IL1B protein results in increased expression of CXCL8 mRNA]; Antimycin A promotes the reaction [IL1B protein results in increased expression of CXCL8 protein]; Antimycin A promotes the reaction [IL1B protein results in increased expression of PTGS2 protein]; BAY 11-7085 inhibits the reaction [[Antimycin A co-treated with IL1B protein] results in increased expression of CXCL8 protein]; IL1B protein promotes the reaction [Antimycin A results in increased expression of PTGS2 protein]; Resveratrol inhibits the reaction [[Antimycin A co-treated with IL1B protein] results in increased expression of CXCL8 protein] |
CTD |
PMID:22549761 PMID:24609059 |
|
NCBI chr 3:121,876,256...121,882,637
Ensembl chr 3:121,876,263...121,882,726
|
|
G |
Il6 |
interleukin 6 |
multiple interactions increases expression |
ISO |
1,2-bis(2-aminophenoxy)ethane N,N,N',N'-tetraacetic acid acetoxymethyl ester inhibits the reaction [Antimycin A results in increased expression of and results in increased secretion of IL6 protein]; 23-epi-26-deoxyactein inhibits the reaction [Antimycin A results in increased expression of IL6 protein]; 6-hydroxy-2,5,7,8-tetramethylchroman-2-carboxylic acid inhibits the reaction [Antimycin A results in increased expression of and results in increased secretion of IL6 protein]; Antimycin A results in increased expression of and results in increased secretion of IL6 protein; Cyclosporine inhibits the reaction [Antimycin A results in increased expression of and results in increased secretion of IL6 protein] |
CTD |
PMID:21381053 PMID:21910134 |
|
NCBI chr 4:3,043,231...3,047,807
Ensembl chr 4:3,043,231...3,047,807
|
|
G |
Il6r |
interleukin 6 receptor |
decreases expression |
ISO |
Antimycin A results in decreased expression of IL6R protein modified form |
CTD |
PMID:20116850 |
|
NCBI chr 2:189,196,180...189,255,987
Ensembl chr 2:189,205,701...189,254,628
|
|
G |
Itgb7 |
integrin subunit beta 7 |
increases expression |
ISO |
Antimycin A results in increased expression of ITGB7 mRNA |
CTD |
PMID:19304788 |
|
NCBI chr 7:143,820,236...143,837,802
Ensembl chr 7:143,820,900...143,837,780
|
|
G |
Jun |
Jun proto-oncogene, AP-1 transcription factor subunit |
multiple interactions increases expression |
ISO |
[Antimycin A co-treated with Paraquat] results in increased expression of JUN protein Antimycin A results in increased expression of JUN protein |
CTD |
PMID:16237197 |
|
NCBI chr 5:114,011,184...114,014,277
Ensembl chr 5:114,011,189...114,014,277
|
|
G |
Lamp1 |
lysosomal-associated membrane protein 1 |
multiple interactions |
ISO |
[PINK1 protein affects the susceptibility to [Trifluoperazine co-treated with Antimycin A co-treated with oligomycin A]] which affects the expression of LAMP1 mRNA |
CTD |
PMID:28366621 |
|
NCBI chr16:81,689,576...81,714,341
Ensembl chr16:81,689,335...81,714,419
|
|
G |
Lsm6 |
LSM6 homolog, U6 small nuclear RNA and mRNA degradation associated |
decreases expression |
ISO |
Antimycin A results in decreased expression of LSM6 mRNA |
CTD |
PMID:19304788 |
|
NCBI chr19:32,770,640...32,785,215
Ensembl chr19:32,770,655...32,785,215
|
|
G |
Mapk14 |
mitogen activated protein kinase 14 |
multiple interactions |
ISO |
Antimycin A inhibits the reaction [Hydrogen Peroxide results in increased phosphorylation of MAPK14 protein] |
CTD |
PMID:15650392 |
|
NCBI chr20:5,933,290...5,995,137
Ensembl chr20:5,933,303...5,995,137
|
|
G |
Mmp13 |
matrix metallopeptidase 13 |
increases expression |
ISO |
Antimycin A results in increased expression of MMP13 mRNA |
CTD |
PMID:19304788 |
|
NCBI chr 8:5,522,739...5,533,018
Ensembl chr 8:5,522,739...5,533,018
|
|
G |
Mmp2 |
matrix metallopeptidase 2 |
multiple interactions increases activity |
ISO |
[Antimycin A results in increased abundance of Reactive Oxygen Species] which results in increased activity of MMP2 protein Antimycin A results in increased activity of MMP2 protein |
CTD |
PMID:11929863 |
|
NCBI chr19:15,542,771...15,570,589
Ensembl chr19:15,542,765...15,570,611
|
|
G |
Ndrg1 |
N-myc downstream regulated 1 |
increases expression |
ISO |
Antimycin A results in increased expression of NDRG1 mRNA |
CTD |
PMID:19304788 |
|
NCBI chr 7:107,734,326...107,775,701
Ensembl chr 7:107,734,323...107,775,714
|
|
G |
Nfkbia |
NFKB inhibitor alpha |
multiple interactions |
ISO |
Antimycin A inhibits the reaction [TNF protein results in increased phosphorylation of NFKBIA protein] |
CTD |
PMID:24316229 |
|
NCBI chr 6:76,267,227...76,270,457
Ensembl chr 6:76,267,228...76,270,457
|
|
G |
Nrp1 |
neuropilin 1 |
decreases expression |
ISO |
Antimycin A results in decreased expression of NRP1 mRNA |
CTD |
PMID:19304788 |
|
NCBI chr19:61,332,351...61,486,166
Ensembl chr19:61,332,351...61,485,858
|
|
G |
Nt5e |
5' nucleotidase, ecto |
increases expression |
ISO |
Antimycin A results in increased expression of NT5E mRNA |
CTD |
PMID:19304788 |
|
NCBI chr 8:95,969,002...96,012,733
Ensembl chr 8:95,968,652...96,012,696
|
|
G |
Nupr1 |
nuclear protein 1, transcriptional regulator |
increases expression |
ISO |
Antimycin A results in increased expression of NUPR1 mRNA |
CTD |
PMID:19304788 |
|
NCBI chr 1:194,767,484...194,769,519
Ensembl chr 1:194,767,474...194,769,524
|
|
G |
Parp1 |
poly (ADP-ribose) polymerase 1 |
increases cleavage multiple interactions |
ISO |
Antimycin A results in increased cleavage of PARP1 protein [Antimycin A co-treated with Paraquat] results in increased cleavage of PARP1 protein |
CTD |
PMID:16237197 |
|
NCBI chr13:98,857,255...98,889,444
Ensembl chr13:98,857,177...98,889,716
|
|
G |
Pink1 |
PTEN induced kinase 1 |
multiple interactions |
ISO |
[PINK1 protein affects the susceptibility to [Trifluoperazine co-treated with Antimycin A co-treated with oligomycin A]] which affects the expression of ATP6V1H mRNA; [PINK1 protein affects the susceptibility to [Trifluoperazine co-treated with Antimycin A co-treated with oligomycin A]] which affects the expression of LAMP1 mRNA; [PINK1 protein affects the susceptibility to [Trifluoperazine co-treated with Antimycin A co-treated with oligomycin A]] which affects the expression of TFEB mRNA; PINK1 protein affects the reaction [[oligomycin A co-treated with Antimycin A] affects the localization of PRKN protein]; PINK1 protein affects the reaction [[oligomycin A co-treated with Antimycin A] affects the localization of TFEB protein]; PINK1 protein affects the reaction [[oligomycin A co-treated with Antimycin A] results in increased expression of SQSTM1 mRNA]; PINK1 protein affects the susceptibility to [Trifluoperazine co-treated with Antimycin A co-treated with oligomycin A]; Trifluoperazine affects the reaction [PINK1 protein affects the reaction [[oligomycin A co-treated with Antimycin A] affects the localization of TFEB protein]] |
CTD |
PMID:28366621 |
|
NCBI chr 5:156,677,146...156,689,258
Ensembl chr 5:156,677,146...156,689,415
|
|
G |
Ppl |
periplakin |
decreases expression |
ISO |
Antimycin A results in decreased expression of PPL mRNA |
CTD |
PMID:19304788 |
|
NCBI chr10:10,644,572...10,690,223
Ensembl chr10:10,644,572...10,690,223
|
|
G |
Ppp1r15a |
protein phosphatase 1, regulatory subunit 15A |
increases expression |
ISO |
Antimycin A results in increased expression of PPP1R15A mRNA |
CTD |
PMID:19304788 |
|
NCBI chr 1:101,511,899...101,515,043
Ensembl chr 1:101,511,901...101,514,974
|
|
G |
Prkn |
parkin RBR E3 ubiquitin protein ligase |
multiple interactions |
ISO |
[oligomycin A co-treated with Antimycin A] affects the localization of PRKN protein; [Oligomycins co-treated with Antimycin A] affects the localization of PRKN protein; PINK1 protein affects the reaction [[oligomycin A co-treated with Antimycin A] affects the localization of PRKN protein] |
CTD |
PMID:28366621 PMID:28673964 |
|
NCBI chr 1:48,880,015...50,069,998
|
|
G |
Ptgs2 |
prostaglandin-endoperoxide synthase 2 |
increases expression multiple interactions |
ISO |
Antimycin A results in increased expression of PTGS2 protein Antimycin A results in increased expression of PTGS2 mRNA Antimycin A promotes the reaction [IL1B protein results in increased expression of PTGS2 protein]; IL1B protein promotes the reaction [Antimycin A results in increased expression of PTGS2 protein] |
CTD |
PMID:19304788 PMID:24609059 |
|
NCBI chr13:67,351,230...67,356,920
Ensembl chr13:67,351,087...67,359,335
|
|
G |
Rbl1 |
RB transcriptional corepressor like 1 |
decreases expression |
ISO |
Antimycin A results in decreased expression of RBL1 mRNA |
CTD |
PMID:19304788 |
|
NCBI chr 3:153,263,692...153,321,351
Ensembl chr 3:153,263,692...153,321,352
|
|
G |
Rela |
RELA proto-oncogene, NF-kB subunit |
affects localization multiple interactions |
ISO |
Antimycin A affects the localization of RELA protein Antimycin A inhibits the reaction [TNF protein results in increased phosphorylation of RELA protein] |
CTD |
PMID:24316229 PMID:24609059 |
|
NCBI chr 1:220,992,770...221,003,249
Ensembl chr 1:220,992,770...221,003,249
|
|
G |
Rnd1 |
Rho family GTPase 1 |
increases expression |
ISO |
Antimycin A results in increased expression of RND1 mRNA |
CTD |
PMID:19304788 |
|
NCBI chr 7:140,349,138...140,356,209
Ensembl chr 7:140,349,138...140,356,209
|
|
G |
Rrm2 |
ribonucleotide reductase regulatory subunit M2 |
decreases expression |
ISO |
Antimycin A results in decreased expression of RRM2 mRNA |
CTD |
PMID:19304788 |
|
NCBI chr 6:43,884,627...43,890,818
Ensembl chr 6:43,884,678...43,889,515
|
|
G |
Snai2 |
snail family transcriptional repressor 2 |
increases expression |
ISO |
Antimycin A results in increased expression of SNAI2 mRNA |
CTD |
PMID:19304788 |
|
NCBI chr11:90,404,421...90,406,730
Ensembl chr11:90,403,333...90,406,797
|
|
G |
Sod2 |
superoxide dismutase 2 |
multiple interactions increases expression |
ISO EXP |
Antimycin A inhibits the reaction [TNF protein results in increased expression of SOD2 mRNA] [Antimycin A co-treated with Resveratrol] affects the expression of SOD2 mRNA; [Antimycin A co-treated with Resveratrol] affects the expression of SOD2 protein; FOXO1 mutant form affects the reaction [[Antimycin A co-treated with Resveratrol] affects the expression of SOD2 mRNA]; FOXO1 mutant form affects the reaction [[Antimycin A co-treated with Resveratrol] affects the expression of SOD2 protein]; FOXO3 mutant form affects the reaction [[Antimycin A co-treated with Resveratrol] affects the expression of SOD2 mRNA]; FOXO3 mutant form affects the reaction [[Antimycin A co-treated with Resveratrol] affects the expression of SOD2 protein]; FOXO4 mutant form affects the reaction [[Antimycin A co-treated with Resveratrol] affects the expression of SOD2 mRNA]; FOXO4 mutant form affects the reaction [[Antimycin A co-treated with Resveratrol] affects the expression of SOD2 protein] Antimycin A inhibits the reaction [Lipopolysaccharides results in increased expression of SOD2 mRNA] Antimycin A results in increased expression of SOD2 protein |
CTD |
PMID:11264281 PMID:22718889 PMID:24040102 |
|
NCBI chr 1:47,914,757...47,921,587
Ensembl chr 1:47,914,759...47,921,587
|
|
G |
Sqstm1 |
sequestosome 1 |
increases expression multiple interactions |
ISO |
Antimycin A results in increased expression of SQSTM1 mRNA [oligomycin A co-treated with Antimycin A] results in increased expression of SQSTM1 mRNA; PINK1 protein affects the reaction [[oligomycin A co-treated with Antimycin A] results in increased expression of SQSTM1 mRNA] |
CTD |
PMID:19304788 PMID:28366621 |
|
NCBI chr10:35,704,728...35,716,316
Ensembl chr10:35,704,730...35,716,294
|
|
G |
Star |
steroidogenic acute regulatory protein |
decreases expression |
ISO |
Antimycin A results in decreased expression of STAR protein |
CTD |
PMID:16469751 |
|
NCBI chr16:71,036,204...71,040,847
Ensembl chr16:71,036,204...71,040,847
|
|
G |
Tfeb |
transcription factor EB |
multiple interactions |
ISO |
[oligomycin A co-treated with Antimycin A] affects the localization of TFEB protein; [PINK1 protein affects the susceptibility to [Trifluoperazine co-treated with Antimycin A co-treated with oligomycin A]] which affects the expression of TFEB mRNA; PINK1 protein affects the reaction [[oligomycin A co-treated with Antimycin A] affects the localization of TFEB protein]; Trifluoperazine affects the reaction [PINK1 protein affects the reaction [[oligomycin A co-treated with Antimycin A] affects the localization of TFEB protein]] |
CTD |
PMID:28366621 |
|
NCBI chr 9:15,208,141...15,264,101
Ensembl chr 9:15,207,822...15,214,596
|
|
G |
Tnf |
tumor necrosis factor |
increases expression multiple interactions |
ISO |
Antimycin A results in increased expression of TNF protein Antimycin A inhibits the reaction [TNF protein results in increased expression of SOD2 mRNA]; Antimycin A promotes the reaction [TNF protein results in increased expression of CXCL8 mRNA]; Antimycin A promotes the reaction [TNF protein results in increased expression of CXCL8 protein] 1,2-bis(2-aminophenoxy)ethane N,N,N',N'-tetraacetic acid acetoxymethyl ester inhibits the reaction [Antimycin A results in increased expression of and results in increased secretion of TNF protein]; 23-epi-26-deoxyactein inhibits the reaction [Antimycin A results in increased expression of TNF protein]; 6-hydroxy-2,5,7,8-tetramethylchroman-2-carboxylic acid inhibits the reaction [Antimycin A results in increased expression of and results in increased secretion of TNF protein]; Antimycin A inhibits the reaction [TNF protein results in increased expression of CXCL1 mRNA]; Antimycin A inhibits the reaction [TNF protein results in increased expression of TNFAIP3 mRNA]; Antimycin A inhibits the reaction [TNF protein results in increased phosphorylation of NFKBIA protein]; Antimycin A inhibits the reaction [TNF protein results in increased phosphorylation of RELA protein]; Antimycin A results in increased expression of and results in increased secretion of TNF protein; Cyclosporine inhibits the reaction [Antimycin A results in increased expression of and results in increased secretion of TNF protein]; sciadopitysin inhibits the reaction [Antimycin A results in increased expression of TNF protein] |
CTD |
PMID:11264281 PMID:21381053 PMID:21910134 PMID:22549761 PMID:23624148 PMID:24316229 |
|
NCBI chr20:5,189,382...5,192,000
Ensembl chr20:5,189,390...5,192,000
|
|
G |
Tnfaip3 |
TNF alpha induced protein 3 |
multiple interactions |
ISO |
Antimycin A inhibits the reaction [TNF protein results in increased expression of TNFAIP3 mRNA] |
CTD |
PMID:24316229 |
|
NCBI chr 1:14,401,103...14,416,369
Ensembl chr 1:14,402,913...14,412,807
|
|
G |
Tnfrsf11b |
TNF receptor superfamily member 11B |
decreases expression |
ISO |
Antimycin A results in decreased expression of TNFRSF11B protein |
CTD |
PMID:21381053 |
|
NCBI chr 7:93,798,580...93,826,586
Ensembl chr 7:93,798,545...93,826,665
|
|
G |
Tnfsf11 |
TNF superfamily member 11 |
increases expression multiple interactions |
ISO |
Antimycin A results in increased expression of TNFSF11 protein 23-epi-26-deoxyactein inhibits the reaction [Antimycin A results in increased expression of TNFSF11 protein]; 6-hydroxy-2,5,7,8-tetramethylchroman-2-carboxylic acid inhibits the reaction [Antimycin A results in increased expression of TNFSF11 protein] |
CTD |
PMID:21381053 PMID:21910134 |
|
NCBI chr15:60,482,527...60,512,704
Ensembl chr15:60,482,527...60,512,704
|
|
G |
Tnxb |
tenascin XB |
decreases expression |
ISO |
Antimycin A results in decreased expression of TNXB mRNA |
CTD |
PMID:19304788 |
|
|
|
G |
Tp53 |
tumor protein p53 |
multiple interactions increases response to substance increases acetylation |
ISO |
6-chloro-2,3,4,9-tetrahydro-1H-carbazole-1-carboxamide promotes the reaction [Antimycin A results in increased acetylation of TRP53 protein]; Resveratrol inhibits the reaction [Antimycin A results in increased acetylation of TRP53 protein] TRP53 protein results in increased susceptibility to Antimycin A |
CTD |
PMID:24040102 |
|
NCBI chr10:56,186,299...56,198,449
Ensembl chr10:56,187,020...56,198,449
|
|
G |
Trib3 |
tribbles pseudokinase 3 |
increases expression |
ISO |
Antimycin A results in increased expression of TRIB3 mRNA |
CTD |
PMID:19304788 |
|
NCBI chr 3:147,814,056...147,819,650
Ensembl chr 3:147,813,473...147,819,571
|
|
G |
Trip12 |
thyroid hormone receptor interactor 12 |
decreases expression |
ISO |
Antimycin A results in decreased expression of TRIP12 mRNA |
CTD |
PMID:19304788 |
|
NCBI chr 9:92,305,059...92,435,388
Ensembl chr 9:92,305,051...92,435,365
|
|
G |
Tshz2 |
teashirt zinc finger homeobox 2 |
decreases expression |
ISO |
Antimycin A results in decreased expression of TSHZ2 mRNA |
CTD |
PMID:19304788 |
|
NCBI chr 3:166,469,752...166,748,558
Ensembl chr 3:166,743,544...166,746,597
|
|
G |
Ucp2 |
uncoupling protein 2 |
increases expression |
ISO |
Antimycin A results in increased expression of UCP2 protein |
CTD |
PMID:18082129 |
|
NCBI chr 1:165,506,375...165,512,744
Ensembl chr 1:165,506,361...165,512,744
|
|
G |
Ulk1 |
unc-51 like autophagy activating kinase 1 |
increases expression multiple interactions |
ISO |
Antimycin A results in increased expression of ULK1 mRNA; Antimycin A results in increased expression of ULK1 protein Antimycin A inhibits the reaction [Cycloheximide results in decreased expression of ULK1 protein]; Antimycin A inhibits the reaction [Nitrogen deficiency results in decreased expression of ULK1 protein]; Antimycin A promotes the reaction [ATG13 protein results in increased expression of ULK1 protein]; ATG13 protein promotes the reaction [Antimycin A results in increased expression of ULK1 protein]; Cycloheximide inhibits the reaction [Antimycin A results in increased expression of ULK1 protein]; Nitrogen deficiency inhibits the reaction [Antimycin A results in increased expression of ULK1 protein] |
CTD |
PMID:27629431 |
|
NCBI chr12:51,908,105...51,934,704
Ensembl chr12:51,908,448...51,934,702
|
|
G |
Uts2 |
urotensin 2 |
increases expression |
ISO |
Antimycin A results in increased expression of UTS2 mRNA |
CTD |
PMID:19304788 |
|
NCBI chr 5:168,078,748...168,084,133
Ensembl chr 5:168,078,748...168,084,145
|
|
G |
Vegfa |
vascular endothelial growth factor A |
decreases expression |
ISO |
Antimycin A results in decreased expression of VEGFA protein |
CTD |
PMID:20116850 |
|
NCBI chr 9:17,340,341...17,355,681
Ensembl chr 9:17,340,341...17,355,681
|
|
G |
Wnt7a |
Wnt family member 7A |
increases expression |
ISO |
Antimycin A results in increased expression of WNT7A mRNA |
CTD |
PMID:19304788 |
|
NCBI chr 4:122,994,425...123,040,609
Ensembl chr 4:122,994,425...123,040,609
|
|
G |
Xbp1 |
X-box binding protein 1 |
increases expression |
EXP |
Antimycin A results in increased expression of XBP1 protein |
CTD |
PMID:21337367 |
|
NCBI chr14:85,753,736...85,758,820
Ensembl chr14:85,753,760...85,758,145
|
|
G |
Zhx1 |
zinc fingers and homeoboxes 1 |
decreases expression |
ISO |
Antimycin A results in decreased expression of ZHX1 mRNA |
CTD |
PMID:19304788 |
|
NCBI chr 7:97,915,280...97,944,787
Ensembl chr 7:97,915,581...97,944,491
|
|
|
G |
Gclm |
glutamate cysteine ligase, modifier subunit |
multiple interactions increases expression |
ISO |
NFE2L2 protein affects the reaction [benphothiamine metabolite results in increased expression of GCLM mRNA]; NFE2L2 protein affects the reaction [benphothiamine results in increased expression of GCLM mRNA] benphothiamine metabolite results in increased expression of GCLM mRNA; benphothiamine results in increased expression of GCLM mRNA |
CTD |
PMID:29860433 |
|
NCBI chr 2:225,827,504...225,847,876
Ensembl chr 2:225,827,504...225,847,874
|
|
G |
Gsr |
glutathione-disulfide reductase |
multiple interactions increases expression |
ISO |
NFE2L2 protein affects the reaction [benphothiamine results in increased expression of GSR mRNA] |
CTD |
PMID:29860433 |
|
NCBI chr16:62,197,617...62,239,987
Ensembl chr16:62,197,617...62,241,361
|
|
G |
Hmox1 |
heme oxygenase 1 |
increases expression multiple interactions |
ISO |
benphothiamine metabolite results in increased expression of HMOX1 mRNA; benphothiamine results in increased expression of HMOX1 mRNA benphothiamine inhibits the reaction [MAPT protein results in increased expression of HMOX1 mRNA]; NFE2L2 protein affects the reaction [benphothiamine metabolite results in increased expression of HMOX1 mRNA]; NFE2L2 protein affects the reaction [benphothiamine results in increased expression of HMOX1 mRNA] |
CTD |
PMID:29860433 |
|
NCBI chr19:14,508,634...14,515,455
Ensembl chr19:14,508,616...14,515,456
|
|
G |
Il1b |
interleukin 1 beta |
multiple interactions |
ISO |
[benphothiamine co-treated with MAPT protein] results in decreased expression of IL1B protein |
CTD |
PMID:29860433 |
|
NCBI chr 3:121,876,256...121,882,637
Ensembl chr 3:121,876,263...121,882,726
|
|
G |
Mapt |
microtubule-associated protein tau |
decreases phosphorylation multiple interactions |
ISO |
benphothiamine results in decreased phosphorylation of MAPT protein [benphothiamine co-treated with MAPT protein] results in decreased expression of IL1B protein; [benphothiamine co-treated with MAPT protein] results in decreased expression of NOS2 protein; [benphothiamine co-treated with MAPT protein] results in decreased expression of PTGS2 protein; [benphothiamine co-treated with MAPT protein] results in decreased expression of RELA protein; [benphothiamine co-treated with MAPT protein] results in decreased expression of TNF protein; [benphothiamine co-treated with MAPT protein] results in increased expression of NQO1 mRNA; [benphothiamine co-treated with MAPT protein] results in increased expression of TXN mRNA; benphothiamine inhibits the reaction [MAPT protein results in decreased activity of TKT protein]; benphothiamine inhibits the reaction [MAPT protein results in decreased expression of NOS2 mRNA]; benphothiamine inhibits the reaction [MAPT protein results in decreased expression of PPARGC1A protein]; benphothiamine inhibits the reaction [MAPT protein results in decreased expression of SOD1 protein]; benphothiamine inhibits the reaction [MAPT protein results in increased expression of HMOX1 mRNA] |
CTD |
PMID:29860433 |
|
NCBI chr10:92,289,002...92,386,517
Ensembl chr10:92,288,910...92,386,517
|
|
G |
Nfe2l2 |
nuclear factor, erythroid 2-like 2 |
multiple interactions |
ISO |
NFE2L2 protein affects the reaction [benphothiamine metabolite results in increased expression of GCLM mRNA]; NFE2L2 protein affects the reaction [benphothiamine metabolite results in increased expression of HMOX1 mRNA]; NFE2L2 protein affects the reaction [benphothiamine metabolite results in increased expression of NQO1 mRNA]; NFE2L2 protein affects the reaction [benphothiamine results in increased expression of GCLM mRNA]; NFE2L2 protein affects the reaction [benphothiamine results in increased expression of GSR mRNA]; NFE2L2 protein affects the reaction [benphothiamine results in increased expression of HMOX1 mRNA]; NFE2L2 protein affects the reaction [benphothiamine results in increased expression of NQO1 mRNA] |
CTD |
PMID:29860433 |
|
NCBI chr 3:62,497,568...62,525,146
Ensembl chr 3:62,497,571...62,524,996
|
|
G |
Nos2 |
nitric oxide synthase 2 |
multiple interactions |
ISO |
[benphothiamine co-treated with MAPT protein] results in decreased expression of NOS2 protein; benphothiamine inhibits the reaction [MAPT protein results in decreased expression of NOS2 mRNA] |
CTD |
PMID:29860433 |
|
NCBI chr10:66,188,290...66,221,621
Ensembl chr10:66,189,786...66,313,190
|
|
G |
Nqo1 |
NAD(P)H quinone dehydrogenase 1 |
increases expression multiple interactions |
ISO |
benphothiamine metabolite results in increased expression of NQO1 mRNA; benphothiamine results in increased expression of NQO1 mRNA [benphothiamine co-treated with MAPT protein] results in increased expression of NQO1 mRNA; NFE2L2 protein affects the reaction [benphothiamine metabolite results in increased expression of NQO1 mRNA]; NFE2L2 protein affects the reaction [benphothiamine results in increased expression of NQO1 mRNA] |
CTD |
PMID:29860433 |
|
NCBI chr19:38,422,210...38,437,103
Ensembl chr19:38,422,164...38,437,180
|
|
G |
Ppargc1a |
PPARG coactivator 1 alpha |
multiple interactions |
ISO |
benphothiamine inhibits the reaction [MAPT protein results in decreased expression of PPARGC1A protein] |
CTD |
PMID:29860433 |
|
NCBI chr14:63,095,291...63,190,688
Ensembl chr14:63,095,720...63,187,009
|
|
G |
Ptgs2 |
prostaglandin-endoperoxide synthase 2 |
multiple interactions |
ISO |
[benphothiamine co-treated with MAPT protein] results in decreased expression of PTGS2 protein |
CTD |
PMID:29860433 |
|
NCBI chr13:67,351,230...67,356,920
Ensembl chr13:67,351,087...67,359,335
|
|
G |
Rela |
RELA proto-oncogene, NF-kB subunit |
multiple interactions |
ISO |
[benphothiamine co-treated with MAPT protein] results in decreased expression of RELA protein |
CTD |
PMID:29860433 |
|
NCBI chr 1:220,992,770...221,003,249
Ensembl chr 1:220,992,770...221,003,249
|
|
G |
Sod1 |
superoxide dismutase 1 |
multiple interactions |
ISO |
benphothiamine inhibits the reaction [MAPT protein results in decreased expression of SOD1 protein] |
CTD |
PMID:29860433 |
|
NCBI chr11:30,363,282...30,368,858
Ensembl chr11:30,363,280...30,368,862
|
|
G |
Tkt |
transketolase |
multiple interactions |
EXP ISO |
[benphothiamine co-treated with Streptozocin] results in increased activity of TKT protein benphothiamine inhibits the reaction [MAPT protein results in decreased activity of TKT protein] |
CTD |
PMID:12592403 PMID:29860433 |
|
NCBI chr16:6,609,670...6,634,608
Ensembl chr16:6,609,668...6,634,595
|
|
G |
Tnf |
tumor necrosis factor |
multiple interactions |
ISO |
[benphothiamine co-treated with MAPT protein] results in decreased expression of TNF protein |
CTD |
PMID:29860433 |
|
NCBI chr20:5,189,382...5,192,000
Ensembl chr20:5,189,390...5,192,000
|
|
G |
Txn1 |
thioredoxin 1 |
multiple interactions |
ISO |
[benphothiamine co-treated with MAPT protein] results in increased expression of TXN mRNA |
CTD |
PMID:29860433 |
|
NCBI chr 5:75,049,735...75,057,731
Ensembl chr 5:75,049,747...75,057,752
|
|
|
G |
Slc14a1 |
solute carrier family 14 member 1 (Kidd blood group) |
affects transport |
ISO |
SLC14A1 protein affects the transport of formamide |
CTD |
PMID:17506977 |
|
NCBI chr18:74,461,064...74,504,475
Ensembl chr18:74,461,055...74,485,139
|
|
|
G |
Abcb1b |
ATP-binding cassette, subfamily B (MDR/TAP), member 1B |
decreases expression |
EXP |
Dimethylformamide results in decreased expression of ABCB1B mRNA |
CTD |
PMID:12883083 |
|
NCBI chr 4:22,225,123...22,307,577
Ensembl chr 4:22,133,521...22,425,515
|
|
G |
Bax |
BCL2 associated X, apoptosis regulator |
multiple interactions increases expression |
ISO |
Thiocarbamates analog inhibits the reaction [Dimethylformamide results in increased expression of BAX protein] |
CTD |
PMID:29984871 |
|
NCBI chr 1:101,451,801...101,457,207
Ensembl chr 1:101,451,802...101,457,207
|
|
G |
Bcl2l1 |
Bcl2-like 1 |
multiple interactions increases expression |
EXP ISO |
[Dimethylformamide co-treated with Carbon Tetrachloride] results in decreased expression of BCL2L1 protein Dimethylformamide results in increased expression of BCL2L1 protein Thiocarbamates analog inhibits the reaction [Dimethylformamide results in decreased expression of BCL2L1 protein] |
CTD |
PMID:20097184 PMID:29984871 |
|
NCBI chr 3:148,259,594...148,314,191
Ensembl chr 3:148,259,596...148,313,810
|
|
G |
Casp3 |
caspase 3 |
multiple interactions increases expression |
EXP ISO |
[Dimethylformamide co-treated with Carbon Tetrachloride] results in increased activity of CASP3 protein Dimethylformamide results in increased expression of CASP3 protein modified form CAT protein inhibits the reaction [Dimethylformamide results in increased expression of CASP3 protein modified form]; Thiocarbamates analog inhibits the reaction [Dimethylformamide results in increased expression of CASP3 protein modified form] |
CTD |
PMID:20097184 PMID:29984871 |
|
NCBI chr16:48,845,011...48,863,249
Ensembl chr16:48,845,012...48,863,204
|
|
G |
Casp9 |
caspase 9 |
multiple interactions increases expression |
ISO |
CAT protein inhibits the reaction [Dimethylformamide results in increased expression of CASP9 protein modified form]; Thiocarbamates analog inhibits the reaction [Dimethylformamide results in increased expression of CASP9 protein modified form] |
CTD |
PMID:29984871 |
|
NCBI chr 5:160,356,211...160,373,774
Ensembl chr 5:160,355,833...160,373,778
|
|
G |
Cat |
catalase |
multiple interactions |
ISO |
CAT protein inhibits the reaction [Dimethylformamide results in increased expression of CASP3 protein modified form]; CAT protein inhibits the reaction [Dimethylformamide results in increased expression of CASP9 protein modified form]; CAT protein inhibits the reaction [Dimethylformamide results in increased expression of TP53 protein] |
CTD |
PMID:29984871 |
|
NCBI chr 3:93,379,872...93,412,058
Ensembl chr 3:93,379,874...93,412,058
|
|
G |
Cyp2e1 |
cytochrome P450, family 2, subfamily e, polypeptide 1 |
affects metabolic processing increases response to substance increases abundance multiple interactions increases expression increases metabolic processing increases oxidation |
ISO EXP |
CYP2E1 protein polymorphism affects the metabolism of Dimethylformamide CYP2E1 protein results in increased susceptibility to Dimethylformamide CYP2E1 polymorphism results in increased abundance of Dimethylformamide metabolite CYP2E1 protein affects the reaction [Dimethylformamide results in increased activity of GPT protein]; CYP2E1 protein affects the reaction [Dimethylformamide results in increased expression of HSP90B1 protein] Dimethylformamide results in increased expression of CYP2E1 protein CYP2E1 protein results in increased metabolism of Dimethylformamide CYP2E1 protein affects the metabolism of Dimethylformamide CYP2E1 protein results in increased oxidation of Dimethylformamide |
CTD |
PMID:9817075 PMID:10207612 PMID:11305777 PMID:15772367 PMID:29984871 PMID:31501917 |
|
NCBI chr 1:213,511,892...213,522,195
Ensembl chr 1:213,511,874...213,535,542
|
|
G |
Ddit3 |
DNA-damage inducible transcript 3 |
multiple interactions |
EXP |
[Dimethylformamide co-treated with Carbon Tetrachloride] results in increased expression of DDIT3 mRNA |
CTD |
PMID:20097184 |
|
NCBI chr 7:70,578,564...70,585,074
Ensembl chr 7:70,580,198...70,585,084
|
|
G |
Eif2ak3 |
eukaryotic translation initiation factor 2 alpha kinase 3 |
multiple interactions |
EXP |
[Dimethylformamide co-treated with Carbon Tetrachloride] results in increased expression of EIF2AK3 protein modified form |
CTD |
PMID:20097184 |
|
NCBI chr 4:98,648,513...98,709,695
Ensembl chr 4:98,648,545...98,709,694
|
|
G |
Gpt |
glutamic--pyruvic transaminase |
multiple interactions increases activity |
ISO |
CYP2E1 protein affects the reaction [Dimethylformamide results in increased activity of GPT protein] |
CTD |
PMID:31501917 |
|
NCBI chr 7:117,759,083...117,761,932
Ensembl chr 7:117,759,083...117,761,931
|
|
G |
Gsr |
glutathione-disulfide reductase |
decreases expression |
EXP |
Dimethylformamide results in decreased expression of GSR mRNA |
CTD |
PMID:12883083 |
|
NCBI chr16:62,197,617...62,239,987
Ensembl chr16:62,197,617...62,241,361
|
|
G |
H2ax |
H2A.X variant histone |
increases expression |
ISO |
Dimethylformamide results in increased expression of H2AX protein |
CTD |
PMID:26387567 |
|
NCBI chr 8:48,665,652...48,666,981
Ensembl chr 8:48,665,652...48,666,981
|
|
G |
Hsp90b1 |
heat shock protein 90 beta family member 1 |
multiple interactions increases expression |
EXP ISO |
[Dimethylformamide co-treated with Carbon Tetrachloride] results in increased expression of HSP90B1 protein Dimethylformamide results in increased expression of HSP90B1 protein CYP2E1 protein affects the reaction [Dimethylformamide results in increased expression of HSP90B1 protein] |
CTD |
PMID:20097184 PMID:31501917 |
|
NCBI chr 7:27,226,570...27,240,533
Ensembl chr 7:27,226,569...27,240,533
|
|
G |
Hspa5 |
heat shock protein family A (Hsp70) member 5 |
multiple interactions |
EXP |
[Dimethylformamide co-treated with Carbon Tetrachloride] results in increased expression of HSPA5 mRNA; [Dimethylformamide co-treated with Carbon Tetrachloride] results in increased expression of HSPA5 protein |
CTD |
PMID:20097184 |
|
NCBI chr 3:13,838,304...13,842,763
Ensembl chr 3:13,838,304...13,842,762
|
|
G |
Ltf |
lactotransferrin |
increases expression |
ISO |
Dimethylformamide results in increased expression of LTF mRNA |
CTD |
PMID:18063697 |
|
NCBI chr 8:119,290,416...119,313,261
Ensembl chr 8:119,290,416...119,313,261
|
|
G |
Mpo |
myeloperoxidase |
increases expression |
ISO |
Dimethylformamide results in increased expression of MPO mRNA |
CTD |
PMID:18063697 |
|
NCBI chr10:75,087,892...75,098,260
Ensembl chr10:75,087,892...75,098,260
|
|
G |
Mre11 |
MRE11 homolog, double strand break repair nuclease |
increases expression |
ISO |
Dimethylformamide results in increased expression of MRE11 mRNA; Dimethylformamide results in increased expression of MRE11 protein |
CTD |
PMID:26387567 |
|
NCBI chr 8:13,304,355...13,350,329
Ensembl chr 8:13,305,152...13,352,489
|
|
G |
Ncf1 |
neutrophil cytosolic factor 1 |
increases expression |
ISO |
Dimethylformamide results in increased expression of NCF1 mRNA |
CTD |
PMID:18063697 |
|
NCBI chr12:25,497,104...25,506,300
Ensembl chr12:25,497,104...25,506,300
|
|
G |
Nefh |
neurofilament heavy |
affects expression |
EXP |
Dimethylformamide affects the expression of NEFH mRNA |
CTD |
PMID:22954530 |
|
NCBI chr14:85,181,572...85,191,557
Ensembl chr14:85,181,572...85,191,557
|
|
G |
Parp1 |
poly (ADP-ribose) polymerase 1 |
multiple interactions |
EXP |
[Dimethylformamide co-treated with Carbon Tetrachloride] results in increased cleavage of PARP1 protein |
CTD |
PMID:20097184 |
|
NCBI chr13:98,857,255...98,889,444
Ensembl chr13:98,857,177...98,889,716
|
|
G |
Rad50 |
RAD50 double strand break repair protein |
increases expression |
ISO |
Dimethylformamide results in increased expression of RAD50 mRNA; Dimethylformamide results in increased expression of RAD50 protein |
CTD |
PMID:26387567 |
|
NCBI chr10:39,002,130...39,054,042
Ensembl chr10:39,001,498...39,054,142
|
|
G |
Rad51 |
RAD51 recombinase |
increases expression |
ISO |
Dimethylformamide results in increased expression of RAD51 mRNA; Dimethylformamide results in increased expression of RAD51 protein |
CTD |
PMID:26387567 |
|
NCBI chr 3:110,918,240...110,942,920
Ensembl chr 3:110,918,243...110,942,917
|
|
G |
Sult1a1 |
sulfotransferase family 1A member 1 |
multiple interactions |
ISO |
Dimethylformamide inhibits the reaction [SULT1A1 protein results in increased sulfation of 1-hydroxypyrene]; Dimethylformamide inhibits the reaction [SULT1A1 protein results in increased sulfation of 4-nitrophenol] |
CTD |
PMID:14570759 |
|
NCBI chr 1:198,100,586...198,104,106
Ensembl chr 1:198,100,586...198,104,109
|
|
G |
Sult2a1 |
sulfotransferase family 2A member 1 |
multiple interactions |
ISO |
Dimethylformamide inhibits the reaction [SULT2A1 protein results in increased sulfation of 1-hydroxypyrene] |
CTD |
PMID:14570759 |
|
NCBI chr 1:76,558,721...76,614,315
Ensembl chr 1:76,252,329...76,780,230
|
|
G |
Tnfsf10 |
TNF superfamily member 10 |
increases expression |
ISO |
Dimethylformamide results in increased expression of TNFSF10 mRNA; Dimethylformamide results in increased expression of TNFSF10 protein |
CTD |
PMID:18063697 |
|
NCBI chr 2:113,008,008...113,026,899
Ensembl chr 2:113,007,549...113,026,899
|
|
G |
Tp53 |
tumor protein p53 |
multiple interactions increases expression |
ISO |
CAT protein inhibits the reaction [Dimethylformamide results in increased expression of TP53 protein]; Thiocarbamates analog inhibits the reaction [Dimethylformamide results in increased expression of TP53 protein] Dimethylformamide results in increased expression of TP53 protein modified form |
CTD |
PMID:29984871 |
|
NCBI chr10:56,186,299...56,198,449
Ensembl chr10:56,187,020...56,198,449
|
|
G |
Xrcc2 |
X-ray repair cross complementing 2 |
increases expression affects expression |
ISO |
Dimethylformamide results in increased expression of XRCC2 protein Dimethylformamide affects the expression of XRCC2 mRNA |
CTD |
PMID:26387567 |
|
NCBI chr 4:5,842,013...5,860,516
Ensembl chr 4:5,841,998...5,860,527
|
|
G |
Xrcc3 |
X-ray repair cross complementing 3 |
increases expression |
ISO |
Dimethylformamide results in increased expression of XRCC3 mRNA; Dimethylformamide results in increased expression of XRCC3 protein |
CTD |
PMID:26387567 |
|
NCBI chr 6:136,366,917...136,380,751
Ensembl chr 6:136,371,555...136,379,348
|
|
|
G |
Adamts7 |
ADAM metallopeptidase with thrombospondin type 1 motif, 7 |
affects expression |
ISO |
methylformamide affects the expression of ADAMTS7 mRNA; methylformamide analog affects the expression of ADAMTS7 mRNA |
CTD |
PMID:17040096 |
|
NCBI chr 8:97,535,777...97,575,661
Ensembl chr 8:97,535,777...97,575,655
|
|
G |
Ampd2 |
adenosine monophosphate deaminase 2 |
decreases expression |
ISO |
methylformamide analog results in decreased expression of AMPD2 mRNA; methylformamide results in decreased expression of AMPD2 mRNA |
CTD |
PMID:17040096 |
|
NCBI chr 2:210,861,624...210,874,348
Ensembl chr 2:210,861,625...210,874,304
|
|
G |
Angptl4 |
angiopoietin-like 4 |
increases expression |
ISO |
methylformamide analog results in increased expression of ANGPTL4 mRNA; methylformamide results in increased expression of ANGPTL4 mRNA |
CTD |
PMID:17040096 |
|
NCBI chr 7:18,627,814...18,634,043
Ensembl chr 7:18,627,808...18,634,079
|
|
G |
Ankrd10 |
ankyrin repeat domain 10 |
decreases expression |
ISO |
methylformamide analog results in decreased expression of ANKRD10 mRNA; methylformamide results in decreased expression of ANKRD10 mRNA |
CTD |
PMID:17040096 |
|
NCBI chr16:83,205,898...83,229,147
Ensembl chr16:83,206,004...83,228,194
|
|
G |
Anxa6 |
annexin A6 |
decreases expression |
ISO |
methylformamide analog results in decreased expression of ANXA6 mRNA; methylformamide results in decreased expression of ANXA6 mRNA |
CTD |
PMID:17040096 |
|
NCBI chr10:40,320,581...40,375,605
Ensembl chr10:40,320,581...40,375,605
|
|
G |
Aox1 |
aldehyde oxidase 1 |
increases expression |
ISO |
methylformamide analog results in increased expression of AOX1 mRNA; methylformamide results in increased expression of AOX1 mRNA |
CTD |
PMID:17040096 |
|
NCBI chr 9:64,929,682...65,007,872
Ensembl chr 9:64,929,721...65,007,870
|
|
G |
Arl4a |
ADP-ribosylation factor like GTPase 4A |
affects expression |
ISO |
methylformamide affects the expression of ARL4A mRNA; methylformamide analog affects the expression of ARL4A mRNA |
CTD |
PMID:17040096 |
|
NCBI chr 6:59,945,926...59,950,586
Ensembl chr 6:59,948,577...59,950,586
|
|
G |
B3galnt1 |
beta-1,3-N-acetylgalactosaminyltransferase 1 (globoside blood group) |
decreases expression |
ISO |
methylformamide analog results in decreased expression of B3GALNT1 mRNA; methylformamide results in decreased expression of B3GALNT1 mRNA |
CTD |
PMID:17040096 |
|
NCBI chr 2:166,226,736...166,255,978
Ensembl chr 2:166,226,754...166,255,302
|
|
G |
Birc2 |
baculoviral IAP repeat-containing 2 |
decreases expression |
ISO |
methylformamide analog results in decreased expression of BIRC2 mRNA; methylformamide results in decreased expression of BIRC2 mRNA |
CTD |
PMID:17040096 |
|
NCBI chr 8:6,014,014...6,036,668
Ensembl chr 8:6,013,207...6,034,142
|
|
G |
Cacybp |
calcyclin binding protein |
increases expression |
ISO |
methylformamide analog results in increased expression of CACYBP mRNA; methylformamide results in increased expression of CACYBP mRNA |
CTD |
PMID:17040096 |
|
NCBI chr13:77,948,771...77,959,089
Ensembl chr13:77,948,771...77,959,110
|
|
G |
Cavin2 |
caveolae associated protein 2 |
decreases expression |
ISO |
methylformamide analog results in decreased expression of CAVIN2 mRNA; methylformamide results in decreased expression of CAVIN2 mRNA |
CTD |
PMID:17040096 |
|
NCBI chr 9:55,244,136...55,256,153
Ensembl chr 9:55,243,255...55,256,340
|
|
G |
Ccl3 |
C-C motif chemokine ligand 3 |
increases expression |
ISO |
methylformamide analog results in increased expression of CCL3 mRNA; methylformamide results in increased expression of CCL3 mRNA |
CTD |
PMID:17040096 |
|
NCBI chr10:70,869,516...70,871,066
Ensembl chr10:70,869,513...70,871,066
|
|
G |
Ccn2 |
cellular communication network factor 2 |
increases expression |
ISO |
methylformamide analog results in increased expression of CCN2 mRNA; methylformamide results in increased expression of CCN2 mRNA |
CTD |
PMID:17040096 |
|
NCBI chr 1:21,851,657...21,854,773
Ensembl chr 1:21,851,660...21,854,773
|
|
G |
Ccnd1 |
cyclin D1 |
decreases expression |
ISO |
methylformamide analog results in decreased expression of CCND1 mRNA; methylformamide results in decreased expression of CCND1 mRNA |
CTD |
PMID:17040096 |
|
NCBI chr 1:218,090,750...218,100,447
Ensembl chr 1:218,090,750...218,100,325
|
|
G |
Ccnd2 |
cyclin D2 |
decreases expression |
ISO |
methylformamide analog results in decreased expression of CCND2 mRNA; methylformamide results in decreased expression of CCND2 mRNA |
CTD |
PMID:17040096 |
|
NCBI chr 4:159,674,885...159,697,207
Ensembl chr 4:159,674,885...159,697,207
|
|
G |
Cdc45 |
cell division cycle 45 |
increases expression |
ISO |
methylformamide analog results in increased expression of CDC45 mRNA; methylformamide results in increased expression of CDC45 mRNA |
CTD |
PMID:17040096 |
|
NCBI chr11:86,328,785...86,354,099
Ensembl chr11:86,329,012...86,358,453
|
|
G |
Cish |
cytokine inducible SH2-containing protein |
decreases expression |
ISO |
methylformamide analog results in decreased expression of CISH mRNA; methylformamide results in decreased expression of CISH mRNA |
CTD |
PMID:17040096 |
|
NCBI chr 8:116,054,547...116,059,494
Ensembl chr 8:116,054,465...116,060,723
|
|
G |
Clstn2 |
calsyntenin 2 |
increases expression |
ISO |
methylformamide analog results in increased expression of CLSTN2 mRNA; methylformamide results in increased expression of CLSTN2 mRNA |
CTD |
PMID:17040096 |
|
NCBI chr 8:105,322,577...106,036,821
Ensembl chr 8:105,323,837...105,462,168
|
|
G |
Csnk1d |
casein kinase 1, delta |
affects expression |
ISO |
methylformamide affects the expression of CSNK1D mRNA; methylformamide analog affects the expression of CSNK1D mRNA |
CTD |
PMID:17040096 |
|
NCBI chr10:110,147,786...110,182,413
Ensembl chr10:110,148,600...110,182,408
|
|
G |
Cxadr |
CXADR, Ig-like cell adhesion molecule |
affects expression |
ISO |
methylformamide affects the expression of CXADR mRNA; methylformamide analog affects the expression of CXADR mRNA |
CTD |
PMID:17040096 |
|
NCBI chr11:16,826,269...16,873,564
Ensembl chr11:16,826,399...16,873,562
|
|
G |
Cyp2e1 |
cytochrome P450, family 2, subfamily e, polypeptide 1 |
increases metabolic processing multiple interactions |
ISO EXP |
CYP2E1 protein results in increased metabolism of methylformamide 4-nitrophenol inhibits the reaction [CYP2E1 protein results in increased metabolism of methylformamide]; Dimethyl Sulfoxide inhibits the reaction [CYP2E1 protein results in increased metabolism of methylformamide]; Ditiocarb inhibits the reaction [CYP2E1 protein results in increased metabolism of methylformamide]; Fomepizole promotes the reaction [CYP2E1 protein results in increased metabolism of methylformamide] |
CTD |
PMID:1538706 |
|
NCBI chr 1:213,511,892...213,522,195
Ensembl chr 1:213,511,874...213,535,542
|
|
G |
Dnaja1 |
DnaJ heat shock protein family (Hsp40) member A1 |
increases expression |
ISO |
methylformamide analog results in increased expression of DNAJA1 mRNA; methylformamide results in increased expression of DNAJA1 mRNA |
CTD |
PMID:17040096 |
|
NCBI chr 5:57,028,467...57,039,378
Ensembl chr 5:57,028,467...57,039,378
|
|
G |
Dnmt3a |
DNA methyltransferase 3 alpha |
affects expression |
ISO |
methylformamide affects the expression of DNMT3A mRNA; methylformamide analog affects the expression of DNMT3A mRNA |
CTD |
PMID:17040096 |
|
NCBI chr 6:28,205,375...28,346,052
Ensembl chr 6:28,235,695...28,340,577
|
|
G |
Dusp10 |
dual specificity phosphatase 10 |
affects expression |
ISO |
methylformamide affects the expression of DUSP10 mRNA; methylformamide analog affects the expression of DUSP10 mRNA |
CTD |
PMID:17040096 |
|
NCBI chr13:104,284,660...104,321,455
Ensembl chr13:104,284,660...104,321,455
|
|
G |
Dusp6 |
dual specificity phosphatase 6 |
increases expression |
ISO |
methylformamide analog results in increased expression of DUSP6 mRNA; methylformamide results in increased expression of DUSP6 mRNA |
CTD |
PMID:17040096 |
|
NCBI chr 7:41,475,163...41,479,393
Ensembl chr 7:41,475,163...41,479,392
|
|
G |
Dusp7 |
dual specificity phosphatase 7 |
decreases expression |
ISO |
methylformamide analog results in decreased expression of DUSP7 mRNA; methylformamide results in decreased expression of DUSP7 mRNA |
CTD |
PMID:17040096 |
|
NCBI chr 8:115,069,095...115,076,130
Ensembl chr 8:115,069,095...115,076,130
|
|
G |
Egfr |
epidermal growth factor receptor |
decreases expression |
ISO |
methylformamide analog results in decreased expression of EGFR mRNA; methylformamide results in decreased expression of EGFR mRNA |
CTD |
PMID:17040096 |
|
NCBI chr14:99,919,485...100,104,136
Ensembl chr14:99,919,485...100,098,796
|
|
G |
Entpd5 |
ectonucleoside triphosphate diphosphohydrolase 5 |
affects expression |
ISO |
methylformamide affects the expression of ENTPD5 mRNA; methylformamide analog affects the expression of ENTPD5 mRNA |
CTD |
PMID:17040096 |
|
NCBI chr 6:108,087,677...108,123,811
Ensembl chr 6:108,087,418...108,120,579
|
|
G |
Fgf21 |
fibroblast growth factor 21 |
increases expression |
ISO |
methylformamide analog results in increased expression of FGF21 mRNA; methylformamide results in increased expression of FGF21 mRNA |
CTD |
PMID:17040096 |
|
NCBI chr 1:101,595,579...101,596,822
Ensembl chr 1:101,595,579...101,596,822
|
|
G |
Fn1 |
fibronectin 1 |
decreases expression |
ISO |
methylformamide analog results in decreased expression of FN1 mRNA; methylformamide results in decreased expression of FN1 mRNA |
CTD |
PMID:17040096 |
|
NCBI chr 9:78,900,111...78,969,018
Ensembl chr 9:78,900,103...78,969,078
|
|
G |
Fos |
Fos proto-oncogene, AP-1 transcription factor subunit |
increases expression |
ISO |
methylformamide analog results in increased expression of FOS mRNA; methylformamide results in increased expression of FOS mRNA |
CTD |
PMID:17040096 |
|
NCBI chr 6:109,300,433...109,303,299
Ensembl chr 6:109,300,433...109,303,299
|
|
G |
Gabarapl1 |
GABA type A receptor associated protein like 1 |
increases expression |
ISO |
methylformamide analog results in increased expression of GABARAPL1 mRNA; methylformamide results in increased expression of GABARAPL1 mRNA |
CTD |
PMID:17040096 |
|
NCBI chr 4:163,293,724...163,302,866
Ensembl chr 4:163,293,724...163,302,858
|
|
G |
Gas2 |
growth arrest-specific 2 |
decreases expression |
ISO |
methylformamide analog results in decreased expression of GAS2 mRNA; methylformamide results in decreased expression of GAS2 mRNA |
CTD |
PMID:17040096 |
|
NCBI chr 1:107,234,389...107,363,624
Ensembl chr 1:107,262,659...107,363,788
|
|
G |
Gclc |
glutamate-cysteine ligase, catalytic subunit |
affects expression |
ISO |
methylformamide affects the expression of GCLC mRNA; methylformamide analog affects the expression of GCLC mRNA |
CTD |
PMID:17040096 |
|
NCBI chr 8:85,059,051...85,097,471
Ensembl chr 8:85,059,051...85,097,468
|
|
G |
Gdf15 |
growth differentiation factor 15 |
increases expression |
ISO |
methylformamide analog results in increased expression of GDF15 mRNA; methylformamide results in increased expression of GDF15 mRNA |
CTD |
PMID:17040096 |
|
NCBI chr16:20,555,395...20,557,978
Ensembl chr16:20,555,395...20,557,978
|
|
G |
Gdf9 |
growth differentiation factor 9 |
increases expression |
ISO |
methylformamide analog results in increased expression of GDF9 mRNA; methylformamide results in increased expression of GDF9 mRNA |
CTD |
PMID:17040096 |
|
NCBI chr10:38,782,519...38,793,238
Ensembl chr10:38,788,992...38,792,940
|
|
G |
Grpel2 |
GrpE-like 2, mitochondrial |
increases expression |
ISO |
methylformamide analog results in increased expression of GRPEL2 mRNA; methylformamide results in increased expression of GRPEL2 mRNA |
CTD |
PMID:17040096 |
|
NCBI chr18:57,037,995...57,050,234
Ensembl chr18:57,036,877...57,050,408
|
|
G |
Gsdme |
gasdermin E |
increases expression |
ISO |
methylformamide analog results in increased expression of GSDME mRNA; methylformamide results in increased expression of GSDME mRNA |
CTD |
PMID:17040096 |
|
NCBI chr 4:79,934,075...79,999,678
Ensembl chr 4:79,934,887...79,989,572
|
|
G |
Gsta2 |
glutathione S-transferase alpha 2 |
affects expression |
ISO |
methylformamide affects the expression of GSTA2 mRNA; methylformamide analog affects the expression of GSTA2 mRNA |
CTD |
PMID:17040096 |
|
NCBI chr 8:85,640,081...85,645,621
|
|
G |
Gsta6 |
glutathione S-transferase alpha 6 |
affects expression |
ISO |
methylformamide affects the expression of GSTA2 mRNA; methylformamide analog affects the expression of GSTA2 mRNA |
CTD |
PMID:17040096 |
|
NCBI chr 9:27,475,273...27,533,939
Ensembl chr 9:27,475,273...27,511,176
|
|
G |
Gtf2ird1 |
GTF2I repeat domain containing 1 |
affects expression |
ISO |
methylformamide affects the expression of GTF2IRD1 mRNA; methylformamide analog affects the expression of GTF2IRD1 mRNA |
CTD |
PMID:17040096 |
|
NCBI chr12:25,264,052...25,370,947
Ensembl chr12:25,264,192...25,371,001
|
|
G |
Gtpbp2 |
GTP binding protein 2 |
affects expression |
ISO |
methylformamide affects the expression of GTPBP2 mRNA; methylformamide analog affects the expression of GTPBP2 mRNA |
CTD |
PMID:17040096 |
|
NCBI chr 9:17,198,957...17,208,456
Ensembl chr 9:17,198,957...17,209,220
|
|
G |
Habp2 |
hyaluronan binding protein 2 |
increases expression |
ISO |
methylformamide analog results in increased expression of HABP2 mRNA; methylformamide results in increased expression of HABP2 mRNA |
CTD |
PMID:17040096 |
|
NCBI chr 1:277,068,715...277,104,567
Ensembl chr 1:277,068,761...277,104,566
|
|
G |
Hbp1 |
HMG-box transcription factor 1 |
increases expression |
ISO |
methylformamide analog results in increased expression of HBP1 mRNA; methylformamide results in increased expression of HBP1 mRNA |
CTD |
PMID:17040096 |
|
NCBI chr 6:51,231,479...51,257,699
Ensembl chr 6:51,231,480...51,257,625
|
|
G |
Hmgcr |
3-hydroxy-3-methylglutaryl-CoA reductase |
affects expression |
ISO |
methylformamide affects the expression of HMGCR mRNA; methylformamide analog affects the expression of HMGCR mRNA |
CTD |
PMID:17040096 |
|
NCBI chr 2:27,480,224...27,500,654
Ensembl chr 2:27,480,226...27,500,654
|
|
G |
Hmox1 |
heme oxygenase 1 |
affects expression |
ISO |
methylformamide affects the expression of HMOX1 mRNA; methylformamide analog affects the expression of HMOX1 mRNA |
CTD |
PMID:17040096 |
|
NCBI chr19:14,508,634...14,515,455
Ensembl chr19:14,508,616...14,515,456
|
|
G |
Hnrnpa2b1 |
heterogeneous nuclear ribonucleoprotein A2/B1 |
decreases expression |
ISO |
methylformamide analog results in decreased expression of HNRNPA2B1 mRNA; methylformamide results in decreased expression of HNRNPA2B1 mRNA |
CTD |
PMID:17040096 |
|
NCBI chr 4:81,237,496...81,241,281
Ensembl chr 4:81,237,496...81,241,282
|
|
G |
Hspa1b |
heat shock protein family A (Hsp70) member 1B |
affects expression |
ISO |
methylformamide affects the expression of HSPA1B mRNA; methylformamide analog affects the expression of HSPA1B mRNA |
CTD |
PMID:17040096 |
|
NCBI chr20:4,877,638...4,880,112
Ensembl chr20:2,699,712...2,701,815
|
|
G |
Hspa8 |
heat shock protein family A (Hsp70) member 8 |
increases expression |
ISO |
methylformamide analog results in increased expression of HSPA8 mRNA; methylformamide results in increased expression of HSPA8 mRNA |
CTD |
PMID:17040096 |
|
NCBI chr 8:44,989,401...44,993,261
Ensembl chr 8:44,990,014...44,993,179
|
|
G |
Hspb1 |
heat shock protein family B (small) member 1 |
affects expression |
ISO |
methylformamide affects the expression of HSPB1 mRNA; methylformamide analog affects the expression of HSPB1 mRNA |
CTD |
PMID:17040096 |
|
NCBI chr12:23,839,390...23,841,051
Ensembl chr12:23,839,399...23,841,049
|
|
G |
Hspb8 |
heat shock protein family B (small) member 8 |
affects expression |
ISO |
methylformamide affects the expression of HSPB8 mRNA; methylformamide analog affects the expression of HSPB8 mRNA |
CTD |
PMID:17040096 |
|
NCBI chr12:45,905,371...45,920,014
Ensembl chr12:45,905,371...45,920,013
|
|
G |
Hspd1 |
heat shock protein family D (Hsp60) member 1 |
increases expression |
ISO |
methylformamide analog results in increased expression of HSPD1 mRNA; methylformamide results in increased expression of HSPD1 mRNA |
CTD |
PMID:17040096 |
|
NCBI chr 9:61,680,529...61,691,202
Ensembl chr 9:61,680,530...61,690,956
|
|
G |
Hsph1 |
heat shock protein family H (Hsp110) member 1 |
increases expression |
ISO |
methylformamide analog results in increased expression of HSPH1 mRNA; methylformamide results in increased expression of HSPH1 mRNA |
CTD |
PMID:17040096 |
|
NCBI chr12:6,322,685...6,341,898
Ensembl chr12:6,322,668...6,341,902
|
|
G |
Ikbkg |
inhibitor of nuclear factor kappa B kinase regulatory subunit gamma |
affects expression |
ISO |
methylformamide affects the expression of IKBKG mRNA; methylformamide analog affects the expression of IKBKG mRNA |
CTD |
PMID:17040096 |
|
NCBI chr X:156,254,187...156,280,046
Ensembl chr X:156,257,173...156,270,748
|
|
G |
Il15ra |
interleukin 15 receptor subunit alpha |
decreases expression |
ISO |
methylformamide analog results in decreased expression of IL15RA mRNA; methylformamide results in decreased expression of IL15RA mRNA |
CTD |
PMID:17040096 |
|
NCBI chr17:70,451,861...70,481,838
Ensembl chr17:70,451,411...70,481,750
|
|
G |
Il1rap |
interleukin 1 receptor accessory protein |
decreases expression |
ISO |
methylformamide analog results in decreased expression of IL1RAP mRNA; methylformamide results in decreased expression of IL1RAP mRNA |
CTD |
PMID:17040096 |
|
NCBI chr11:77,456,648...77,593,208
Ensembl chr11:77,463,954...77,593,207
|
|
G |
Inpp1 |
inositol polyphosphate-1-phosphatase |
decreases expression |
ISO |
methylformamide analog results in decreased expression of INPP1 mRNA; methylformamide results in decreased expression of INPP1 mRNA |
CTD |
PMID:17040096 |
|
NCBI chr 9:53,544,602...53,574,303
Ensembl chr 9:53,546,018...53,574,690
|
|
G |
Kcnk5 |
potassium two pore domain channel subfamily K member 5 |
decreases expression |
ISO |
methylformamide analog results in decreased expression of KCNK5 mRNA; methylformamide results in decreased expression of KCNK5 mRNA |
CTD |
PMID:17040096 |
|
NCBI chr15:4,554,603...4,597,000
Ensembl chr15:4,554,603...4,597,000
|
|
G |
Kdm2b |
lysine demethylase 2B |
decreases expression |
ISO |
methylformamide analog results in decreased expression of KDM2B mRNA; methylformamide results in decreased expression of KDM2B mRNA |
CTD |
PMID:17040096 |
|
NCBI chr12:39,021,924...39,161,954
Ensembl chr12:39,078,119...39,161,956
|
|
G |
Klf6 |
Kruppel-like factor 6 |
affects expression |
ISO |
methylformamide affects the expression of KLF6 mRNA; methylformamide analog affects the expression of KLF6 mRNA |
CTD |
PMID:17040096 |
|
NCBI chr17:67,887,939...67,945,052
Ensembl chr17:67,887,939...67,945,037
|
|
G |
Lgals7 |
galectin 7 |
affects expression |
ISO |
methylformamide affects the expression of LGALS7 mRNA; methylformamide analog affects the expression of LGALS7 mRNA |
CTD |
PMID:17040096 |
|
NCBI chr 1:87,044,823...87,047,223
Ensembl chr 1:87,045,335...87,047,223
|
|
G |
Lipg |
lipase G, endothelial type |
decreases expression |
ISO |
methylformamide analog results in decreased expression of LIPG mRNA; methylformamide results in decreased expression of LIPG mRNA |
CTD |
PMID:17040096 |
|
NCBI chr18:70,903,528...70,924,434
Ensembl chr18:70,901,710...70,924,708
|
|
G |
LOC100909544 |
bromodomain-containing protein 2-like |
increases expression |
ISO |
methylformamide analog results in increased expression of BRD2 mRNA; methylformamide results in increased expression of BRD2 mRNA |
CTD |
PMID:17040096 |
|
NCBI chr20:3,910,555...3,918,348
Ensembl chr20:3,910,555...3,917,426
|
|
G |
Lpin2 |
lipin 2 |
increases expression |
ISO |
methylformamide analog results in increased expression of LPIN2 mRNA; methylformamide results in increased expression of LPIN2 mRNA |
CTD |
PMID:17040096 |
|
NCBI chr 9:119,517,101...119,591,533
Ensembl chr 9:119,517,101...119,591,533
|
|
G |
Ly96 |
lymphocyte antigen 96 |
affects expression |
ISO |
methylformamide affects the expression of LY96 mRNA; methylformamide analog affects the expression of LY96 mRNA |
CTD |
PMID:17040096 |
|
NCBI chr 5:1,972,212...1,989,448
|
|
G |
Mafk |
MAF bZIP transcription factor K |
affects expression |
ISO |
methylformamide affects the expression of MAFK mRNA; methylformamide analog affects the expression of MAFK mRNA |
CTD |
PMID:17040096 |
|
NCBI chr12:16,923,989...16,934,706
Ensembl chr12:16,923,990...16,934,706
|
|
G |
Nde1 |
nudE neurodevelopment protein 1 |
decreases expression |
ISO |
methylformamide analog results in decreased expression of NDE1 mRNA; methylformamide results in decreased expression of NDE1 mRNA |
CTD |
PMID:17040096 |
|
NCBI chr10:860,513...904,624
Ensembl chr10:860,521...896,938
|
|
G |
Noct |
nocturnin |
decreases expression |
ISO |
methylformamide analog results in decreased expression of NOCT mRNA; methylformamide results in decreased expression of NOCT mRNA |
CTD |
PMID:17040096 |
|
NCBI chr 2:140,286,661...140,306,869
Ensembl chr 2:140,286,661...140,306,869
|
|
G |
Nr1d2 |
nuclear receptor subfamily 1, group D, member 2 |
increases expression |
ISO |
methylformamide analog results in increased expression of NR1D2 mRNA; methylformamide results in increased expression of NR1D2 mRNA |
CTD |
PMID:17040096 |
|
NCBI chr15:8,730,871...8,757,165
Ensembl chr15:8,730,871...8,757,165
|
|
G |
Pgd |
phosphogluconate dehydrogenase |
affects expression |
ISO |
methylformamide affects the expression of PGD mRNA; methylformamide analog affects the expression of PGD mRNA |
CTD |
PMID:17040096 |
|
NCBI chr 5:165,966,128...165,982,327
|
|
G |
Plk3 |
polo-like kinase 3 |
increases expression |
ISO |
methylformamide analog results in increased expression of PLK3 mRNA; methylformamide results in increased expression of PLK3 mRNA |
CTD |
PMID:17040096 |
|
NCBI chr 5:135,997,725...136,002,900
Ensembl chr 5:135,997,725...136,002,900
|
|
G |
Pnrc1 |
proline-rich nuclear receptor coactivator 1 |
affects expression |
ISO |
methylformamide affects the expression of PNRC1 mRNA; methylformamide analog affects the expression of PNRC1 mRNA |
CTD |
PMID:17040096 |
|
NCBI chr 5:48,501,472...48,504,511
Ensembl chr 5:48,501,472...48,504,511
|
|
G |
Ppp1r10 |
protein phosphatase 1, regulatory subunit 10 |
increases expression |
ISO |
methylformamide analog results in increased expression of PPP1R10 mRNA; methylformamide results in increased expression of PPP1R10 mRNA |
CTD |
PMID:17040096 |
|
NCBI chr20:3,329,677...3,344,286
Ensembl chr20:3,329,677...3,344,286
|
|
G |
Rbpms |
RNA binding protein, mRNA processing factor |
affects expression |
ISO |
methylformamide affects the expression of RBPMS mRNA; methylformamide analog affects the expression of RBPMS mRNA |
CTD |
PMID:17040096 |
|
NCBI chr16:61,954,569...62,109,998
Ensembl chr16:61,954,590...62,096,497
|
|
G |
Rcan1 |
regulator of calcineurin 1 |
affects expression |
ISO |
methylformamide affects the expression of RCAN1 mRNA; methylformamide analog affects the expression of RCAN1 mRNA |
CTD |
PMID:17040096 |
|
NCBI chr11:32,539,689...32,620,274
Ensembl chr11:32,539,683...32,550,539
|
|
G |
RT1-DMb |
RT1 class II, locus DMb |
decreases expression |
ISO |
methylformamide analog results in decreased expression of H2-DMB2 mRNA; methylformamide results in decreased expression of H2-DMB2 mRNA |
CTD |
PMID:17040096 |
|
NCBI chr20:3,945,383...3,952,838
Ensembl chr20:5,227,045...5,234,290
|
|
G |
Rtp3 |
receptor (chemosensory) transporter protein 3 |
decreases expression |
ISO |
methylformamide analog results in decreased expression of RTP3 mRNA; methylformamide results in decreased expression of RTP3 mRNA |
CTD |
PMID:17040096 |
|
NCBI chr 8:119,260,609...119,265,501
Ensembl chr 8:119,260,618...119,265,157
|
|
G |
Sgk1 |
serum/glucocorticoid regulated kinase 1 |
increases expression |
ISO |
methylformamide analog results in increased expression of SGK1 mRNA; methylformamide results in increased expression of SGK1 mRNA |
CTD |
PMID:17040096 |
|
NCBI chr 1:24,185,451...24,302,309
Ensembl chr 1:24,185,435...24,302,298
|
|
G |
Sgk2 |
serum/glucocorticoid regulated kinase 2 |
increases expression |
ISO |
methylformamide analog results in increased expression of SGK2 mRNA; methylformamide results in increased expression of SGK2 mRNA |
CTD |
PMID:17040096 |
|
NCBI chr 3:159,361,313...159,385,843
Ensembl chr 3:159,368,273...159,384,775
|
|
G |
Sirt1 |
sirtuin 1 |
increases expression |
ISO |
methylformamide analog results in increased expression of SIRT1 mRNA; methylformamide results in increased expression of SIRT1 mRNA |
CTD |
PMID:17040096 |
|
NCBI chr20:26,831,971...26,851,587
Ensembl chr20:26,833,357...26,852,199
|
|
G |
Slc14a1 |
solute carrier family 14 member 1 (Kidd blood group) |
multiple interactions affects transport |
ISO |
methylformamide inhibits the reaction [SLC14A1 protein affects the transport of Urea] SLC14A1 protein affects the transport of methylformamide |
CTD |
PMID:17506977 |
|
NCBI chr18:74,461,064...74,504,475
Ensembl chr18:74,461,055...74,485,139
|
|
G |
Slc25a19 |
solute carrier family 25 member 19 |
decreases expression |
ISO |
methylformamide analog results in decreased expression of SLC25A19 mRNA; methylformamide results in decreased expression of SLC25A19 mRNA |
CTD |
PMID:17040096 |
|
NCBI chr10:104,166,594...104,179,523
Ensembl chr10:104,166,598...104,179,523
|
|
G |
Slc38a2 |
solute carrier family 38, member 2 |
increases expression |
ISO |
methylformamide analog results in increased expression of SLC38A2 mRNA; methylformamide results in increased expression of SLC38A2 mRNA |
CTD |
PMID:17040096 |
|
NCBI chr 7:138,088,654...138,100,869
Ensembl chr 7:138,088,649...138,100,841
|
|
G |
Slc39a8 |
solute carrier family 39 member 8 |
increases expression |
ISO |
methylformamide analog results in increased expression of SLC39A8 mRNA; methylformamide results in increased expression of SLC39A8 mRNA |
CTD |
PMID:17040096 |
|
NCBI chr 2:241,028,851...241,092,584
Ensembl chr 2:241,029,693...241,092,582
|
|
G |
Sqstm1 |
sequestosome 1 |
affects expression |
ISO |
methylformamide affects the expression of SQSTM1 mRNA; methylformamide analog affects the expression of SQSTM1 mRNA |
CTD |
PMID:17040096 |
|
NCBI chr10:35,704,728...35,716,316
Ensembl chr10:35,704,730...35,716,294
|
|
G |
Srebf1 |
sterol regulatory element binding transcription factor 1 |
decreases expression |
ISO |
methylformamide analog results in decreased expression of SREBF1 mRNA; methylformamide results in decreased expression of SREBF1 mRNA |
CTD |
PMID:17040096 |
|
NCBI chr10:46,570,996...46,593,021
Ensembl chr10:46,570,996...46,593,009
|
|
G |
Srpk2 |
SRSF protein kinase 2 |
increases expression |
ISO |
methylformamide analog results in increased expression of SRPK2 mRNA; methylformamide results in increased expression of SRPK2 mRNA |
CTD |
PMID:17040096 |
|
NCBI chr 4:7,994,025...8,187,455
Ensembl chr 4:8,066,737...8,185,935
|
|
G |
Srxn1 |
sulfiredoxin 1 |
affects expression |
ISO |
methylformamide affects the expression of SRXN1 mRNA; methylformamide analog affects the expression of SRXN1 mRNA |
CTD |
PMID:17040096 |
|
NCBI chr 3:147,608,850...147,614,410
Ensembl chr 3:147,609,095...147,632,801
|
|
G |
Thrsp |
thyroid hormone responsive |
decreases expression |
ISO |
methylformamide analog results in decreased expression of THRSP mRNA; methylformamide results in decreased expression of THRSP mRNA |
CTD |
PMID:17040096 |
|
NCBI chr 1:162,381,251...162,385,575
Ensembl chr 1:162,381,253...162,385,575
|
|
G |
Tnfaip6 |
TNF alpha induced protein 6 |
affects expression |
ISO |
methylformamide affects the expression of TNFAIP6 mRNA; methylformamide analog affects the expression of TNFAIP6 mRNA |
CTD |
PMID:17040096 |
|
NCBI chr 3:37,545,238...37,564,704
Ensembl chr 3:37,545,238...37,564,699
|
|
G |
Tob1 |
transducer of ErbB-2.1 |
decreases expression |
ISO |
methylformamide analog results in decreased expression of TOB1 mRNA; methylformamide results in decreased expression of TOB1 mRNA |
CTD |
PMID:17040096 |
|
NCBI chr10:81,913,689...81,915,727
Ensembl chr10:81,913,689...81,915,716
|
|
G |
Topors |
TOP1 binding arginine/serine rich protein, E3 ubiquitin ligase |
increases expression |
ISO |
methylformamide analog results in increased expression of TOPORS mRNA; methylformamide results in increased expression of TOPORS mRNA |
CTD |
PMID:17040096 |
|
NCBI chr 5:56,554,956...56,566,503
Ensembl chr 5:56,554,969...56,567,320
|
|
G |
Trib3 |
tribbles pseudokinase 3 |
affects expression |
ISO |
methylformamide affects the expression of TRIB3 mRNA; methylformamide analog affects the expression of TRIB3 mRNA |
CTD |
PMID:17040096 |
|
NCBI chr 3:147,814,056...147,819,650
Ensembl chr 3:147,813,473...147,819,571
|
|
G |
Txnrd1 |
thioredoxin reductase 1 |
affects expression |
ISO |
methylformamide affects the expression of TXNRD1 mRNA; methylformamide analog affects the expression of TXNRD1 mRNA |
CTD |
PMID:17040096 |
|
NCBI chr 7:26,946,124...26,984,400
Ensembl chr 7:26,946,125...26,984,400
|
|
G |
Ubap1 |
ubiquitin-associated protein 1 |
affects expression |
ISO |
methylformamide affects the expression of UBAP1 mRNA; methylformamide analog affects the expression of UBAP1 mRNA |
CTD |
PMID:17040096 |
|
NCBI chr 5:57,738,309...57,778,724
Ensembl chr 5:57,738,321...57,778,723
|
|
G |
Ugdh |
UDP-glucose 6-dehydrogenase |
affects expression |
ISO |
methylformamide affects the expression of UGDH mRNA; methylformamide analog affects the expression of UGDH mRNA |
CTD |
PMID:17040096 |
|
NCBI chr14:44,479,614...44,502,845
Ensembl chr14:44,479,614...44,502,845
|
|
G |
Ugp2 |
UDP-glucose pyrophosphorylase 2 |
increases expression |
ISO |
methylformamide analog results in increased expression of UGP2 mRNA; methylformamide results in increased expression of UGP2 mRNA |
CTD |
PMID:17040096 |
|
NCBI chr14:106,208,174...106,249,322
Ensembl chr14:106,208,176...106,248,539
|
|
G |
Usp9x |
ubiquitin specific peptidase 9, X-linked |
increases expression |
ISO |
methylformamide analog results in increased expression of USP9X mRNA; methylformamide results in increased expression of USP9X mRNA |
CTD |
PMID:17040096 |
|
NCBI chr X:10,510,033...10,660,555
Ensembl chr X:10,510,033...10,630,297
|
|
G |
Vegfd |
vascular endothelial growth factor D |
increases expression |
ISO |
methylformamide analog results in increased expression of VEGFD mRNA; methylformamide results in increased expression of VEGFD mRNA |
CTD |
PMID:17040096 |
|
NCBI chr X:31,816,480...31,852,239
Ensembl chr X:31,816,436...31,851,715
|
|
G |
Zfp467 |
zinc finger protein 467 |
decreases expression |
ISO |
methylformamide analog results in decreased expression of ZFP467 mRNA; methylformamide results in decreased expression of ZFP467 mRNA |
CTD |
PMID:17040096 |
|
NCBI chr 4:78,068,822...78,077,962
Ensembl chr 4:78,067,689...78,075,398
|
|
G |
Zfx |
zinc finger protein X-linked |
increases expression |
ISO |
methylformamide analog results in increased expression of ZFX mRNA; methylformamide results in increased expression of ZFX mRNA |
CTD |
PMID:17040096 |
|
NCBI chr X:63,158,368...63,204,971
Ensembl chr X:63,158,976...63,204,530
|
|
G |
Zwint |
ZW10 interacting kinetochore protein |
affects expression |
ISO |
methylformamide affects the expression of ZWINT mRNA; methylformamide analog affects the expression of ZWINT mRNA |
CTD |
PMID:17040096 |
|
NCBI chr20:17,075,781...17,091,715
Ensembl chr20:17,075,771...17,091,766
|
|
|
G |
Abhd12 |
abhydrolase domain containing 12, lysophospholipase |
decreases activity |
ISO |
orlistat results in decreased activity of ABHD12 protein |
CTD |
PMID:18657971 |
|
NCBI chr 3:146,630,298...146,690,375
Ensembl chr 3:146,630,299...146,690,375
|
|
G |
Abhd16a |
abhydrolase domain containing 16A, phospholipase |
decreases activity |
ISO |
orlistat results in decreased activity of ABHD16A protein |
CTD |
PMID:18657971 |
|
NCBI chr20:5,080,070...5,094,935
Ensembl chr20:5,080,070...5,094,935
|
|
G |
Acot8 |
acyl-CoA thioesterase 8 |
decreases expression |
ISO |
Orlistat results in decreased expression of ACOT8 protein |
CTD |
PMID:30667213 |
|
NCBI chr 3:161,260,837...161,272,495
Ensembl chr 3:161,259,735...161,272,460
|
|
G |
Adipoq |
adiponectin, C1Q and collagen domain containing |
multiple interactions |
EXP |
orlistat inhibits the reaction [Dietary Fats results in decreased expression of ADIPOQ protein] |
CTD |
PMID:25087745 |
|
NCBI chr11:81,330,845...81,344,488
Ensembl chr11:81,330,293...81,344,488
|
|
G |
App |
amyloid beta precursor protein |
multiple interactions |
ISO |
[1,1,1,2,2-pentafluoro-7-phenylheptan-3-one co-treated with Orlistat] inhibits the reaction [APP protein modified form results in increased secretion of Arachidonic Acid] |
CTD |
PMID:28721267 |
|
NCBI chr11:24,425,013...24,641,872
Ensembl chr11:24,425,005...24,641,858
|
|
G |
Atf4 |
activating transcription factor 4 |
increases expression |
ISO |
orlistat results in increased expression of ATF4 mRNA |
CTD |
PMID:17283163 |
|
NCBI chr 7:121,480,723...121,482,781
Ensembl chr 7:121,480,723...121,482,772
|
|
G |
Bax |
BCL2 associated X, apoptosis regulator |
multiple interactions |
EXP |
Orlistat inhibits the reaction [Dietary Fats results in increased expression of BAX mRNA] |
CTD |
PMID:32450208 |
|
NCBI chr 1:101,451,801...101,457,207
Ensembl chr 1:101,451,802...101,457,207
|
|
G |
Bcl2 |
BCL2, apoptosis regulator |
multiple interactions |
EXP |
Orlistat inhibits the reaction [Dietary Fats results in decreased expression of BCL2 mRNA] |
CTD |
PMID:32450208 |
|
NCBI chr13:26,605,426...26,769,374
Ensembl chr13:26,605,426...26,769,374
|
|
G |
Casp3 |
caspase 3 |
increases activity multiple interactions increases cleavage |
ISO EXP |
orlistat results in increased activity of CASP3 protein Orlistat inhibits the reaction [Dietary Fats results in increased expression of CASP3 mRNA] orlistat results in increased cleavage of CASP3 protein |
CTD |
PMID:17283163 PMID:20805790 PMID:21723078 PMID:32450208 |
|
NCBI chr16:48,845,011...48,863,249
Ensembl chr16:48,845,012...48,863,204
|
|
G |
Casp8 |
caspase 8 |
multiple interactions |
ISO EXP |
orlistat analog results in increased cleavage of and results in increased activity of CASP8 protein; orlistat results in increased cleavage of and results in increased activity of CASP8 protein Orlistat inhibits the reaction [Dietary Fats results in increased expression of CASP8 mRNA] |
CTD |
PMID:18796435 PMID:20577697 PMID:32450208 |
|
NCBI chr 9:65,614,142...65,662,624
Ensembl chr 9:65,614,142...65,662,106
|
|
G |
Casp9 |
caspase 9 |
increases activity multiple interactions |
ISO EXP |
orlistat results in increased activity of CASP9 protein Orlistat inhibits the reaction [Dietary Fats results in increased expression of CASP9 mRNA] |
CTD |
PMID:20805790 PMID:32450208 |
|
NCBI chr 5:160,356,211...160,373,774
Ensembl chr 5:160,355,833...160,373,778
|
|
G |
Cat |
catalase |
multiple interactions decreases expression |
EXP ISO |
Orlistat inhibits the reaction [Dietary Fats results in decreased activity of CAT protein]; Orlistat inhibits the reaction [Dietary Fats results in decreased expression of CAT mRNA]; Orlistat inhibits the reaction [Dietary Fats results in decreased expression of CAT protein] Orlistat results in decreased expression of CAT protein |
CTD |
PMID:25087745 PMID:30667213 PMID:32450208 |
|
NCBI chr 3:93,379,872...93,412,058
Ensembl chr 3:93,379,874...93,412,058
|
|
G |
Cck |
cholecystokinin |
multiple interactions decreases secretion |
ISO |
[[orlistat results in decreased abundance of Fatty Acids, Nonesterified] which results in decreased secretion of CCK protein] which results in decreased secretion of PNLIP protein; orlistat inhibits the reaction [Fats results in increased secretion of CCK protein]; orlistat inhibits the reaction [Olive Oil results in increased secretion of CCK protein] orlistat results in decreased secretion of CCK protein |
CTD |
PMID:11408251 PMID:18303078 PMID:18647814 |
|
NCBI chr 8:130,120,525...130,127,515
Ensembl chr 8:130,120,523...130,127,392
|
|
G |
Ccna2 |
cyclin A2 |
decreases expression |
ISO |
Orlistat results in decreased expression of CCNA2 protein |
CTD |
PMID:30667213 |
|
NCBI chr 2:123,274,727...123,282,266
Ensembl chr 2:123,275,881...123,282,214
|
|
G |
Ccnd1 |
cyclin D1 |
increases expression |
ISO |
Orlistat results in increased expression of CCND1 protein |
CTD |
PMID:30667213 |
|
NCBI chr 1:218,090,750...218,100,447
Ensembl chr 1:218,090,750...218,100,325
|
|
G |
Ccne1 |
cyclin E1 |
increases expression |
ISO |
Orlistat results in increased expression of CCNE1 protein |
CTD |
PMID:30667213 |
|
NCBI chr 1:94,485,830...94,495,112
Ensembl chr 1:94,485,832...94,494,980
|
|
G |
Cdk1 |
cyclin-dependent kinase 1 |
decreases expression |
ISO |
Orlistat results in decreased expression of CDK1 protein |
CTD |
PMID:30667213 |
|
NCBI chr20:20,576,341...20,591,510
Ensembl chr20:20,576,377...20,591,549
|
|
G |
Cdk2 |
cyclin dependent kinase 2 |
decreases expression |
ISO |
Orlistat results in decreased expression of CDK2 protein |
CTD |
PMID:30667213 |
|
NCBI chr 7:3,124,953...3,132,533
Ensembl chr 7:3,124,954...3,132,457
|
|
G |
Cdk4 |
cyclin-dependent kinase 4 |
decreases expression |
ISO |
Orlistat results in decreased expression of CDK4 protein |
CTD |
PMID:30667213 |
|
NCBI chr 7:70,345,971...70,352,689
Ensembl chr 7:70,349,863...70,352,418
|
|
G |
Cdkn1a |
cyclin-dependent kinase inhibitor 1A |
increases expression |
ISO |
Orlistat results in increased expression of CDKN1A protein |
CTD |
PMID:30667213 |
|
NCBI chr20:6,348,422...6,358,864
Ensembl chr20:6,351,458...6,358,864
|
|
G |
Cdkn1b |
cyclin-dependent kinase inhibitor 1B |
increases expression |
ISO |
orlistat results in increased expression of CDKN1B protein |
CTD |
PMID:15138278 |
|
NCBI chr 4:168,689,043...168,694,159
Ensembl chr 4:168,689,163...168,693,964
|
|
G |
Cel |
carboxyl ester lipase |
decreases activity |
ISO |
orlistat results in decreased activity of CEL protein |
CTD |
PMID:11592731 PMID:12381337 |
|
NCBI chr 3:7,134,021...7,141,522
Ensembl chr 3:7,134,021...7,141,522
|
|
G |
Clps |
colipase |
multiple interactions |
ISO |
orlistat inhibits the reaction [[PNLIP protein co-treated with CLPS protein] results in increased hydrolysis of Olive Oil] |
CTD |
PMID:15158758 |
|
NCBI chr20:5,803,447...5,806,107
Ensembl chr20:5,803,383...5,806,097
|
|
G |
Cpb2 |
carboxypeptidase B2 |
decreases expression |
ISO |
orlistat results in decreased expression of CPB2 protein |
CTD |
PMID:16959692 |
|
NCBI chr15:57,290,849...57,339,762
Ensembl chr15:57,290,849...57,339,760
|
|
G |
Cpt1a |
carnitine palmitoyltransferase 1A |
decreases expression |
ISO |
Orlistat results in decreased expression of CPT1A protein |
CTD |
PMID:30667213 |
|
NCBI chr 1:218,568,157...218,629,679
Ensembl chr 1:218,569,510...218,629,678
|
|
G |
Cpt2 |
carnitine palmitoyltransferase 2 |
decreases expression |
ISO |
Orlistat results in decreased expression of CPT2 protein |
CTD |
PMID:30667213 |
|
NCBI chr 5:127,505,646...127,523,016
Ensembl chr 5:127,505,614...127,523,089
|
|
G |
Cyp3a62 |
cytochrome P450, family 3, subfamily a, polypeptide 62 |
increases expression |
ISO |
Orlistat results in increased expression of CYP3A4 mRNA; Orlistat results in increased expression of CYP3A4 protein |
CTD |
PMID:20599501 |
|
NCBI chr12:18,679,809...18,709,397
Ensembl chr12:18,678,594...18,709,397
|
|
G |
Dagla |
diacylglycerol lipase, alpha |
decreases activity |
ISO |
orlistat results in decreased activity of DAGLA protein |
CTD |
PMID:16466961 |
|
NCBI chr 1:226,297,013...226,353,712
Ensembl chr 1:226,297,016...226,353,611
|
|
G |
Ddit3 |
DNA-damage inducible transcript 3 |
increases expression |
ISO |
orlistat results in increased expression of DDIT3 mRNA |
CTD |
PMID:17283163 |
|
NCBI chr 7:70,578,564...70,585,074
Ensembl chr 7:70,580,198...70,585,084
|
|
G |
Ddit4 |
DNA-damage-inducible transcript 4 |
increases expression |
ISO |
orlistat results in increased expression of DDIT4 mRNA |
CTD |
PMID:18796435 |
|
NCBI chr20:29,509,283...29,511,382
Ensembl chr20:29,509,289...29,511,382
|
|
G |
Eif2a |
eukaryotic translation initiation factor 2A |
increases phosphorylation multiple interactions |
ISO |
orlistat results in increased phosphorylation of EIF2A protein orlistat promotes the reaction [EIF2AK3 protein results in increased phosphorylation of EIF2A protein] Cycloheximide inhibits the reaction [orlistat results in increased phosphorylation of EIF2A protein] orlistat analog results in increased phosphorylation of EIF2A protein; orlistat results in increased phosphorylation of EIF2A protein |
CTD |
PMID:17283163 PMID:20577697 |
|
NCBI chr 2:148,722,343...148,755,781
Ensembl chr 2:148,722,231...148,755,520
|
|
G |
Eif2ak3 |
eukaryotic translation initiation factor 2 alpha kinase 3 |
increases response to substance multiple interactions |
ISO |
EIF2AK3 gene mutant form results in increased susceptibility to orlistat orlistat promotes the reaction [EIF2AK3 protein results in increased phosphorylation of EIF2A protein] |
CTD |
PMID:17283163 |
|
NCBI chr 4:98,648,513...98,709,695
Ensembl chr 4:98,648,545...98,709,694
|
|
G |
Eif4e |
eukaryotic translation initiation factor 4E |
increases phosphorylation |
ISO |
orlistat results in increased phosphorylation of EIF4E protein |
CTD |
PMID:18796435 |
|
NCBI chr 2:243,819,616...243,853,987
Ensembl chr 2:243,820,661...243,852,631
|
|
G |
Erbb2 |
erb-b2 receptor tyrosine kinase 2 |
affects response to substance affects localization decreases expression |
ISO |
ERBB2 protein affects the susceptibility to orlistat orlistat affects the localization of ERBB2 protein orlistat results in decreased expression of ERBB2 mRNA; orlistat results in decreased expression of ERBB2 protein |
CTD |
PMID:15870086 |
|
NCBI chr10:86,367,596...86,391,728
Ensembl chr10:86,367,596...86,391,728
|
|
G |
Ern1 |
endoplasmic reticulum to nucleus signaling 1 |
multiple interactions |
ISO |
orlistat affects the reaction [ERN1 protein affects the splicing of XBP1 mRNA] |
CTD |
PMID:17283163 |
|
NCBI chr10:94,588,555...94,682,072
Ensembl chr10:94,588,555...94,681,914
|
|
G |
Etv4 |
ETS variant transcription factor 4 |
increases expression |
ISO |
orlistat results in increased expression of ETV4 protein |
CTD |
PMID:15870086 |
|
NCBI chr10:89,685,058...89,700,300
Ensembl chr10:89,685,058...89,700,283
|
|
G |
Fabp1 |
fatty acid binding protein 1 |
decreases expression |
ISO |
Orlistat results in decreased expression of FABP1 protein |
CTD |
PMID:30667213 |
|
NCBI chr 4:99,063,181...99,066,957
Ensembl chr 4:99,063,181...99,066,954
|
|
G |
Fasn |
fatty acid synthase |
affects binding decreases expression decreases activity multiple interactions affects response to substance |
ISO |
orlistat analog binds to FASN protein Orlistat results in decreased expression of FASN protein orlistat results in decreased activity of FASN protein [orlistat results in decreased activity of FASN protein] which affects the abundance of Fatty Acids, Nonesterified; orlistat inhibits the reaction [FASN protein results in increased chemical synthesis of Palmitic Acid] orlistat analog results in decreased activity of FASN protein; orlistat results in decreased activity of FASN protein [orlistat results in decreased activity of FASN protein] which results in decreased abundance of Fatty Acids; [orlistat results in decreased activity of FASN protein] which results in decreased abundance of Phosphatidylcholines; [orlistat results in decreased activity of FASN protein] which results in decreased abundance of Phosphorylcholine; [orlistat results in decreased activity of FASN protein] which results in decreased chemical synthesis of Fatty Acids; [orlistat results in decreased activity of FASN protein] which results in decreased expression of SKP2 protein; orlistat binds to and results in decreased activity of FASN protein; orlistat inhibits the reaction [FASN protein results in decreased susceptibility to Doxorubicin]; orlistat inhibits the reaction [FASN protein results in decreased susceptibility to Mitoxantrone] FASN protein affects the susceptibility to orlistat |
CTD |
PMID:15026345 PMID:15138278 PMID:15870086 PMID:17012255 PMID:17618296 PMID:17847090 PMID:18281512 PMID:18710210 PMID:18723500 PMID:20148945 PMID:20577697 PMID:21213365 PMID:30667213 |
|
NCBI chr10:109,987,735...110,005,901
Ensembl chr10:109,987,735...110,005,901
|
|
G |
Gcg |
glucagon |
multiple interactions decreases secretion decreases expression |
ISO |
orlistat inhibits the reaction [Dietary Fats results in increased secretion of GCG protein]; orlistat inhibits the reaction [Olive Oil results in increased secretion of GCG protein] orlistat results in decreased secretion of GCG protein orlistat results in decreased expression of GCG protein |
CTD |
PMID:12915676 PMID:18647814 PMID:19837920 |
|
NCBI chr 3:48,442,635...48,451,650
Ensembl chr 3:48,442,635...48,451,650
|
|
G |
Ghrl |
ghrelin and obestatin prepropeptide |
multiple interactions |
ISO |
orlistat inhibits the reaction [Olive Oil results in decreased expression of GHRL protein]; orlistat inhibits the reaction [Triglycerides results in decreased secretion of GHRL protein] |
CTD |
PMID:15998659 PMID:17138722 |
|
NCBI chr 4:145,674,157...145,678,066
Ensembl chr 4:145,674,157...145,678,066
|
|
G |
Gip |
gastric inhibitory polypeptide |
decreases expression |
ISO |
orlistat results in decreased expression of GIP protein |
CTD |
PMID:12915676 |
|
NCBI chr10:83,835,080...83,848,399
Ensembl chr10:83,840,303...83,848,396
|
|
G |
Gpt |
glutamic--pyruvic transaminase |
multiple interactions |
EXP |
orlistat inhibits the reaction [[Corn Oil co-treated with (5'-(4-amino-7,7-dimethyl-2-trifluoromethyl-7H-pyrimido(4,5-b)(1,4)oxazin-6-yl)-2',3'-dihydrospiro(cyclohexane-1,1'-inden)-4-yl)acetic acid] results in increased activity of GPT protein] |
CTD |
PMID:29479035 |
|
NCBI chr 7:117,759,083...117,761,932
Ensembl chr 7:117,759,083...117,761,931
|
|
G |
Gpx1 |
glutathione peroxidase 1 |
multiple interactions |
EXP |
Orlistat inhibits the reaction [Dietary Fats results in decreased expression of GPX1 mRNA] |
CTD |
PMID:32450208 |
|
NCBI chr 8:117,117,430...117,118,528
Ensembl chr 8:117,117,430...117,118,522
|
|
G |
Gpx8 |
glutathione peroxidase 8 |
increases expression |
ISO |
orlistat results in increased expression of GPX8 mRNA |
CTD |
PMID:18796435 |
|
NCBI chr 2:44,903,337...44,907,046
Ensembl chr 2:44,903,337...44,907,030
|
|
G |
Gsr |
glutathione-disulfide reductase |
multiple interactions |
EXP |
Orlistat inhibits the reaction [Dietary Fats results in decreased expression of GSR protein] |
CTD |
PMID:32450208 |
|
NCBI chr16:62,197,617...62,239,987
Ensembl chr16:62,197,617...62,241,361
|
|
G |
Hba-a2 |
hemoglobin alpha, adult chain 2 |
decreases expression |
ISO |
orlistat results in decreased expression of HBA1 protein modified form |
CTD |
PMID:19207292 PMID:19461584 |
|
NCBI chr10:15,589,364...15,590,207
Ensembl chr10:15,589,364...15,590,220
|
|
G |
Hmgcr |
3-hydroxy-3-methylglutaryl-CoA reductase |
multiple interactions |
EXP |
orlistat inhibits the reaction [Dietary Fats results in increased expression of HMGCR protein] |
CTD |
PMID:25087745 |
|
NCBI chr 2:27,480,224...27,500,654
Ensembl chr 2:27,480,226...27,500,654
|
|
G |
Hspa5 |
heat shock protein family A (Hsp70) member 5 |
increases expression |
ISO |
orlistat results in increased expression of HSPA5 mRNA |
CTD |
PMID:17283163 |
|
NCBI chr 3:13,838,304...13,842,763
Ensembl chr 3:13,838,304...13,842,762
|
|
G |
Il10 |
interleukin 10 |
increases expression |
EXP |
Orlistat results in increased expression of IL10 mRNA |
CTD |
PMID:32450208 |
|
NCBI chr13:47,738,933...47,743,392
Ensembl chr13:47,739,526...47,743,392
|
|
G |
Il1b |
interleukin 1 beta |
multiple interactions |
EXP |
Orlistat inhibits the reaction [Dietary Fats results in increased expression of IL1B mRNA] |
CTD |
PMID:32450208 |
|
NCBI chr 3:121,876,256...121,882,637
Ensembl chr 3:121,876,263...121,882,726
|
|
G |
Il6 |
interleukin 6 |
multiple interactions |
ISO |
orlistat inhibits the reaction [Lipopolysaccharides results in increased expression of IL6 mRNA] |
CTD |
PMID:21088047 |
|
NCBI chr 4:3,043,231...3,047,807
Ensembl chr 4:3,043,231...3,047,807
|
|
G |
Ins2 |
insulin 2 |
decreases expression affects expression increases expression |
ISO |
orlistat results in decreased expression of INS protein orlistat affects the expression of INS protein orlistat results in increased expression of INS protein |
CTD |
PMID:10095983 PMID:11274935 PMID:12915676 |
|
NCBI chr 1:215,856,967...215,858,034
Ensembl chr 1:215,856,971...215,858,034
|
|
G |
Kdelr3 |
KDEL endoplasmic reticulum protein retention receptor 3 |
increases expression |
ISO |
orlistat results in increased expression of KDELR3 mRNA |
CTD |
PMID:18796435 |
|
NCBI chr 7:120,749,680...120,760,163
Ensembl chr 7:120,749,752...120,760,160
|
|
G |
Kdr |
kinase insert domain receptor |
decreases expression |
ISO |
orlistat results in decreased expression of KDR protein |
CTD |
PMID:17012255 |
|
NCBI chr14:34,727,677...34,787,127
Ensembl chr14:34,727,623...34,787,183
|
|
G |
Krt81 |
keratin 81 |
increases expression |
ISO |
orlistat results in increased expression of KRT81 mRNA |
CTD |
PMID:18796435 |
|
NCBI chr 7:143,107,901...143,113,006
Ensembl chr 7:143,107,901...143,112,960
|
|
G |
Lcat |
lecithin cholesterol acyltransferase |
multiple interactions |
EXP |
orlistat inhibits the reaction [Dietary Fats results in decreased expression of LCAT protein] |
CTD |
PMID:25087745 |
|
NCBI chr19:37,913,333...37,916,799
Ensembl chr19:37,913,336...37,916,813
|
|
G |
Lep |
leptin |
multiple interactions |
ISO EXP |
orlistat inhibits the reaction [Dietary Fats results in increased expression of LEP protein] |
CTD |
PMID:21332399 PMID:25087745 |
|
NCBI chr 4:56,337,695...56,351,818
Ensembl chr 4:56,337,695...56,351,818
|
|
G |
Lipf |
lipase F, gastric type |
decreases activity |
ISO |
orlistat results in decreased activity of LIPF protein |
CTD |
PMID:11408251 PMID:12381337 |
|
NCBI chr 1:252,284,464...252,302,811
Ensembl chr 1:252,284,464...252,302,811
|
|
G |
Lpl |
lipoprotein lipase |
decreases activity multiple interactions |
ISO EXP |
orlistat results in decreased activity of LPL protein [orlistat results in decreased activity of LPL protein] which affects the uptake of Triglycerides orlistat inhibits the reaction [[LPL protein results in increased hydrolysis of Triglycerides] which results in increased uptake of Triglycerides]; orlistat inhibits the reaction [LPL protein results in decreased activity of TNF protein]; orlistat inhibits the reaction [very low density lipoprotein triglyceride results in increased activity of LPL protein] orlistat inhibits the reaction [Dietary Fats results in decreased expression of LPL protein] |
CTD |
PMID:12388125 PMID:12573449 PMID:15910848 PMID:15994321 PMID:18698144 PMID:25087745 |
|
NCBI chr16:22,537,687...22,561,487
Ensembl chr16:22,537,056...22,561,496
|
|
G |
Napepld |
N-acyl phosphatidylethanolamine phospholipase D |
decreases activity |
EXP |
orlistat results in decreased activity of NAPEPLD protein |
CTD |
PMID:16466961 |
|
NCBI chr 4:9,965,323...10,004,650
Ensembl chr 4:9,966,891...10,002,247
|
|
G |
Nfe2l2 |
nuclear factor, erythroid 2-like 2 |
multiple interactions |
EXP |
Orlistat inhibits the reaction [Dietary Fats results in decreased expression of NFE2L2 mRNA] |
CTD |
PMID:32450208 |
|
NCBI chr 3:62,497,568...62,525,146
Ensembl chr 3:62,497,571...62,524,996
|
|
G |
Nos2 |
nitric oxide synthase 2 |
multiple interactions |
EXP |
Orlistat inhibits the reaction [Dietary Fats results in increased expression of NOS2 mRNA]; Orlistat inhibits the reaction [Dietary Fats results in increased expression of NOS2 protein] |
CTD |
PMID:32450208 |
|
NCBI chr10:66,188,290...66,221,621
Ensembl chr10:66,189,786...66,313,190
|
|
G |
Npy |
neuropeptide Y |
increases expression |
ISO |
orlistat results in increased expression of NPY protein |
CTD |
PMID:15962606 |
|
NCBI chr 4:79,557,856...79,565,059
Ensembl chr 4:79,557,854...79,565,097
|
|
G |
Nr1i2 |
nuclear receptor subfamily 1, group I, member 2 |
increases activity |
ISO |
orlistat results in increased activity of NR1I2 protein |
CTD |
PMID:20599501 |
|
NCBI chr11:65,022,100...65,058,546
Ensembl chr11:65,022,100...65,058,545
|
|
G |
Nr1i3 |
nuclear receptor subfamily 1, group I, member 3 |
multiple interactions |
ISO |
Orlistat binds to and results in increased activity of NR1I3 protein alternative form |
CTD |
PMID:31312845 |
|
NCBI chr13:89,585,072...89,591,278
Ensembl chr13:89,586,283...89,591,277
|
|
G |
Nts |
neurotensin |
multiple interactions |
ISO |
Orlistat inhibits the reaction [Fats results in increased secretion of NTS protein]; Orlistat inhibits the reaction [Olive Oil results in increased secretion of NTS protein] |
CTD |
PMID:18303078 |
|
NCBI chr 7:44,111,594...44,120,998
Ensembl chr 7:44,111,151...44,121,130
|
|
G |
Parp1 |
poly (ADP-ribose) polymerase 1 |
multiple interactions increases cleavage |
ISO |
[orlistat co-treated with Thapsigargin] results in increased cleavage of PARP1 protein orlistat results in increased cleavage of PARP1 protein |
CTD |
PMID:15870086 PMID:17283163 |
|
NCBI chr13:98,857,255...98,889,444
Ensembl chr13:98,857,177...98,889,716
|
|
G |
Pla2g7 |
phospholipase A2 group VII |
decreases activity multiple interactions |
ISO |
orlistat results in decreased activity of PLA2G7 protein [orlistat co-treated with Ezetimibe] results in decreased activity of PLA2G7 protein; [orlistat co-treated with Fenofibrate] results in decreased activity of PLA2G7 protein |
CTD |
PMID:16911813 PMID:18513463 PMID:18657971 |
|
NCBI chr 9:19,935,754...19,978,013
Ensembl chr 9:19,935,768...19,978,013
|
|
G |
Pnlip |
pancreatic lipase |
decreases secretion multiple interactions affects folding decreases activity |
ISO EXP |
orlistat results in decreased secretion of PNLIP protein [[orlistat results in decreased abundance of Fatty Acids, Nonesterified] which results in decreased secretion of CCK protein] which results in decreased secretion of PNLIP protein; orlistat inhibits the reaction [[PNLIP protein co-treated with CLPS protein] results in increased hydrolysis of Olive Oil] orlistat affects the folding of PNLIP protein orlistat inhibits the reaction [Taurocholic Acid results in increased activity of PNLIP protein] orlistat results in decreased activity of PNLIP protein |
CTD |
PMID:11408251 PMID:11668201 PMID:12381337 PMID:15158758 PMID:19346257 |
|
NCBI chr 1:279,798,187...279,811,372
Ensembl chr 1:279,798,187...279,811,372
|
|
G |
Pnliprp2 |
pancreatic lipase related protein 2 |
decreases activity |
ISO EXP |
orlistat results in decreased activity of PNLIPRP2 protein Orlistat results in decreased activity of PNLIPRP2 protein |
CTD |
PMID:9822688 PMID:17401110 |
|
NCBI chr 1:279,896,973...279,927,600
Ensembl chr 1:279,896,973...279,927,600
|
|
G |
Pon1 |
paraoxonase 1 |
increases activity |
ISO |
orlistat results in increased activity of PON1 protein |
CTD |
PMID:11820148 PMID:17134960 |
|
NCBI chr 4:30,249,749...30,276,297
Ensembl chr 4:30,249,742...30,276,372
|
|
G |
Ppt1 |
palmitoyl-protein thioesterase 1 |
decreases expression |
ISO |
Orlistat results in decreased expression of PPT1 protein |
CTD |
PMID:30667213 |
|
NCBI chr 5:140,538,260...140,558,163
Ensembl chr 5:140,538,260...140,558,162
|
|
G |
Ppy |
pancreatic polypeptide |
multiple interactions |
ISO |
orlistat inhibits the reaction [Triglycerides results in increased secretion of PPY protein] |
CTD |
PMID:15998659 |
|
NCBI chr10:90,041,582...90,043,316
Ensembl chr10:90,041,591...90,042,877
|
|
G |
Prkaa1 |
protein kinase AMP-activated catalytic subunit alpha 1 |
multiple interactions |
EXP ISO |
orlistat inhibits the reaction [Isoproterenol results in increased phosphorylation of PRKAA1 protein] orlistat inhibits the reaction [1-Methyl-3-isobutylxanthine results in increased phosphorylation of and results in increased activity of PRKAA1 protein]; orlistat inhibits the reaction [Isoproterenol results in increased phosphorylation of and results in increased activity of PRKAA1 protein] |
CTD |
PMID:18390901 PMID:19167487 |
|
NCBI chr 2:54,857,688...54,893,404
Ensembl chr 2:54,857,688...54,893,404
|
|
G |
Pyy |
peptide YY |
decreases secretion multiple interactions |
ISO |
orlistat results in decreased secretion of PYY protein orlistat inhibits the reaction [Olive Oil results in increased expression of PYY protein]; orlistat inhibits the reaction [Triglycerides results in increased secretion of PYY protein] |
CTD |
PMID:15998659 PMID:17138722 PMID:18647814 |
|
NCBI chr10:90,047,989...90,049,155
Ensembl chr10:90,047,993...90,049,112
|
|
G |
Rb1 |
RB transcriptional corepressor 1 |
decreases phosphorylation |
ISO |
orlistat results in decreased phosphorylation of RB1 protein |
CTD |
PMID:15138278 |
|
NCBI chr15:55,081,582...55,209,060
Ensembl chr15:55,083,140...55,209,342
|
|
G |
Rela |
RELA proto-oncogene, NF-kB subunit |
multiple interactions |
EXP |
Orlistat inhibits the reaction [Dietary Fats results in increased expression of RELA mRNA] |
CTD |
PMID:32450208 |
|
NCBI chr 1:220,992,770...221,003,249
Ensembl chr 1:220,992,770...221,003,249
|
|
G |
Sec24d |
SEC24 homolog D, COPII coat complex component |
increases expression |
ISO |
orlistat results in increased expression of SEC24D mRNA |
CTD |
PMID:18796435 |
|
NCBI chr 2:227,455,704...227,562,801
Ensembl chr 2:227,455,722...227,562,319
|
|
G |
Skp2 |
S-phase kinase associated protein 2 |
multiple interactions decreases expression |
ISO |
[orlistat results in decreased activity of FASN protein] which results in decreased expression of SKP2 protein orlistat results in decreased expression of SKP2 protein |
CTD |
PMID:15138278 |
|
NCBI chr 2:58,506,146...58,534,211
Ensembl chr 2:58,506,151...58,534,211
|
|
G |
Slc22a2 |
solute carrier family 22 member 2 |
multiple interactions |
ISO |
orlistat inhibits the reaction [SLC22A2 protein results in increased uptake of 4-(4-dimethylaminostyryl)-1-methylpyridinium] |
CTD |
PMID:21599003 |
|
NCBI chr 1:48,318,025...48,360,219
Ensembl chr 1:48,317,995...48,360,261
|
|
G |
Tnf |
tumor necrosis factor |
multiple interactions |
ISO EXP |
orlistat inhibits the reaction [LPL protein results in decreased activity of TNF protein] Orlistat inhibits the reaction [Dietary Fats results in increased expression of TNF mRNA] |
CTD |
PMID:15994321 PMID:32450208 |
|
NCBI chr20:5,189,382...5,192,000
Ensembl chr20:5,189,390...5,192,000
|
|
G |
Tnfsf10 |
TNF superfamily member 10 |
increases response to substance |
ISO |
orlistat results in increased susceptibility to TNFSF10 protein |
CTD |
PMID:18796435 PMID:21406729 |
|
NCBI chr 2:113,008,008...113,026,899
Ensembl chr 2:113,007,549...113,026,899
|
|
G |
Tp53 |
tumor protein p53 |
multiple interactions |
EXP |
Orlistat inhibits the reaction [Dietary Fats results in increased expression of TP53 mRNA] |
CTD |
PMID:32450208 |
|
NCBI chr10:56,186,299...56,198,449
Ensembl chr10:56,187,020...56,198,449
|
|
G |
Xbp1 |
X-box binding protein 1 |
multiple interactions |
ISO |
orlistat affects the reaction [ERN1 protein affects the splicing of XBP1 mRNA] |
CTD |
PMID:17283163 |
|
NCBI chr14:85,753,736...85,758,820
Ensembl chr14:85,753,760...85,758,145
|
|
|
G |
Nr1i2 |
nuclear receptor subfamily 1, group I, member 2 |
multiple interactions |
ISO |
triforine binds to and results in increased activity of NR1I2 protein |
CTD |
PMID:21115097 |
|
NCBI chr11:65,022,100...65,058,546
Ensembl chr11:65,022,100...65,058,545
|
|
|
G |
Aamdc |
adipogenesis associated, Mth938 domain containing |
increases expression |
ISO |
Vincristine results in increased expression of AAMDC mRNA |
CTD |
PMID:23649840 |
|
NCBI chr 1:162,519,513...162,549,211
Ensembl chr 1:162,519,521...162,533,893
|
|
G |
Abca1 |
ATP binding cassette subfamily A member 1 |
multiple interactions |
ISO |
[Vincristine results in decreased susceptibility to Vincristine] which results in increased expression of ABCA1 mRNA |
CTD |
PMID:19944135 |
|
NCBI chr 5:69,857,717...69,983,042
Ensembl chr 5:69,857,771...69,983,015
|
|
G |
Abca12 |
ATP binding cassette subfamily A member 12 |
increases expression multiple interactions |
ISO |
Vincristine results in increased expression of ABCA12 mRNA [Vincristine results in decreased susceptibility to Vincristine] which results in increased expression of ABCA12 mRNA |
CTD |
PMID:19944135 PMID:23649840 |
|
NCBI chr 9:78,521,477...78,693,421
Ensembl chr 9:78,522,464...78,693,028
|
|
G |
Abca4 |
ATP binding cassette subfamily A member 4 |
multiple interactions |
ISO |
[Vincristine results in decreased susceptibility to Vincristine] which results in increased expression of ABCA4 mRNA |
CTD |
PMID:19944135 |
|
NCBI chr 2:225,645,539...225,783,288
Ensembl chr 2:225,645,568...225,783,287
|
|
G |
Abca5 |
ATP binding cassette subfamily A member 5 |
multiple interactions |
ISO |
[Vincristine results in decreased susceptibility to Vincristine] which affects the expression of ABCA5 mRNA |
CTD |
PMID:19944135 |
|
NCBI chr10:98,573,226...98,645,028
Ensembl chr10:98,576,039...98,644,938
|
|
G |
Abca8 |
ATP binding cassette subfamily A member 8 |
multiple interactions |
ISO |
[Vincristine results in decreased susceptibility to Vincristine] which affects the expression of ABCA8 mRNA |
CTD |
PMID:19944135 |
|
NCBI chr10:98,236,919...98,308,288
Ensembl chr10:98,237,141...98,294,522
|
|
G |
Abcb1a |
ATP binding cassette subfamily B member 1A |
affects response to substance increases expression multiple interactions increases transport decreases uptake decreases response to substance affects uptake |
ISO EXP |
ABCB1 protein affects the susceptibility to Vincristine Vincristine results in increased expression of ABCB1A mRNA Vincristine results in increased expression of ABCB1 protein [Estradiol results in decreased expression of ABCB1 protein] which results in increased uptake of and results in increased susceptibility to Vincristine; [MGMT protein co-treated with ABCB1 protein] results in decreased susceptibility to Vincristine; [Paclitaxel results in increased expression of ABCB1] which results in decreased susceptibility to Vincristine; [Vincristine results in decreased susceptibility to Vincristine] which affects the expression of ABCB1 mRNA; [Vincristine results in increased activity of NR1I2 protein] which results in increased expression of ABCB1 mRNA; CEP 33779 inhibits the reaction [ABCB1 protein results in decreased susceptibility to Vincristine]; Cyclosporine inhibits the reaction [ABCB1 protein results in decreased susceptibility to Vincristine]; Fenofibrate inhibits the reaction [ABCB1 protein results in increased transport of Vincristine]; Flupenthixol analog inhibits the reaction [ABCB1 protein results in decreased susceptibility to Vincristine]; NR1I2 protein promotes the reaction [Vincristine results in increased expression of ABCB1 protein]; Verapamil inhibits the reaction [ABCB1 protein results in decreased susceptibility to Vincristine]; zosuquidar trihydrochloride inhibits the reaction [ABCB1 protein results in decreased susceptibility to Vincristine] ABCB1 protein results in decreased uptake of Vincristine ABCB1 protein affects the uptake of Vincristine |
CTD |
PMID:7905786 PMID:10617675 PMID:11792417 PMID:11934808 PMID:15239124 PMID:15645438 PMID:16038730 PMID:16221289 PMID:16316932 PMID:16925584 PMID:19944135 PMID:20041327 PMID:21344920 PMID:21833476 PMID:25058526 |
|
NCBI chr 4:22,339,829...22,517,642
Ensembl chr 4:22,133,521...22,425,515
|
|
G |
Abcb1b |
ATP-binding cassette, subfamily B (MDR/TAP), member 1B |
affects uptake |
EXP |
ABCB1B protein affects the uptake of Vincristine |
CTD |
PMID:11934808 |
|
NCBI chr 4:22,225,123...22,307,577
Ensembl chr 4:22,133,521...22,425,515
|
|
G |
Abcb4 |
ATP binding cassette subfamily B member 4 |
multiple interactions |
ISO |
[Vincristine results in decreased susceptibility to Vincristine] which affects the expression of ABCB4 mRNA |
CTD |
PMID:19944135 |
|
NCBI chr 4:22,133,984...22,192,687
Ensembl chr 4:22,133,521...22,425,515
|
|
G |
Abcb6 |
ATP binding cassette subfamily B member 6 |
multiple interactions |
ISO |
[Vincristine results in decreased susceptibility to Vincristine] which affects the expression of ABCB6 mRNA |
CTD |
PMID:19944135 |
|
NCBI chr 9:82,373,950...82,382,228
Ensembl chr 9:82,373,946...82,382,272
|
|
G |
Abcc1 |
ATP binding cassette subfamily C member 1 |
increases response to substance increases expression multiple interactions decreases response to substance affects transport affects response to substance affects export |
ISO EXP |
ABCC1 gene SNP results in increased susceptibility to Vincristine Vincristine results in increased expression of ABCC1 mRNA [Genistein results in decreased activity of ABCC1 protein] which results in increased uptake of Vincristine; [Indomethacin results in decreased activity of ABCC1 protein] which results in increased uptake of Vincristine; [Probenecid results in decreased activity of ABCC1 protein] which results in increased uptake of Vincristine; [Sulfinpyrazone results in decreased activity of ABCC1 protein] which results in increased uptake of Vincristine; [verlukast results in decreased activity of ABCC1 protein] which results in increased uptake of Vincristine ABCC1 protein results in decreased susceptibility to Vincristine; ABCC1 results in decreased susceptibility to Vincristine [MYCN protein affects the expression of ABCC1 mRNA] which affects the susceptibility to Vincristine; [Vincristine results in decreased susceptibility to Vincristine] which results in increased expression of ABCC1 mRNA; ABCC1 protein affects the export of and results in decreased susceptibility to Vincristine; Buthionine Sulfoximine inhibits the reaction [ABCC1 protein results in decreased susceptibility to Vincristine]; Cyclosporine inhibits the reaction [ABCC1 protein results in decreased susceptibility to Vincristine]; Doxorubicin inhibits the reaction [ABCC1 protein affects the transport of Vincristine]; GSTP1 protein promotes the reaction [ABCC1 protein results in decreased susceptibility to Vincristine]; myricetin inhibits the reaction [ABCC1 protein affects the export of and results in decreased susceptibility to Vincristine]; myricetin inhibits the reaction [ABCC1 protein affects the export of Vincristine]; myricetin inhibits the reaction [ABCC1 protein results in decreased susceptibility to Vincristine]; Quercetin promotes the reaction [ABCC1 protein results in decreased susceptibility to Vincristine]; Verapamil inhibits the reaction [ABCC1 protein results in decreased susceptibility to Vincristine]; verlukast inhibits the reaction [ABCC1 protein results in decreased susceptibility to Vincristine]; Vincristine inhibits the reaction [ABCC1 protein affects the transport of fluorexon]; Vincristine inhibits the reaction [Glutathione promotes the reaction [ABCC1 results in increased transport of methylarsine analog]]; zafirlukast inhibits the reaction [ABCC1 protein results in decreased susceptibility to Vincristine] ABCC1 protein affects the transport of Vincristine; ABCC1 protein mutant form affects the transport of Vincristine ABCC1 protein affects the susceptibility to Vincristine |
CTD |
PMID:7954421 PMID:8649356 PMID:8968083 PMID:10348353 PMID:10685512 PMID:10900222 PMID:11278867 PMID:11306701 PMID:11778547 PMID:12067707 PMID:12731862 PMID:12893836 PMID:15044619 PMID:15180633 PMID:15581632 PMID:15896345 PMID:16042792 PMID:16221289 PMID:19232821 PMID:19944135 PMID:20864405 PMID:21918036 PMID:22095822 |
|
NCBI chr10:549,537...672,235
Ensembl chr10:549,883...672,196
|
|
G |
Abcc10 |
ATP binding cassette subfamily C member 10 |
multiple interactions decreases response to substance |
ISO |
4-methyl-N-(3-(4-methylimidazol-1-yl)-5-(trifluoromethyl)phenyl)-3-((4-pyridin-3-ylpyrimidin-2-yl)amino)benzamide inhibits the reaction [ABCC10 protein results in decreased susceptibility to Vincristine]; Imatinib Mesylate inhibits the reaction [ABCC10 protein results in decreased susceptibility to Vincristine] |
CTD |
PMID:19841739 |
|
NCBI chr 9:17,041,351...17,061,263
Ensembl chr 9:17,041,389...17,063,780
|
|
G |
Abcc2 |
ATP binding cassette subfamily C member 2 |
affects export multiple interactions decreases response to substance |
ISO |
ABCC2 protein affects the export of Vincristine [Vincristine results in decreased susceptibility to Vincristine] which results in increased expression of ABCC2 mRNA; ABCC2 protein affects the export of and results in decreased susceptibility to Vincristine; myricetin inhibits the reaction [ABCC2 protein affects the export of and results in decreased susceptibility to Vincristine]; myricetin inhibits the reaction [ABCC2 protein affects the export of Vincristine]; myricetin inhibits the reaction [ABCC2 protein results in decreased susceptibility to Vincristine] |
CTD |
PMID:15896345 PMID:19944135 PMID:22095822 |
|
NCBI chr 1:263,554,426...263,612,556
Ensembl chr 1:263,554,453...263,613,252
|
|
G |
Abcc3 |
ATP binding cassette subfamily C member 3 |
multiple interactions |
ISO |
[Vincristine results in decreased susceptibility to Vincristine] which results in increased expression of ABCC3 mRNA |
CTD |
PMID:19944135 |
|
NCBI chr10:82,047,308...82,116,928
Ensembl chr10:82,047,863...82,117,109
|
|
G |
Abcc4 |
ATP binding cassette subfamily C member 4 |
multiple interactions |
ISO |
[Vincristine results in decreased susceptibility to Vincristine] which results in decreased expression of ABCC4 mRNA |
CTD |
PMID:19944135 |
|
NCBI chr15:103,695,415...103,927,980
Ensembl chr15:103,696,557...103,927,592
|
|
G |
Abcc5 |
ATP binding cassette subfamily C member 5 |
multiple interactions |
ISO |
[Vincristine results in decreased susceptibility to Vincristine] which affects the expression of ABCC5 mRNA |
CTD |
PMID:19944135 |
|
NCBI chr11:84,395,982...84,490,215
Ensembl chr11:84,396,033...84,490,211
|
|
G |
Abcc6 |
ATP binding cassette subfamily C member 6 |
multiple interactions |
ISO |
[Vincristine results in decreased susceptibility to Vincristine] which results in decreased expression of ABCC6 mRNA |
CTD |
PMID:19944135 |
|
NCBI chr 1:101,954,786...102,013,252
Ensembl chr 1:101,959,540...102,013,243
|
|
G |
Abcd3 |
ATP binding cassette subfamily D member 3 |
multiple interactions |
ISO |
[Vincristine results in decreased susceptibility to Vincristine] which results in decreased expression of ABCD3 mRNA |
CTD |
PMID:19944135 |
|
NCBI chr 2:225,335,708...225,389,120
Ensembl chr 2:225,335,718...225,389,120
|
|
G |
Abcg1 |
ATP binding cassette subfamily G member 1 |
multiple interactions |
ISO |
[Vincristine results in decreased susceptibility to Vincristine] which results in decreased expression of ABCG1 mRNA |
CTD |
PMID:19944135 |
|
NCBI chr20:9,743,269...9,842,735
Ensembl chr20:9,743,269...9,840,489
|
|
G |
Abcg2 |
ATP binding cassette subfamily G member 2 |
multiple interactions |
ISO |
[Paclitaxel results in decreased expression of ABCG2] which results in decreased susceptibility to Vincristine; [Vincristine results in decreased susceptibility to Vincristine] which results in increased expression of ABCG2 mRNA |
CTD |
PMID:19944135 PMID:21833476 |
|
NCBI chr 4:88,765,441...88,890,268
Ensembl chr 4:88,832,178...88,890,621
|
|
G |
Abcg4 |
ATP binding cassette subfamily G member 4 |
multiple interactions |
ISO |
[Vincristine results in decreased susceptibility to Vincristine] which results in decreased expression of ABCG4 mRNA |
CTD |
PMID:19944135 |
|
NCBI chr 8:48,604,915...48,626,219
Ensembl chr 8:48,606,403...48,619,592
|
|
G |
Abhd11 |
abhydrolase domain containing 11 |
decreases expression |
ISO |
Vincristine results in decreased expression of ABHD11 mRNA |
CTD |
PMID:23649840 |
|
NCBI chr12:24,722,277...24,725,760
Ensembl chr12:24,722,283...24,724,997
|
|
G |
Abtb2 |
ankyrin repeat and BTB domain containing 2 |
increases expression |
ISO |
Vincristine results in increased expression of ABTB2 mRNA |
CTD |
PMID:23649840 |
|
NCBI chr 3:93,494,706...93,648,750
Ensembl chr 3:93,495,106...93,647,721
|
|
G |
Acad9 |
acyl-CoA dehydrogenase family, member 9 |
decreases expression |
ISO |
Vincristine results in decreased expression of ACAD9 mRNA |
CTD |
PMID:23649840 |
|
NCBI chr 2:122,782,051...122,806,166
Ensembl chr 2:122,782,060...122,805,768
|
|
G |
Ache |
acetylcholinesterase |
decreases expression multiple interactions |
EXP |
Vincristine results in decreased expression of ACHE protein xaliproden inhibits the reaction [Vincristine results in decreased expression of ACHE protein] |
CTD |
PMID:8413926 |
|
NCBI chr12:22,472,358...22,477,052
Ensembl chr12:22,472,358...22,478,753
|
|
G |
Ackr3 |
atypical chemokine receptor 3 |
increases expression |
ISO |
Vincristine results in increased expression of ACKR3 mRNA |
CTD |
PMID:23649840 |
|
NCBI chr 9:97,355,881...97,367,455
Ensembl chr 9:97,355,924...97,367,445
|
|
G |
Actr2 |
actin related protein 2 |
increases expression |
ISO |
Vincristine results in increased expression of ACTR2 mRNA |
CTD |
PMID:23649840 |
|
NCBI chr14:104,338,486...104,375,840
Ensembl chr14:104,340,434...104,375,649
|
|
G |
Adat2 |
adenosine deaminase, tRNA-specific 2 |
decreases expression |
ISO |
Vincristine results in decreased expression of ADAT2 mRNA |
CTD |
PMID:23649840 |
|
NCBI chr 1:7,726,447...7,743,112
Ensembl chr 1:7,726,529...7,742,484
|
|
G |
Adgrf4 |
adhesion G protein-coupled receptor F4 |
increases expression |
ISO |
Vincristine results in increased expression of ADGRF4 mRNA |
CTD |
PMID:23649840 |
|
NCBI chr 9:20,951,249...20,982,493
Ensembl chr 9:20,951,260...20,982,487
|
|
G |
Adrb1 |
adrenoceptor beta 1 |
decreases expression |
ISO |
Vincristine results in decreased expression of ADRB1 mRNA |
CTD |
PMID:23649840 |
|
NCBI chr 1:277,537,585...277,538,985
Ensembl chr 1:277,537,585...277,538,985
|
|
G |
Adrb2 |
adrenoceptor beta 2 |
increases response to substance |
ISO |
ADRB2 gene SNP results in increased susceptibility to Vincristine |
CTD |
PMID:21245421 |
|
NCBI chr18:57,513,792...57,515,834
Ensembl chr18:57,513,793...57,515,834
|
|
G |
Agbl3 |
AGBL carboxypeptidase 3 |
decreases expression |
ISO |
Vincristine results in decreased expression of AGBL3 mRNA |
CTD |
PMID:23649840 |
|
NCBI chr 4:62,293,158...62,377,740
Ensembl chr 4:62,299,044...62,376,533
|
|
G |
Ahsa2 |
activator of HSP90 ATPase homolog 2 |
decreases expression |
ISO |
Vincristine results in decreased expression of AHSA2P mRNA |
CTD |
PMID:23649840 |
|
NCBI chr14:108,262,795...108,274,000
Ensembl chr14:108,265,207...108,273,938
|
|
G |
Aim2 |
absent in melanoma 2 |
increases expression |
ISO |
Vincristine results in increased expression of AIM2 mRNA |
CTD |
PMID:23649840 |
|
NCBI chr13:91,919,834...91,963,080
Ensembl chr13:91,954,138...91,962,588
|
|
G |
Ak1 |
adenylate kinase 1 |
decreases expression |
EXP |
Vincristine results in decreased expression of AK1 mRNA |
CTD |
PMID:20624997 |
|
NCBI chr 3:11,652,143...11,659,135
|
|
G |
Ak3 |
adenylate kinase 3 |
decreases expression |
ISO |
Vincristine results in decreased expression of AK3 mRNA |
CTD |
PMID:23649840 |
|
NCBI chr 1:247,144,486...247,169,690
Ensembl chr 1:247,144,491...247,169,693
|
|
G |
Akap10 |
A-kinase anchoring protein 10 |
increases expression |
ISO |
Vincristine results in increased expression of AKAP10 mRNA |
CTD |
PMID:23649840 |
|
NCBI chr10:48,150,902...48,210,074
Ensembl chr10:48,150,902...48,210,074
|
|
G |
Akt1 |
AKT serine/threonine kinase 1 |
multiple interactions |
ISO |
Vincristine inhibits the reaction [Doxorubicin results in decreased phosphorylation of AKT1 protein] Vincristine promotes the reaction [NVP ADW742 inhibits the reaction [IGF1 protein results in increased phosphorylation of AKT1 protein]] |
CTD |
PMID:16740780 PMID:18590705 |
|
NCBI chr 6:137,218,398...137,239,970
Ensembl chr 6:137,218,376...137,236,258
|
|
G |
Aldoc |
aldolase, fructose-bisphosphate C |
decreases expression |
ISO |
Vincristine results in decreased expression of ALDOC mRNA |
CTD |
PMID:23649840 |
|
NCBI chr10:65,586,504...65,590,093
Ensembl chr10:65,586,504...65,590,126
|
|
G |
Alms1 |
ALMS1, centrosome and basal body associated protein |
decreases expression |
ISO |
Vincristine results in decreased expression of ALMS1 mRNA |
CTD |
PMID:23649840 |
|
NCBI chr 4:117,371,544...117,472,310
Ensembl chr 4:117,371,659...117,472,198
|
|
G |
Alpk2 |
alpha-kinase 2 |
increases expression |
ISO |
Vincristine results in increased expression of ALPK2 mRNA |
CTD |
PMID:23649840 |
|
NCBI chr18:60,960,009...61,072,116
Ensembl chr18:60,960,662...61,057,365
|
|
G |
Amh |
anti-Mullerian hormone |
decreases secretion |
ISO |
Vincristine results in decreased secretion of AMH protein |
CTD |
PMID:30657998 |
|
NCBI chr 7:11,775,155...11,777,503
Ensembl chr 7:11,775,155...11,777,503
|
|
G |
Anapc5 |
anaphase-promoting complex subunit 5 |
increases expression |
ISO |
Vincristine results in increased expression of ANAPC5 mRNA |
CTD |
PMID:23649840 |
|
NCBI chr12:39,209,134...39,242,696
Ensembl chr12:39,209,129...39,242,690
|
|
G |
Ankdd1a |
ankyrin repeat and death domain containing 1A |
decreases expression |
ISO |
Vincristine results in decreased expression of ANKDD1A mRNA |
CTD |
PMID:23649840 |
|
NCBI chr 8:71,034,630...71,057,265
Ensembl chr 8:71,035,309...71,055,969
|
|
G |
Ankhd1 |
ankyrin repeat and KH domain containing 1 |
increases expression |
ISO |
Vincristine results in increased expression of ANKHD1 mRNA |
CTD |
PMID:23649840 |
|
NCBI chr18:29,386,906...29,485,611
Ensembl chr18:29,386,809...29,492,718
|
|
G |
Ankra2 |
ankyrin repeat family A member 2 |
increases expression |
ISO |
Vincristine results in increased expression of ANKRA2 mRNA |
CTD |
PMID:23649840 |
|
NCBI chr X:82,407,601...82,418,229
Ensembl chr X:82,407,598...82,418,425
|
|
G |
Ankrd13c |
ankyrin repeat domain 13C |
decreases expression |
ISO |
Vincristine results in decreased expression of ANKRD13C mRNA |
CTD |
PMID:23649840 |
|
NCBI chr 2:264,785,379...264,833,283
Ensembl chr 2:264,786,242...264,833,283
|
|
G |
Ankrd33b |
ankyrin repeat domain 33B |
increases expression |
ISO |
Vincristine results in increased expression of ANKRD33B mRNA |
CTD |
PMID:23649840 |
|
NCBI chr 2:84,361,061...84,436,912
Ensembl chr 2:84,361,061...84,437,084
|
|
G |
Ankrd37 |
ankyrin repeat domain 37 |
decreases expression |
ISO |
Vincristine results in decreased expression of ANKRD37 mRNA |
CTD |
PMID:23649840 |
|
NCBI chr16:49,463,016...49,465,905
Ensembl chr16:49,462,889...49,465,888
|
|
G |
Anp32e |
acidic nuclear phosphoprotein 32 family member E |
decreases expression |
ISO |
Vincristine results in decreased expression of ANP32E mRNA |
CTD |
PMID:23649840 |
|
NCBI chr 2:198,040,573...198,057,005
Ensembl chr 2:198,040,536...198,057,003
|
|
G |
Anxa1 |
annexin A1 |
increases expression |
ISO |
Vincristine results in increased expression of ANXA1 mRNA |
CTD |
PMID:23649840 |
|
NCBI chr 1:237,893,983...237,910,002
Ensembl chr 1:237,893,966...237,910,012
|
|
G |
Anxa2 |
annexin A2 |
increases expression |
ISO |
Vincristine results in increased expression of ANXA2 mRNA |
CTD |
PMID:23649840 |
|
NCBI chr 8:75,687,134...75,723,589
Ensembl chr 8:75,687,100...75,723,594
|
|
G |
Ap1s2 |
adaptor related protein complex 1 subunit sigma 2 |
decreases expression |
ISO |
Vincristine results in decreased expression of AP1S2 mRNA |
CTD |
PMID:23649840 |
|
NCBI chr X:32,329,883...32,376,301
Ensembl chr X:32,329,598...32,355,307
|
|
G |
Apex2 |
apurinic/apyrimidinic endodeoxyribonuclease 2 |
decreases expression |
ISO |
Vincristine results in decreased expression of APEX2 mRNA |
CTD |
PMID:23649840 |
|
NCBI chr X:23,146,085...23,166,676
Ensembl chr X:23,146,085...23,166,675
|
|
G |
Apln |
apelin |
decreases expression |
EXP |
Vincristine results in decreased expression of APLN mRNA |
CTD |
PMID:20624997 |
|
NCBI chr X:134,856,719...134,866,210
Ensembl chr X:134,856,726...134,866,210
|
|
G |
Apod |
apolipoprotein D |
increases expression |
ISO |
Vincristine results in increased expression of APOD mRNA |
CTD |
PMID:23649840 |
|
NCBI chr11:72,705,204...72,726,263
Ensembl chr11:72,705,129...72,726,301
|
|
G |
Apold1 |
apolipoprotein L domain containing 1 |
increases expression |
ISO |
Vincristine results in increased expression of APOLD1 mRNA |
CTD |
PMID:23649840 |
|
NCBI chr 4:168,752,142...168,755,024
Ensembl chr 4:168,752,133...168,755,023
|
|
G |
Aqp9 |
aquaporin 9 |
increases expression |
ISO |
Vincristine results in increased expression of AQP9 mRNA |
CTD |
PMID:23649840 |
|
NCBI chr 8:77,559,621...77,599,781
Ensembl chr 8:77,559,624...77,599,781
|
|
G |
Arap2 |
ArfGAP with RhoGAP domain, ankyrin repeat and PH domain 2 |
decreases expression |
ISO |
Vincristine results in decreased expression of ARAP2 mRNA |
CTD |
PMID:23649840 |
|
NCBI chr14:48,726,033...48,922,809
Ensembl chr14:48,726,045...48,922,983
|
|
G |
Arf1 |
ADP-ribosylation factor 1 |
increases expression |
ISO |
Vincristine results in increased expression of ARF1 mRNA |
CTD |
PMID:23649840 |
|
NCBI chr10:45,562,700...45,579,214
Ensembl chr10:45,563,547...45,579,029
|
|
G |
Arhgap15 |
Rho GTPase activating protein 15 |
increases expression |
ISO |
Vincristine results in increased expression of ARHGAP15 mRNA |
CTD |
PMID:23649840 |
|
NCBI chr 3:28,626,987...29,236,225
Ensembl chr 3:28,627,084...29,236,219
|
|
G |
Arhgap18 |
Rho GTPase activating protein 18 |
decreases expression |
ISO |
Vincristine results in decreased expression of ARHGAP18 mRNA |
CTD |
PMID:23649840 |
|
NCBI chr 1:19,227,115...19,463,139
Ensembl chr 1:19,227,121...19,376,301
|
|
G |
Arhgap5 |
Rho GTPase activating protein 5 |
decreases expression |
ISO |
Vincristine results in decreased expression of ARHGAP5 mRNA |
CTD |
PMID:23649840 |
|
NCBI chr 6:73,345,129...73,408,304
Ensembl chr 6:73,345,392...73,405,880
|
|
G |
Arhgef6 |
Rac/Cdc42 guanine nucleotide exchange factor 6 |
increases expression |
ISO |
Vincristine results in increased expression of ARHGEF6 mRNA |
CTD |
PMID:23649840 |
|
NCBI chr X:159,722,031...159,841,344
Ensembl chr X:159,723,866...159,841,072
|
|
G |
Arhgef7 |
Rho guanine nucleotide exchange factor 7 |
increases expression |
ISO |
Vincristine results in increased expression of ARHGEF7 mRNA |
CTD |
PMID:23649840 |
|
NCBI chr16:83,006,732...83,117,065
Ensembl chr16:83,006,718...83,132,785
|
|
G |
Arid2 |
AT-rich interaction domain 2 |
increases expression |
ISO |
Vincristine results in increased expression of ARID2 mRNA |
CTD |
PMID:23649840 |
|
NCBI chr 7:137,680,564...137,798,329
Ensembl chr 7:137,680,530...137,795,655
|
|
G |
Arid4b |
AT-rich interaction domain 4B |
increases expression |
ISO |
Vincristine results in increased expression of ARID4B mRNA |
CTD |
PMID:23649840 |
|
NCBI chr17:53,831,353...53,955,897
Ensembl chr17:53,833,023...53,915,076
|
|
G |
Arl5a |
ADP-ribosylation factor like GTPase 5A |
decreases expression |
ISO |
Vincristine results in decreased expression of ARL5A mRNA |
CTD |
PMID:23649840 |
|
NCBI chr 3:37,922,544...37,947,434
Ensembl chr 3:37,924,793...37,947,283
|
|
G |
Arl5b |
ADP-ribosylation factor like GTPase 5B |
increases expression |
ISO |
Vincristine results in increased expression of ARL5B mRNA |
CTD |
PMID:23649840 |
|
NCBI chr17:82,065,893...82,092,693
Ensembl chr17:82,065,937...82,091,362
|
|
G |
Arl6ip1 |
ADP-ribosylation factor like GTPase 6 interacting protein 1 |
decreases expression |
ISO |
Vincristine results in decreased expression of ARL6IP1 mRNA |
CTD |
PMID:23649840 |
|
NCBI chr 1:187,770,160...187,779,675
Ensembl chr 1:187,770,160...187,779,675
|
|
G |
Armc8 |
armadillo repeat containing 8 |
decreases expression |
ISO |
Vincristine results in decreased expression of ARMC8 mRNA |
CTD |
PMID:23649840 |
|
NCBI chr 8:107,723,359...107,819,208
Ensembl chr 8:107,723,359...107,819,050
|
|
G |
Aspm |
assembly factor for spindle microtubules |
increases expression |
ISO |
Vincristine results in increased expression of ASPM mRNA |
CTD |
PMID:17374387 |
|
NCBI chr13:56,546,021...56,591,793
Ensembl chr13:56,546,021...56,591,793
|
|
G |
Asxl1 |
ASXL transcriptional regulator 1 |
increases expression |
ISO |
Vincristine results in increased expression of ASXL1 mRNA |
CTD |
PMID:23649840 |
|
NCBI chr 3:148,832,231...148,902,356
Ensembl chr 3:148,837,814...148,900,452
|
|
G |
Atad2 |
ATPase family, AAA domain containing 2 |
decreases expression |
ISO |
Vincristine results in decreased expression of ATAD2 mRNA |
CTD |
PMID:23649840 |
|
NCBI chr 7:97,984,754...98,027,379
Ensembl chr 7:97,984,862...98,026,052
|
|
G |
Atf3 |
activating transcription factor 3 |
increases expression |
ISO |
Vincristine results in increased expression of ATF3 mRNA |
CTD |
PMID:23649840 |
|
NCBI chr13:109,817,892...109,849,632
Ensembl chr13:109,817,728...109,849,632
|
|
G |
Atf5 |
activating transcription factor 5 |
increases expression |
ISO |
Vincristine results in increased expression of ATF5 mRNA |
CTD |
PMID:23649840 |
|
NCBI chr 1:100,807,821...100,812,410
Ensembl chr 1:100,808,241...100,810,522
|
|
G |
Atp2b4 |
ATPase plasma membrane Ca2+ transporting 4 |
increases expression |
ISO |
Vincristine results in increased expression of ATP2B4 mRNA |
CTD |
PMID:23649840 |
|
NCBI chr13:50,091,644...50,153,808
Ensembl chr13:50,091,430...50,153,823
|
|
G |
Atp5f1c |
ATP synthase F1 subunit gamma |
decreases expression |
ISO |
Vincristine results in decreased expression of ATP5F1C mRNA |
CTD |
PMID:23649840 |
|
NCBI chr17:72,209,321...72,231,562
Ensembl chr17:72,209,373...72,394,271
|
|
G |
Atp6v0e1 |
ATPase H+ transporting V0 subunit e1 |
increases expression |
ISO |
Vincristine results in increased expression of ATP6V0E1 mRNA |
CTD |
PMID:23649840 |
|
NCBI chr10:16,769,857...16,792,930
Ensembl chr10:16,769,666...16,792,909
|
|
G |
Atp7a |
ATPase copper transporting alpha |
decreases response to substance |
ISO |
ATP7A protein results in decreased susceptibility to Vincristine |
CTD |
PMID:17510416 |
|
NCBI chr X:77,076,085...77,193,644
Ensembl chr X:77,076,106...77,193,644
|
|
G |
Atp8a1 |
ATPase phospholipid transporting 8A1 |
decreases expression |
ISO |
Vincristine results in decreased expression of ATP8A1 mRNA |
CTD |
PMID:23649840 |
|
NCBI chr14:41,972,398...42,210,555
Ensembl chr14:42,015,347...42,206,311
|
|
G |
Aurka |
aurora kinase A |
increases response to substance increases expression |
ISO |
AURKA gene SNP results in increased susceptibility to Vincristine Vincristine results in increased expression of AURKA mRNA |
CTD |
PMID:17374387 PMID:20864405 |
|
NCBI chr 3:170,364,177...170,380,278
Ensembl chr 3:170,364,181...170,378,210
|
|
G |
Aurkb |
aurora kinase B |
decreases expression |
ISO |
Vincristine results in decreased expression of AURKB mRNA |
CTD |
PMID:23649840 |
|
NCBI chr10:55,625,860...55,632,399
Ensembl chr10:55,626,741...55,634,991
|
|
G |
Avp |
arginine vasopressin |
increases expression |
ISO |
Vincristine results in increased expression of AVP protein |
CTD |
PMID:4356234 |
|
NCBI chr 3:123,117,482...123,119,460
Ensembl chr 3:123,117,492...123,119,460
|
|
G |
B3galt6 |
Beta-1,3-galactosyltransferase 6 |
decreases expression |
ISO |
Vincristine results in decreased expression of B3GALT6 mRNA |
CTD |
PMID:23649840 |
|
NCBI chr 5:173,423,475...173,425,611
Ensembl chr 5:173,423,475...173,425,611
|
|
G |
B3gnt5 |
UDP-GlcNAc:betaGal beta-1,3-N-acetylglucosaminyltransferase 5 |
increases expression |
ISO |
Vincristine results in increased expression of B3GNT5 mRNA |
CTD |
PMID:23649840 |
|
NCBI chr11:84,919,055...84,931,160
Ensembl chr11:84,919,066...84,931,160
|
|
G |
Bak1 |
BCL2-antagonist/killer 1 |
affects response to substance |
ISO |
BAK1 protein affects the susceptibility to Vincristine |
CTD |
PMID:22178383 |
|
NCBI chr20:5,609,620...5,618,899
Ensembl chr20:5,609,625...5,618,260
|
|
G |
Bambi |
BMP and activin membrane-bound inhibitor |
increases expression |
ISO |
Vincristine results in increased expression of BAMBI mRNA |
CTD |
PMID:23649840 |
|
NCBI chr17:56,905,419...56,909,675
Ensembl chr17:56,905,112...56,909,992
|
|
G |
Bard1 |
BRCA1 associated RING domain 1 |
decreases expression |
ISO |
Vincristine results in decreased expression of BARD1 mRNA |
CTD |
PMID:23649840 |
|
NCBI chr 9:78,297,723...78,368,777
Ensembl chr 9:78,294,834...78,369,031
|
|
G |
Basp1 |
brain abundant, membrane attached signal protein 1 |
increases expression |
ISO |
Vincristine results in increased expression of BASP1 mRNA |
CTD |
PMID:23649840 |
|
NCBI chr 2:77,586,424...77,632,626
Ensembl chr 2:77,586,424...77,632,628
|
|
G |
Batf |
basic leucine zipper ATF-like transcription factor |
increases expression |
ISO |
Vincristine results in increased expression of BATF mRNA |
CTD |
PMID:23649840 |
|
NCBI chr 6:109,562,415...109,584,541
Ensembl chr 6:109,562,587...109,584,545
|
|
G |
Bax |
BCL2 associated X, apoptosis regulator |
decreases expression affects response to substance multiple interactions |
ISO |
Vincristine results in decreased expression of BAX mRNA BAX protein affects the susceptibility to Vincristine [Doxorubicin co-treated with Vincristine co-treated with Etoposide co-treated with Mitotane] results in decreased expression of BAX protein; Vincristine results in increased cleavage of and results in increased expression of BAX protein |
CTD |
PMID:9815696 PMID:15131059 PMID:16001973 PMID:22178383 |
|
NCBI chr 1:101,451,801...101,457,207
Ensembl chr 1:101,451,802...101,457,207
|
|
G |
Bcat1 |
branched chain amino acid transaminase 1 |
increases expression |
ISO |
Vincristine results in increased expression of BCAT1 mRNA |
CTD |
PMID:23649840 |
|
NCBI chr 4:179,259,305...179,340,021
Ensembl chr 4:179,259,308...179,339,795
|
|
G |
Bcl2 |
BCL2, apoptosis regulator |
decreases response to substance increases phosphorylation multiple interactions |
ISO |
BCL2 protein results in decreased susceptibility to Vincristine Vincristine results in increased phosphorylation of BCL2 protein [Doxorubicin co-treated with Dexamethasone co-treated with Vincristine co-treated with Cytarabine co-treated with Mercaptopurine co-treated with Methotrexate co-treated with Cyclophosphamide co-treated with Enzymes and Coenzymes] results in increased expression of BCL2 protein; [Doxorubicin co-treated with Vincristine co-treated with Etoposide co-treated with Mitotane] results in decreased expression of BCL2 protein; [MIR497 results in decreased expression of BCL2 protein] which results in increased susceptibility to Vincristine; TYMP inhibits the reaction [Vincristine results in increased phosphorylation of BCL2 protein] |
CTD |
PMID:9815696 PMID:15907805 PMID:20162574 PMID:21182165 PMID:21258880 |
|
NCBI chr13:26,605,426...26,769,374
Ensembl chr13:26,605,426...26,769,374
|
|
G |
Bcl2a1 |
BCL2-related protein A1 |
increases expression |
ISO |
Vincristine results in increased expression of BCL2A1 mRNA |
CTD |
PMID:23649840 |
|
NCBI chr 8:96,551,424...96,559,527
Ensembl chr 8:96,551,245...96,559,483
|
|
G |
Bcl2l1 |
Bcl2-like 1 |
increases expression affects response to substance |
ISO |
Vincristine results in increased expression of BCL2L1 mRNA BCL2L1 protein affects the susceptibility to Vincristine |
CTD |
PMID:22178383 PMID:23649840 |
|
NCBI chr 3:148,259,594...148,314,191
Ensembl chr 3:148,259,596...148,313,810
|
|
G |
Bclaf1 |
BCL2-associated transcription factor 1 |
decreases expression |
ISO |
Vincristine results in decreased expression of BCLAF1 mRNA |
CTD |
PMID:23649840 |
|
NCBI chr 1:15,799,753...15,828,838
Ensembl chr 1:15,782,477...15,860,624
|
|
G |
Bcor |
BCL6 co-repressor |
increases expression |
ISO |
Vincristine results in increased expression of BCOR mRNA |
CTD |
PMID:23649840 |
|
NCBI chr X:11,570,155...11,692,022
Ensembl chr X:11,648,989...11,691,099
|
|
G |
Bdkrb1 |
bradykinin receptor B1 |
multiple interactions |
EXP |
[HOE 140, desArg(10)- binds to and results in decreased activity of BDKRB1 protein] which results in decreased susceptibility to Vincristine |
CTD |
PMID:17989505 |
|
NCBI chr 6:129,437,423...129,441,553
Ensembl chr 6:129,438,158...129,440,574
|
|
G |
Bdkrb2 |
bradykinin receptor B2 |
multiple interactions |
EXP |
[icatibant binds to and results in decreased activity of BDKRB2 protein] which results in decreased susceptibility to Vincristine |
CTD |
PMID:17989505 |
|
NCBI chr 6:129,399,468...129,429,676
Ensembl chr 6:129,399,468...129,429,676
|
|
G |
Birc2 |
baculoviral IAP repeat-containing 2 |
increases expression |
ISO |
Vincristine results in increased expression of BIRC2 mRNA |
CTD |
PMID:23649840 |
|
NCBI chr 8:6,014,014...6,036,668
Ensembl chr 8:6,013,207...6,034,142
|
|
G |
Birc3 |
baculoviral IAP repeat-containing 3 |
increases expression |
ISO |
Vincristine results in increased expression of BIRC3 mRNA |
CTD |
PMID:23649840 |
|
NCBI chr 8:6,048,590...6,076,828
Ensembl chr 8:6,048,969...6,076,598
|
|
G |
Blm |
BLM RecQ like helicase |
decreases expression |
ISO |
Vincristine results in decreased expression of BLM mRNA |
CTD |
PMID:23649840 |
|
NCBI chr 1:142,246,773...142,332,616
Ensembl chr 1:142,246,790...142,332,588
|
|
G |
Bmp2 |
bone morphogenetic protein 2 |
increases expression |
ISO |
Vincristine results in increased expression of BMP2 mRNA |
CTD |
PMID:23649840 |
|
NCBI chr 3:126,335,963...126,346,771
Ensembl chr 3:126,335,863...126,346,318
|
|
G |
Bnip3 |
BCL2 interacting protein 3 |
decreases expression multiple interactions |
ISO |
Vincristine results in decreased expression of BNIP3 mRNA Vincristine affects the reaction [Valproic Acid affects the localization of BNIP3 protein] |
CTD |
PMID:23649840 PMID:25446377 |
|
NCBI chr 1:211,248,098...211,265,282
Ensembl chr 1:211,248,098...211,265,282
|
|
G |
Bnip3l |
BCL2 interacting protein 3 like |
decreases expression |
ISO |
Vincristine results in decreased expression of BNIP3L mRNA |
CTD |
PMID:23649840 |
|
NCBI chr15:43,643,897...43,667,123
Ensembl chr15:43,643,897...43,667,029
|
|
G |
Borcs7 |
BLOC-1 related complex subunit 7 |
increases expression |
ISO |
Vincristine results in increased expression of BORCS7 mRNA |
CTD |
PMID:23649840 |
|
NCBI chr 1:266,451,021...266,464,903
Ensembl chr 1:266,451,021...266,464,903
|
|
G |
Brip1 |
BRCA1 interacting protein C-terminal helicase 1 |
decreases expression |
ISO |
Vincristine results in decreased expression of BRIP1 mRNA |
CTD |
PMID:23649840 |
|
NCBI chr10:73,507,009...73,632,742
Ensembl chr10:73,507,100...73,629,581
|
|
G |
Brwd1 |
bromodomain and WD repeat domain containing 1 |
decreases expression |
ISO |
Vincristine results in decreased expression of BRWD1 mRNA |
CTD |
PMID:23649840 |
|
NCBI chr11:36,338,080...36,430,473
Ensembl chr11:36,337,635...36,430,413
|
|
G |
Btg1 |
BTG anti-proliferation factor 1 |
increases expression |
ISO |
Vincristine results in increased expression of BTG1 mRNA |
CTD |
PMID:23649840 |
|
NCBI chr 7:37,812,831...37,815,088
Ensembl chr 7:37,812,831...37,815,088
|
|
G |
Btg2 |
BTG anti-proliferation factor 2 |
increases expression |
ISO |
Vincristine results in increased expression of BTG2 mRNA |
CTD |
PMID:23649840 |
|
NCBI chr13:50,913,185...50,916,944
Ensembl chr13:50,913,180...50,916,982
|
|
G |
Btg4 |
BTG anti-proliferation factor 4 |
increases expression |
ISO |
Vincristine results in increased expression of BTG4 mRNA |
CTD |
PMID:23649840 |
|
NCBI chr 8:55,408,917...55,508,100
Ensembl chr 8:55,504,359...55,508,259
|
|
G |
Bub3 |
BUB3 mitotic checkpoint protein |
decreases expression |
ISO |
Vincristine results in decreased expression of BUB3 mRNA |
CTD |
PMID:23649840 |
|
NCBI chr 1:203,526,853...203,537,459
Ensembl chr 1:203,524,426...203,557,337
|
|
G |
C1galt1 |
core 1 synthase, glycoprotein-N-acetylgalactosamine 3-beta-galactosyltransferase, 1 |
decreases expression |
ISO |
Vincristine results in decreased expression of C1GALT1 mRNA |
CTD |
PMID:23649840 |
|
NCBI chr 4:33,890,353...33,943,219
Ensembl chr 4:33,890,349...33,943,211
|
|
G |
Cables2 |
Cdk5 and Abl enzyme substrate 2 |
decreases expression |
ISO |
Vincristine results in decreased expression of CABLES2 mRNA |
CTD |
PMID:23649840 |
|
NCBI chr 3:175,630,266...175,644,994
Ensembl chr 3:175,631,881...175,644,988
|
|
G |
Cacnb2 |
calcium voltage-gated channel auxiliary subunit beta 2 |
increases expression |
ISO |
Vincristine results in increased expression of CACNB2 mRNA |
CTD |
PMID:23649840 |
|
NCBI chr17:81,673,862...82,019,219
Ensembl chr17:81,798,756...82,017,682
|
|
G |
Cald1 |
caldesmon 1 |
increases expression |
ISO |
Vincristine results in increased expression of CALD1 mRNA |
CTD |
PMID:23649840 |
|
NCBI chr 4:62,103,948...62,291,375
Ensembl chr 4:62,220,736...62,291,489
|
|
G |
Calm2 |
calmodulin 2 |
decreases expression |
ISO |
Vincristine results in decreased expression of CALM2 mRNA |
CTD |
PMID:23649840 |
|
NCBI chr 6:11,067,675...11,080,078
Ensembl chr15:65,506,874...65,507,968
|
|
G |
Calu |
calumenin |
increases expression |
ISO |
Vincristine results in increased expression of CALU mRNA |
CTD |
PMID:23649840 |
|
NCBI chr 4:56,625,611...56,653,112
Ensembl chr 4:56,625,561...56,653,111
|
|
G |
Camk2d |
calcium/calmodulin-dependent protein kinase II delta |
decreases expression |
ISO |
Vincristine results in decreased expression of CAMK2D mRNA |
CTD |
PMID:23649840 |
|
NCBI chr 2:230,900,907...231,132,207
Ensembl chr 2:230,901,126...231,132,039
|
|
G |
Camkk1 |
calcium/calmodulin-dependent protein kinase kinase 1 |
increases response to substance |
ISO |
CAMKK1 gene SNP results in increased susceptibility to Vincristine |
CTD |
PMID:21245421 |
|
NCBI chr10:59,585,023...59,608,180
Ensembl chr10:59,585,072...59,608,165
|
|
G |
Capg |
capping actin protein, gelsolin like |
increases expression |
ISO |
Vincristine results in increased expression of CAPG mRNA |
CTD |
PMID:23649840 |
|
NCBI chr 4:100,395,693...100,419,447
Ensembl chr 4:100,407,658...100,419,446
|
|
G |
Carhsp1 |
calcium regulated heat stable protein 1 |
decreases expression |
ISO |
Vincristine results in decreased expression of CARHSP1 mRNA |
CTD |
PMID:23649840 |
|
NCBI chr10:7,041,510...7,055,107
Ensembl chr10:7,041,510...7,055,101
|
|
G |
Casp1 |
caspase 1 |
increases expression |
ISO |
Vincristine results in increased expression of CASP1 mRNA |
CTD |
PMID:23649840 |
|
NCBI chr 8:2,605,743...2,614,637
Ensembl chr 8:2,604,962...2,614,631
|
|
G |
Casp3 |
caspase 3 |
increases cleavage multiple interactions increases expression |
EXP |
Vincristine results in increased cleavage of CASP3 protein Sumatriptan inhibits the reaction [Vincristine results in increased expression of CASP3 mRNA]; Sumatriptan inhibits the reaction [Vincristine results in increased expression of CASP3 protein] Vincristine results in increased expression of CASP3 mRNA; Vincristine results in increased expression of CASP3 protein |
CTD |
PMID:20624997 PMID:29958920 |
|
NCBI chr16:48,845,011...48,863,249
Ensembl chr16:48,845,012...48,863,204
|
|
G |
Casp6 |
caspase 6 |
increases expression |
ISO |
Vincristine results in increased expression of CASP6 mRNA |
CTD |
PMID:16001973 |
|
NCBI chr 2:235,341,326...235,353,715
Ensembl chr 2:235,341,365...235,353,967 Ensembl chr 2:235,341,365...235,353,967
|
|
G |
Casp8 |
caspase 8 |
increases expression increases response to substance multiple interactions |
ISO |
Vincristine results in increased expression of CASP8 mRNA CASP8 protein results in increased susceptibility to Vincristine Vincristine results in increased expression of and results in increased cleavage of CASP8 protein |
CTD |
PMID:16001973 PMID:22010212 |
|
NCBI chr 9:65,614,142...65,662,624
Ensembl chr 9:65,614,142...65,662,106
|
|
G |
Cat |
catalase |
affects response to substance decreases expression multiple interactions |
ISO EXP |
CAT protein affects the susceptibility to Vincristine Vincristine results in decreased expression of CAT protein tetrahydrocurcumin inhibits the reaction [Vincristine results in decreased expression of CAT protein]; Vincristine inhibits the reaction [Isoproterenol results in decreased activity of CAT protein]; Vincristine inhibits the reaction [Isoproterenol results in decreased expression of CAT protein] |
CTD |
PMID:11178967 PMID:24201307 PMID:25537132 PMID:26102012 |
|
NCBI chr 3:93,379,872...93,412,058
Ensembl chr 3:93,379,874...93,412,058
|
|
G |
Cbx3 |
chromobox 3 |
decreases expression |
ISO |
Vincristine results in decreased expression of CBX3 mRNA |
CTD |
PMID:23649840 |
|
NCBI chr 4:81,243,809...81,257,898
Ensembl chr 4:81,244,469...81,257,897
|
|
G |
Cbx5 |
chromobox 5 |
decreases expression |
ISO |
Vincristine results in decreased expression of CBX5 mRNA |
CTD |
PMID:23649840 |
|
NCBI chr 7:144,819,673...144,865,014
Ensembl chr 7:144,819,420...144,837,583
|
|
G |
Ccar1 |
cell division cycle and apoptosis regulator 1 |
decreases expression |
ISO |
Vincristine results in decreased expression of CCAR1 mRNA |
CTD |
PMID:23649840 |
|
NCBI chr20:32,373,443...32,416,044
Ensembl chr20:32,373,443...32,416,044
|
|
G |
Ccdc12 |
coiled-coil domain containing 12 |
decreases expression |
ISO |
Vincristine results in decreased expression of CCDC12 mRNA |
CTD |
PMID:23649840 |
|
NCBI chr 8:118,925,682...118,977,038
Ensembl chr 8:118,926,478...118,977,051
|
|
G |
Ccdc186 |
coiled-coil domain containing 186 |
decreases expression |
ISO |
Vincristine results in decreased expression of CCDC186 mRNA |
CTD |
PMID:23649840 |
|
NCBI chr 1:277,603,601...277,635,379
Ensembl chr 1:277,606,995...277,629,196
|
|
G |
Ccdc198 |
coiled-coil domain containing 198 |
decreases expression |
ISO |
Vincristine results in decreased expression of CCDC198 mRNA |
CTD |
PMID:23649840 |
|
NCBI chr15:26,090,458...26,106,523
|
|
G |
Ccdc32 |
coiled-coil domain containing 32 |
decreases expression |
ISO |
Vincristine results in decreased expression of CCDC32 mRNA |
CTD |
PMID:23649840 |
|
NCBI chr 3:110,816,327...110,828,824
Ensembl chr 3:110,816,337...110,828,879
|
|
G |
Ccdc82 |
coiled-coil domain containing 82 |
increases expression |
ISO |
Vincristine results in increased expression of CCDC82 mRNA |
CTD |
PMID:23649840 |
|
NCBI chr 8:11,888,460...11,927,920
Ensembl chr 8:11,888,591...11,927,919
|
|
G |
Cchcr1 |
coiled-coil alpha-helical rod protein 1 |
decreases expression |
ISO |
Vincristine results in decreased expression of CCHCR1 mRNA |
CTD |
PMID:23649840 |
|
NCBI chr20:3,730,968...3,745,721
Ensembl chr20:3,730,955...3,740,009
|
|
G |
Ccl1 |
C-C motif chemokine ligand 1 |
increases expression |
ISO |
Vincristine results in increased expression of CCL1 mRNA |
CTD |
PMID:23649840 |
|
NCBI chr10:69,534,976...69,537,836
Ensembl chr10:69,534,933...69,537,882
|
|
G |
Ccl2 |
C-C motif chemokine ligand 2 |
increases expression |
ISO EXP |
Vincristine results in increased expression of CCL2 mRNA |
CTD |
PMID:20624997 PMID:23649840 |
|
NCBI chr10:69,412,065...69,413,863
Ensembl chr10:69,412,017...69,413,870
|
|
G |
Ccl20 |
C-C motif chemokine ligand 20 |
increases expression |
ISO |
Vincristine results in increased expression of CCL20 mRNA |
CTD |
PMID:23649840 |
|
NCBI chr 9:88,918,359...88,921,017
Ensembl chr 9:88,918,433...88,921,001
|
|
G |
Ccl22 |
C-C motif chemokine ligand 22 |
increases expression |
ISO |
Vincristine results in increased expression of CCL22 mRNA |
CTD |
PMID:23649840 |
|
NCBI chr19:10,674,189...10,681,145
Ensembl chr19:10,674,189...10,681,145
|
|
G |
Ccl4 |
C-C motif chemokine ligand 4 |
increases expression |
ISO |
Vincristine results in increased expression of CCL4 mRNA |
CTD |
PMID:23649840 |
|
NCBI chr10:70,870,926...70,886,357
Ensembl chr10:70,884,531...70,886,355
|
|
G |
Ccl5 |
C-C motif chemokine ligand 5 |
increases expression |
ISO |
Vincristine results in increased expression of CCL5 mRNA |
CTD |
PMID:23649840 |
|
NCBI chr10:70,739,764...70,744,303
Ensembl chr10:70,739,800...70,744,315
|
|
G |
Ccn2 |
cellular communication network factor 2 |
decreases response to substance |
ISO |
CCN2 mRNA results in decreased susceptibility to Vincristine |
CTD |
PMID:24154679 |
|
NCBI chr 1:21,851,657...21,854,773
Ensembl chr 1:21,851,660...21,854,773
|
|
G |
Ccnb1 |
cyclin B1 |
affects response to substance increases expression |
ISO |
CCNB1 protein affects the susceptibility to Vincristine Vincristine results in increased expression of CCNB1 mRNA |
CTD |
PMID:22178383 PMID:23649840 |
|
NCBI chr 2:30,782,133...30,791,106
Ensembl chr 2:30,783,915...30,791,221
|
|
G |
Ccnb2 |
cyclin B2 |
increases expression |
ISO |
Vincristine results in increased expression of CCNB2 mRNA |
CTD |
PMID:23649840 |
|
NCBI chr 8:76,847,972...76,861,165
|
|
G |
Ccne1 |
cyclin E1 |
decreases expression |
ISO |
Vincristine results in decreased expression of CCNE1 mRNA |
CTD |
PMID:23649840 |
|
NCBI chr 1:94,485,830...94,495,112
Ensembl chr 1:94,485,832...94,494,980
|
|
G |
Ccne2 |
cyclin E2 |
decreases expression |
ISO |
Vincristine results in decreased expression of CCNE2 mRNA |
CTD |
PMID:23649840 |
|
NCBI chr 5:24,434,077...24,446,406
Ensembl chr 5:24,434,872...24,446,406
|
|
G |
Ccnl1 |
cyclin L1 |
decreases expression |
ISO |
Vincristine results in decreased expression of CCNL1 mRNA |
CTD |
PMID:23649840 |
|
NCBI chr 2:157,747,295...157,759,838
Ensembl chr 2:157,747,542...157,759,838
|
|
G |
Cd109 |
CD109 molecule |
increases expression |
ISO |
Vincristine results in increased expression of CD109 mRNA |
CTD |
PMID:23649840 |
|
NCBI chr 8:85,951,420...86,065,411
Ensembl chr 8:85,951,191...86,065,409
|
|
G |
Cd14 |
CD14 molecule |
increases expression |
EXP |
Vincristine results in increased expression of CD14 mRNA |
CTD |
PMID:20624997 |
|
NCBI chr18:29,560,341...29,562,290
Ensembl chr18:29,560,365...29,562,153
|
|
G |
Cd200 |
Cd200 molecule |
increases expression |
ISO |
Vincristine results in increased expression of CD200 mRNA |
CTD |
PMID:23649840 |
|
NCBI chr11:60,371,617...60,398,450
Ensembl chr11:60,371,684...60,403,196
|
|
G |
Cd274 |
CD274 molecule |
increases expression |
ISO |
Vincristine results in increased expression of CD274 mRNA |
CTD |
PMID:23649840 |
|
NCBI chr 1:247,519,890...247,539,659
Ensembl chr 1:247,519,939...247,537,943
|
|
G |
Cd36 |
CD36 molecule |
increases expression |
EXP |
Vincristine results in increased expression of CD36 mRNA |
CTD |
PMID:20624997 |
|
NCBI chr 4:14,150,309...14,191,498
Ensembl chr 4:14,001,761...14,249,749
|
|
G |
Cd40 |
CD40 molecule |
increases expression |
ISO |
Vincristine results in increased expression of CD40 mRNA |
CTD |
PMID:23649840 |
|
NCBI chr 3:161,519,789...161,534,943
Ensembl chr 3:161,519,743...161,534,704
|
|
G |
Cd44 |
CD44 molecule (Indian blood group) |
increases expression |
ISO |
Vincristine results in increased expression of CD44 mRNA |
CTD |
PMID:23649840 |
|
NCBI chr 3:92,695,083...92,783,820
Ensembl chr 3:92,696,313...92,783,658
|
|
G |
Cd48 |
Cd48 molecule |
increases expression |
ISO |
Vincristine results in increased expression of CD48 mRNA |
CTD |
PMID:23649840 |
|
NCBI chr13:90,116,601...90,140,371
Ensembl chr13:90,116,843...90,140,371
|
|
G |
Cd55 |
CD55 molecule (Cromer blood group) |
increases expression |
ISO |
Vincristine results in increased expression of CD55 mRNA |
CTD |
PMID:23649840 |
|
NCBI chr13:47,125,156...47,153,557
Ensembl chr13:47,126,741...47,154,292
|
|
G |
Cd69 |
Cd69 molecule |
increases expression |
ISO |
Vincristine results in increased expression of CD69 mRNA |
CTD |
PMID:23649840 |
|
NCBI chr 4:163,041,147...163,049,065
Ensembl chr 4:163,041,141...163,049,084
|
|
G |
Cd80 |
Cd80 molecule |
increases expression |
ISO |
Vincristine results in increased expression of CD80 mRNA |
CTD |
PMID:23649840 |
|
NCBI chr11:64,815,201...64,855,293
Ensembl chr11:64,827,635...64,855,353
|
|
G |
Cd83 |
CD83 molecule |
increases expression |
ISO |
Vincristine results in increased expression of CD83 mRNA |
CTD |
PMID:23649840 |
|
NCBI chr17:24,416,651...24,435,790
Ensembl chr17:24,416,651...24,435,790
|
|
G |
Cd86 |
CD86 molecule |
increases expression |
ISO |
Vincristine results in increased expression of CD86 mRNA |
CTD |
PMID:23649840 |
|
NCBI chr11:67,060,305...67,117,990
Ensembl chr11:67,082,193...67,118,795
|
|
G |
Cdc42ep3 |
CDC42 effector protein 3 |
increases expression |
ISO |
Vincristine results in increased expression of CDC42EP3 mRNA |
CTD |
PMID:23649840 |
|
NCBI chr 6:1,922,500...1,942,972
Ensembl chr 6:1,922,500...1,942,972
|
|
G |
Cdc42ep4 |
CDC42 effector protein 4 |
increases expression |
ISO |
Vincristine results in increased expression of CDC42EP4 mRNA |
CTD |
PMID:23649840 |
|
NCBI chr10:102,244,680...102,269,272
Ensembl chr10:102,244,681...102,269,272
|
|
G |
Cdc42se1 |
CDC42 small effector 1 |
increases expression |
ISO |
Vincristine results in increased expression of CDC42SE1 mRNA |
CTD |
PMID:23649840 |
|
NCBI chr 2:196,402,837...196,410,664
Ensembl chr 2:196,402,837...196,410,659
|
|
G |
Cdc6 |
cell division cycle 6 |
decreases expression |
ISO |
Vincristine results in decreased expression of CDC6 mRNA |
CTD |
PMID:23649840 |
|
NCBI chr10:86,819,477...86,833,301
Ensembl chr10:86,819,472...86,833,402
|
|
G |
Cdca3 |
cell division cycle associated 3 |
decreases expression |
ISO |
Vincristine results in decreased expression of CDCA3 mRNA |
CTD |
PMID:23649840 |
|
NCBI chr 4:157,347,876...157,351,889
Ensembl chr 4:157,348,020...157,351,604
|
|
G |
Cdca7 |
cell division cycle associated 7 |
decreases expression |
ISO |
Vincristine results in decreased expression of CDCA7 mRNA |
CTD |
PMID:23649840 |
|
NCBI chr 3:59,153,281...59,163,916
Ensembl chr 3:59,153,280...59,163,913
|
|
G |
Cdh1 |
cadherin 1 |
increases expression |
ISO |
Vincristine results in increased expression of CDH1 mRNA |
CTD |
PMID:23649840 |
|
NCBI chr19:38,768,467...38,838,395
Ensembl chr19:38,768,467...38,838,395
|
|
G |
Cdk1 |
cyclin-dependent kinase 1 |
decreases expression |
ISO |
Vincristine results in decreased expression of CDK1 mRNA |
CTD |
PMID:23649840 |
|
NCBI chr20:20,576,341...20,591,510
Ensembl chr20:20,576,377...20,591,549
|
|
G |
Cdk10 |
cyclin-dependent kinase 10 |
decreases expression |
ISO |
Vincristine results in decreased expression of CDK10 mRNA |
CTD |
PMID:23649840 |
|
NCBI chr19:56,024,903...56,032,610
Ensembl chr19:56,024,903...56,032,605
|
|
G |
Cdk19 |
cyclin-dependent kinase 19 |
decreases expression |
ISO |
Vincristine results in decreased expression of CDK19 mRNA |
CTD |
PMID:23649840 |
|
NCBI chr20:45,458,499...45,598,799
Ensembl chr20:45,458,558...45,598,798
|
|
G |
Cdk2 |
cyclin dependent kinase 2 |
decreases expression |
ISO |
Vincristine results in decreased expression of CDK2 mRNA |
CTD |
PMID:23649840 |
|
NCBI chr 7:3,124,953...3,132,533
Ensembl chr 7:3,124,954...3,132,457
|
|
G |
Cdkn1a |
cyclin-dependent kinase inhibitor 1A |
increases expression multiple interactions |
EXP ISO |
Vincristine results in increased expression of CDKN1A mRNA resveratrol inhibits the reaction [Vincristine results in increased expression of CDKN1A mRNA] |
CTD |
PMID:20624997 PMID:23649840 PMID:26055805 |
|
NCBI chr20:6,348,422...6,358,864
Ensembl chr20:6,351,458...6,358,864
|
|
G |
Cdkn2a |
cyclin-dependent kinase inhibitor 2A |
increases response to substance |
ISO |
CDKN2A protein results in increased susceptibility to Vincristine |
CTD |
PMID:16786135 |
|
NCBI chr 5:107,823,323...107,832,405
Ensembl chr 5:107,823,330...107,841,175
|
|
G |
Cdkn2c |
cyclin-dependent kinase inhibitor 2C |
decreases expression |
ISO |
Vincristine results in decreased expression of CDKN2C mRNA |
CTD |
PMID:23649840 |
|
NCBI chr 5:129,347,731...129,352,886
Ensembl chr 5:129,347,732...129,352,886
|
|
G |
Ceacam1 |
CEA cell adhesion molecule 1 |
increases expression |
ISO |
Vincristine results in increased expression of CEACAM1 mRNA |
CTD |
PMID:23649840 |
|
NCBI chr 1:82,327,955...82,344,345
Ensembl chr 1:82,327,955...82,344,345
|
|
G |
Cebpb |
CCAAT/enhancer binding protein beta |
increases expression |
ISO |
Vincristine results in increased expression of CEBPB mRNA |
CTD |
PMID:16001973 |
|
NCBI chr 3:164,424,502...164,425,933
Ensembl chr 3:164,424,515...164,425,910
|
|
G |
Celf1 |
CUGBP, Elav-like family member 1 |
decreases expression |
ISO |
Vincristine results in decreased expression of CELF1 mRNA |
CTD |
PMID:23649840 |
|
NCBI chr 3:79,768,900...79,844,548
Ensembl chr 3:79,823,945...79,842,082
|
|
G |
Cenpc |
centromere protein C |
decreases expression |
ISO |
Vincristine results in decreased expression of CENPC1 mRNA |
CTD |
PMID:23649840 |
|
NCBI chr14:23,611,909...23,670,314
Ensembl chr14:23,611,735...23,670,475
|
|
G |
Cenpf |
centromere protein F |
decreases expression |
ISO |
Vincristine results in decreased expression of CENPF mRNA |
CTD |
PMID:23649840 |
|
NCBI chr13:108,132,499...108,178,609
Ensembl chr13:108,132,499...108,178,609
|
|
G |
Cenpi |
centromere protein I |
decreases expression |
ISO |
Vincristine results in decreased expression of CENPI mRNA |
CTD |
PMID:23649840 |
|
NCBI chr X:105,147,045...105,198,798
Ensembl chr X:105,147,153...105,198,797
|
|
G |
Cenpu |
centromere protein U |
decreases expression |
ISO |
Vincristine results in decreased expression of CENPU mRNA |
CTD |
PMID:23649840 |
|
NCBI chr16:48,898,032...48,921,248
Ensembl chr16:48,897,982...48,921,242
|
|
G |
Cep135 |
centrosomal protein 135 |
increases expression |
ISO |
Vincristine results in increased expression of CEP135 mRNA |
CTD |
PMID:23649840 |
|
NCBI chr14:34,052,168...34,115,763
Ensembl chr14:34,051,003...34,115,273
|
|
G |
Ces5a |
carboxylesterase 5A |
increases expression |
ISO |
Vincristine results in increased expression of CES5A mRNA |
CTD |
PMID:23649840 |
|
NCBI chr19:12,097,529...12,136,579
Ensembl chr19:12,097,632...12,136,240
|
|
G |
Cflar |
CASP8 and FADD-like apoptosis regulator |
increases expression |
ISO |
Vincristine results in increased expression of CFLAR mRNA |
CTD |
PMID:23649840 |
|
NCBI chr 9:65,534,608...65,586,395
Ensembl chr 9:65,534,704...65,587,251
|
|
G |
Chd1l |
chromodomain helicase DNA binding protein 1-like |
increases expression |
ISO |
Vincristine results in increased expression of CHD1L mRNA |
CTD |
PMID:23649840 |
|
NCBI chr 2:199,714,044...199,792,270
Ensembl chr 2:199,716,713...199,771,896
|
|
G |
Chek2 |
checkpoint kinase 2 |
decreases expression |
ISO |
Vincristine results in decreased expression of CHEK2 mRNA |
CTD |
PMID:23649840 |
|
NCBI chr12:51,845,574...51,878,098
Ensembl chr12:51,845,796...51,877,624
|
|
G |
Chm |
CHM Rab escort protein |
increases expression |
ISO |
Vincristine results in increased expression of CHM mRNA |
CTD |
PMID:23649840 |
|
NCBI chr X:84,666,900...84,821,775
Ensembl chr X:84,666,900...84,821,775
|
|
G |
Chml |
CHM like Rab escort protein |
decreases expression |
ISO |
Vincristine results in decreased expression of CHML mRNA |
CTD |
PMID:23649840 |
|
NCBI chr13:93,740,759...93,742,624
|
|
G |
Chtf18 |
chromosome transmission fidelity factor 18 |
decreases expression |
ISO |
Vincristine results in decreased expression of CHTF18 mRNA |
CTD |
PMID:23649840 |
|
NCBI chr10:15,090,762...15,098,825
Ensembl chr10:15,090,316...15,098,791
|
|
G |
Ciapin1 |
cytokine induced apoptosis inhibitor 1 |
decreases response to substance |
ISO |
CIAPIN1 protein results in decreased susceptibility to Vincristine |
CTD |
PMID:18389626 |
|
NCBI chr19:10,596,923...10,612,414
Ensembl chr19:10,596,960...10,610,049
|
|
G |
Cirbp |
cold inducible RNA binding protein |
decreases expression |
ISO |
Vincristine results in decreased expression of CIRBP mRNA |
CTD |
PMID:23649840 |
|
NCBI chr 7:12,400,066...12,405,054
Ensembl chr 7:12,401,207...12,405,022
|
|
G |
Clasp2 |
cytoplasmic linker associated protein 2 |
increases expression |
ISO |
Vincristine results in increased expression of CLASP2 mRNA |
CTD |
PMID:23649840 |
|
NCBI chr 8:122,003,719...122,185,495
Ensembl chr 8:122,003,916...122,185,495
|
|
G |
Clec2d |
C-type lectin domain family 2, member D |
decreases expression |
ISO |
Vincristine results in decreased expression of CLEC2D mRNA |
CTD |
PMID:23649840 |
|
NCBI chr 4:162,278,252...162,302,881
Ensembl chr 4:162,292,305...162,302,156
|
|
G |
Clic2 |
chloride intracellular channel 2 |
increases expression |
ISO |
Vincristine results in increased expression of CLIC2 mRNA |
CTD |
PMID:23649840 |
|
NCBI chr20:295,338...310,363
Ensembl chr20:295,250...310,380
|
|
G |
Clspn |
claspin |
decreases expression |
ISO |
Vincristine results in decreased expression of CLSPN mRNA |
CTD |
PMID:23649840 |
|
NCBI chr 5:144,577,670...144,617,507
Ensembl chr 5:144,581,427...144,616,335
|
|
G |
Cnksr2 |
connector enhancer of kinase suppressor of Ras 2 |
decreases expression |
ISO |
Vincristine results in decreased expression of CNKSR2 mRNA |
CTD |
PMID:23649840 |
|
NCBI chr X:39,711,001...39,953,860
Ensembl chr X:39,711,201...39,951,847
|
|
G |
Cnot3 |
CCR4-NOT transcription complex, subunit 3 |
decreases expression |
ISO |
Vincristine results in decreased expression of CNOT3 mRNA |
CTD |
PMID:23649840 |
|
NCBI chr 1:64,130,823...64,147,066
Ensembl chr 1:64,130,908...64,147,251
|
|
G |
Cnot6l |
CCR4-NOT transcription complex, subunit 6-like |
decreases expression |
ISO |
Vincristine results in decreased expression of CNOT6L mRNA |
CTD |
PMID:23649840 |
|
NCBI chr14:15,059,101...15,148,255
Ensembl chr14:15,059,387...15,146,586
|
|
G |
Cntln |
centlein |
decreases expression |
ISO |
Vincristine results in decreased expression of CNTLN mRNA |
CTD |
PMID:23649840 |
|
NCBI chr 5:103,251,986...103,367,088
Ensembl chr 5:103,251,986...103,366,264
|
|
G |
Col15a1 |
collagen type XV alpha 1 chain |
decreases response to substance |
ISO |
COL15A1 mRNA results in decreased susceptibility to Vincristine |
CTD |
PMID:25199881 |
|
NCBI chr 5:62,840,360...62,950,240
|
|
G |
Col1a2 |
collagen type I alpha 2 chain |
increases response to substance |
ISO |
COL1A2 mRNA results in increased susceptibility to Vincristine |
CTD |
PMID:25199881 |
|
NCBI chr 4:31,534,225...31,569,152
Ensembl chr 4:31,534,225...31,569,151
|
|
G |
Col3a1 |
collagen type III alpha 1 chain |
decreases response to substance |
ISO |
COL3A1 mRNA results in decreased susceptibility to Vincristine |
CTD |
PMID:25199881 |
|
NCBI chr 9:52,023,295...52,059,221
Ensembl chr 9:52,023,295...52,059,217
|
|
G |
Col5a2 |
collagen type V alpha 2 chain |
decreases response to substance |
ISO |
COL5A2 mRNA results in decreased susceptibility to Vincristine |
CTD |
PMID:25199881 |
|
NCBI chr 9:52,091,088...52,238,735
Ensembl chr 9:52,092,511...52,238,564
|
|
G |
Comtd1 |
catechol-O-methyltransferase domain containing 1 |
decreases expression |
ISO |
Vincristine results in decreased expression of COMTD1 mRNA |
CTD |
PMID:23649840 |
|
NCBI chr15:2,631,529...2,634,640
Ensembl chr15:2,631,529...2,634,640
|
|
G |
Cp |
ceruloplasmin |
increases expression |
EXP |
Vincristine results in increased expression of CP mRNA |
CTD |
PMID:20624997 |
|
NCBI chr 2:104,744,249...104,803,034
Ensembl chr 2:104,744,461...104,799,853
|
|
G |
Cpeb2 |
cytoplasmic polyadenylation element binding protein 2 |
increases expression |
ISO |
Vincristine results in increased expression of CPEB2 mRNA |
CTD |
PMID:23649840 |
|
NCBI chr14:72,327,929...72,382,519
Ensembl chr14:72,331,705...72,380,330
|
|
G |
Cpne3 |
copine 3 |
decreases expression |
ISO |
Vincristine results in decreased expression of CPNE3 mRNA |
CTD |
PMID:23649840 |
|
NCBI chr 5:33,525,307...33,574,610
Ensembl chr 5:33,528,154...33,574,596
|
|
G |
Cpsf6 |
cleavage and polyadenylation specific factor 6 |
decreases expression |
ISO |
Vincristine results in decreased expression of CPSF6 mRNA |
CTD |
PMID:23649840 |
|
NCBI chr 7:60,385,688...60,417,661
Ensembl chr 7:60,385,688...60,416,925
|
|
G |
Crebbp |
CREB binding protein |
increases expression |
ISO |
Vincristine results in increased expression of CREBBP mRNA |
CTD |
PMID:23649840 |
|
NCBI chr10:11,590,994...11,721,039
Ensembl chr10:11,595,044...11,721,039
|
|
G |
Crebrf |
CREB3 regulatory factor |
increases expression |
ISO |
Vincristine results in increased expression of CREBRF mRNA |
CTD |
PMID:23649840 |
|
NCBI chr10:16,693,846...16,753,162
Ensembl chr10:16,694,792...16,752,205
|
|
G |
Crebzf |
CREB/ATF bZIP transcription factor |
decreases expression |
ISO |
Vincristine results in decreased expression of CREBZF mRNA |
CTD |
PMID:23649840 |
|
NCBI chr 1:156,290,215...156,296,891
Ensembl chr 1:156,294,519...156,296,161
|
|
G |
Crtap |
cartilage associated protein |
decreases expression |
ISO |
Vincristine results in decreased expression of CRTAP mRNA |
CTD |
PMID:23649840 |
|
NCBI chr 8:122,382,613...122,402,209
|
|
G |
Crtc3 |
CREB regulated transcription coactivator 3 |
increases expression |
ISO |
Vincristine results in increased expression of CRTC3 mRNA |
CTD |
PMID:23649840 |
|
NCBI chr 1:142,398,248...142,500,562
Ensembl chr 1:142,393,207...142,500,383
|
|
G |
Csad |
cysteine sulfinic acid decarboxylase |
decreases expression |
ISO |
Vincristine results in decreased expression of CSAD mRNA |
CTD |
PMID:23649840 |
|
NCBI chr 7:143,781,520...143,810,880
Ensembl chr 7:143,781,702...143,793,970
|
|
G |
Csf2 |
colony stimulating factor 2 |
increases expression |
ISO |
Vincristine results in increased expression of CSF2 mRNA |
CTD |
PMID:23649840 |
|
NCBI chr10:39,602,089...39,604,070
Ensembl chr10:39,602,089...39,604,070
|
|
G |
Csnk1a1 |
casein kinase 1, alpha 1 |
increases expression |
ISO |
Vincristine results in increased expression of CSNK1A1 mRNA |
CTD |
PMID:23649840 |
|
NCBI chr18:56,887,722...56,910,610
Ensembl chr18:56,887,354...56,918,345
|
|
G |
Csnk1g1 |
casein kinase 1, gamma 1 |
increases expression |
ISO |
Vincristine results in increased expression of CSNK1G1 mRNA |
CTD |
PMID:23649840 |
|
NCBI chr 8:71,533,372...71,688,483
Ensembl chr 8:71,547,468...71,679,666
|
|
G |
Csta |
cystatin A |
increases expression |
ISO |
Vincristine results in increased expression of CSTA mRNA |
CTD |
PMID:23649840 |
|
NCBI chr11:67,555,792...67,566,980
Ensembl chr11:67,555,658...67,566,972
|
|
G |
Cstf1 |
cleavage stimulation factor subunit 1 |
decreases expression |
ISO |
Vincristine results in decreased expression of CSTF1 mRNA |
CTD |
PMID:23649840 |
|
NCBI chr 3:170,380,413...170,392,162
Ensembl chr 3:170,380,719...170,392,160
|
|
G |
Ctc1 |
CST telomere replication complex component 1 |
decreases expression |
ISO |
Vincristine results in decreased expression of CTC1 mRNA |
CTD |
PMID:23649840 |
|
NCBI chr10:55,596,172...55,616,873
Ensembl chr10:55,596,148...55,616,889
|
|
G |
Cth |
cystathionine gamma-lyase |
increases expression |
ISO |
Vincristine results in increased expression of CTH mRNA |
CTD |
PMID:23649840 |
|
NCBI chr 2:264,266,959...264,293,040
Ensembl chr 2:264,266,984...264,293,046
|
|
G |
Ctnnal1 |
catenin alpha-like 1 |
decreases expression |
ISO |
Vincristine results in decreased expression of CTNNAL1 mRNA |
CTD |
PMID:23649840 |
|
NCBI chr 5:73,561,249...73,621,070
Ensembl chr 5:73,561,450...73,621,070
|
|
G |
Ctnnb1 |
catenin beta 1 |
increases expression decreases response to substance |
ISO |
Vincristine results in increased expression of CTNNB1 mRNA CTNNB1 results in decreased susceptibility to Vincristine |
CTD |
PMID:22000491 PMID:23649840 |
|
NCBI chr 8:129,601,511...129,628,378
Ensembl chr 8:129,617,812...129,627,372
|
|
G |
Cul4a |
cullin 4A |
increases expression |
ISO |
Vincristine results in increased expression of CUL4A mRNA |
CTD |
PMID:23649840 |
|
NCBI chr16:81,718,784...81,756,653
Ensembl chr16:81,719,028...81,756,654
|
|
G |
Cxcl10 |
C-X-C motif chemokine ligand 10 |
increases expression |
ISO |
Vincristine results in increased expression of CXCL10 mRNA |
CTD |
PMID:23649840 |
|
NCBI chr14:17,210,733...17,212,930
Ensembl chr14:17,210,733...17,212,930
|
|
G |
Cxcl11 |
C-X-C motif chemokine ligand 11 |
increases expression |
ISO |
Vincristine results in increased expression of CXCL11 mRNA |
CTD |
PMID:23649840 |
|
NCBI chr14:17,195,395...17,198,170
Ensembl chr14:17,195,014...17,198,291
|
|
G |
Cxcl9 |
C-X-C motif chemokine ligand 9 |
increases expression |
ISO |
Vincristine results in increased expression of CXCL9 mRNA |
CTD |
PMID:23649840 |
|
NCBI chr14:17,228,832...17,233,743
Ensembl chr14:17,228,856...17,234,712
|
|
G |
Cyld |
CYLD lysine 63 deubiquitinase |
increases expression |
ISO |
Vincristine results in increased expression of CYLD mRNA |
CTD |
PMID:23649840 |
|
NCBI chr19:19,264,984...19,323,817
Ensembl chr19:19,265,164...19,315,357
|
|
G |
Cyp2c79 |
cytochrome P450, family 2, subfamily c, polypeptide 79 |
increases response to substance |
ISO |
CYP2C8 gene SNP results in increased susceptibility to Vincristine |
CTD |
PMID:21245421 |
|
NCBI chr 1:147,236,480...147,307,988
|
|
G |
Cyp3a62 |
cytochrome P450, family 3, subfamily a, polypeptide 62 |
increases metabolic processing |
ISO |
CYP3A4 protein results in increased metabolism of Vincristine |
CTD |
PMID:19346885 |
|
NCBI chr12:18,679,809...18,709,397
Ensembl chr12:18,678,594...18,709,397
|
|
G |
Cyp3a9 |
cytochrome P450, family 3, subfamily a, polypeptide 9 |
multiple interactions increases metabolic processing |
ISO |
[CYP3A5 gene polymorphism results in increased activity of CYP3A5 protein] which results in increased metabolism of Vincristine CYP3A5 protein results in increased metabolism of Vincristine |
CTD |
PMID:21225912 |
|
NCBI chr12:19,074,288...19,114,491
Ensembl chr12:19,074,583...19,114,399
|
|
G |
Cyp4f18 |
cytochrome P450, family 4, subfamily f, polypeptide 18 |
increases expression |
ISO |
Vincristine results in increased expression of CYP4F3 mRNA |
CTD |
PMID:23649840 |
|
NCBI chr16:19,501,680...19,528,935
Ensembl chr16:19,410,810...19,528,999
|
|
G |
Cyp4v3 |
cytochrome P450, family 4, subfamily v, polypeptide 3 |
decreases expression |
ISO |
Vincristine results in decreased expression of CYP4V2 mRNA |
CTD |
PMID:23649840 |
|
NCBI chr16:50,111,803...50,136,741
Ensembl chr16:50,111,306...50,136,727
|
|
G |
Cysltr1 |
cysteinyl leukotriene receptor 1 |
decreases expression |
ISO |
Vincristine results in decreased expression of CYSLTR1 mRNA |
CTD |
PMID:23649840 |
|
NCBI chr X:77,671,028...77,700,491
Ensembl chr X:77,674,150...77,700,269
|
|
G |
Daam1 |
dishevelled associated activator of morphogenesis 1 |
increases expression |
ISO |
Vincristine results in increased expression of DAAM1 mRNA |
CTD |
PMID:23649840 |
|
NCBI chr 6:94,606,675...94,739,026
Ensembl chr 6:94,636,222...94,739,026
|
|
G |
Dcaf8 |
DDB1 and CUL4 associated factor 8 |
increases expression |
ISO |
Vincristine results in increased expression of DCAF8 mRNA |
CTD |
PMID:23649840 |
|
NCBI chr13:90,532,153...90,587,542
Ensembl chr13:90,532,326...90,591,796
|
|
G |
Dcn |
decorin |
decreases response to substance |
ISO |
DCN mRNA results in decreased susceptibility to Vincristine |
CTD |
PMID:25199881 |
|
NCBI chr 7:38,742,250...38,782,282
Ensembl chr 7:38,742,051...38,782,323
|
|
G |
Dcun1d1 |
defective in cullin neddylation 1 domain containing 1 |
increases expression |
ISO |
Vincristine results in increased expression of DCUN1D1 mRNA |
CTD |
PMID:23649840 |
|
NCBI chr 2:122,476,173...122,527,153
Ensembl chr 2:122,476,173...122,646,445
|
|
G |
Dcun1d4 |
defective in cullin neddylation 1 domain containing 4 |
decreases expression |
ISO |
Vincristine results in decreased expression of DCUN1D4 mRNA |
CTD |
PMID:23649840 |
|
NCBI chr14:37,210,721...37,294,517
Ensembl chr14:37,210,721...37,294,472
|
|
G |
Ddit3 |
DNA-damage inducible transcript 3 |
increases expression |
ISO |
Vincristine results in increased expression of DDIT3 mRNA |
CTD |
PMID:23649840 |
|
NCBI chr 7:70,578,564...70,585,074
Ensembl chr 7:70,580,198...70,585,084
|
|
G |
Ddx50 |
DExD-box helicase 50 |
increases expression |
ISO |
Vincristine results in increased expression of DDX50 mRNA |
CTD |
PMID:23649840 |
|
NCBI chr20:32,239,736...32,269,522
Ensembl chr20:32,239,748...32,269,145
|
|
G |
Ddx52 |
DExD-box helicase 52 |
increases expression |
ISO |
Vincristine results in increased expression of DDX52 mRNA |
CTD |
PMID:23649840 |
|
NCBI chr10:71,253,667...71,276,397
Ensembl chr10:71,253,598...71,277,277
|
|
G |
Dennd5a |
DENN domain containing 5A |
increases expression |
ISO |
Vincristine results in increased expression of DENND5A mRNA |
CTD |
PMID:23649840 |
|
NCBI chr 1:174,524,047...174,588,553
Ensembl chr 1:174,524,047...174,588,529
|
|
G |
Dgcr8 |
DGCR8 microprocessor complex subunit |
decreases expression |
ISO |
Vincristine results in decreased expression of DGCR8 mRNA |
CTD |
PMID:23649840 |
|
NCBI chr11:86,852,682...86,885,233
Ensembl chr11:86,852,711...86,885,224
|
|
G |
Dhfr |
dihydrofolate reductase |
decreases expression |
ISO |
Vincristine results in decreased expression of DHFR mRNA |
CTD |
PMID:23649840 |
|
NCBI chr 2:21,931,887...21,958,927
Ensembl chr 2:21,931,493...21,962,453
|
|
G |
Dhrs11 |
dehydrogenase/reductase 11 |
decreases expression |
ISO |
Vincristine results in decreased expression of DHRS11 mRNA |
CTD |
PMID:23649840 |
|
NCBI chr10:72,144,042...72,153,496
Ensembl chr10:72,144,042...72,153,375
|
|
G |
Dhrs2 |
dehydrogenase/reductase 2 |
increases expression |
ISO |
Vincristine results in increased expression of DHRS2 mRNA |
CTD |
PMID:23649840 |
|
NCBI chr15:33,876,701...33,891,559
Ensembl chr15:33,885,106...33,891,539
|
|
G |
Dhrs7 |
dehydrogenase/reductase 7 |
increases expression |
ISO |
Vincristine results in increased expression of DHRS7 mRNA |
CTD |
PMID:23649840 |
|
NCBI chr 6:95,522,577...95,541,393
Ensembl chr 6:95,522,577...95,541,393
|
|
G |
Diablo |
diablo, IAP-binding mitochondrial protein |
decreases expression |
ISO |
Vincristine results in decreased expression of DIABLO mRNA |
CTD |
PMID:23649840 |
|
NCBI chr12:38,490,230...38,503,344
Ensembl chr12:38,490,230...38,503,330
|
|
G |
Dido1 |
death inducer-obliterator 1 |
decreases expression |
ISO |
Vincristine results in decreased expression of DIDO1 mRNA |
CTD |
PMID:23649840 |
|
NCBI chr 3:176,162,886...176,216,868
Ensembl chr 3:176,162,886...176,197,753
|
|
G |
Dip2a |
disco-interacting protein 2 homolog A |
increases expression |
ISO |
Vincristine results in increased expression of DIP2A mRNA |
CTD |
PMID:23649840 |
|
NCBI chr20:13,044,056...13,127,971
Ensembl chr20:13,044,104...13,127,487
|
|
G |
Dmd |
dystrophin |
increases expression |
ISO |
Vincristine results in increased expression of DMD mRNA |
CTD |
PMID:23649840 |
|
NCBI chr X:51,149,358...53,519,271
Ensembl chr X:51,286,737...53,519,259
|
|
G |
Dna2 |
DNA replication helicase/nuclease 2 |
decreases expression |
ISO |
Vincristine results in decreased expression of DNA2 mRNA |
CTD |
PMID:23649840 |
|
|
|
G |
Dnajb1 |
DnaJ heat shock protein family (Hsp40) member B1 |
decreases expression |
ISO |
Vincristine results in decreased expression of DNAJB1 mRNA |
CTD |
PMID:23649840 |
|
NCBI chr19:24,747,178...24,750,919
Ensembl chr19:24,747,178...24,750,919
|
|
G |
Dnajc7 |
DnaJ heat shock protein family (Hsp40) member C7 |
increases expression |
ISO |
Vincristine results in increased expression of DNAJC7 mRNA |
CTD |
PMID:23649840 |
|
NCBI chr10:88,498,271...88,533,730
Ensembl chr10:88,498,238...88,533,829
|
|
G |
Dnase1l3 |
deoxyribonuclease 1-like 3 |
decreases expression |
ISO |
Vincristine results in decreased expression of DNASE1L3 mRNA |
CTD |
PMID:23649840 |
|
NCBI chr15:18,710,492...18,736,476
Ensembl chr15:18,710,492...18,736,473
|
|
G |
Dnmbp |
dynamin binding protein |
decreases expression |
ISO |
Vincristine results in decreased expression of DNMBP mRNA |
CTD |
PMID:23649840 |
|
NCBI chr 1:263,625,503...263,718,784
Ensembl chr 1:263,625,501...263,718,745
|
|
G |
Dock4 |
dedicator of cytokinesis 4 |
increases expression |
ISO |
Vincristine results in increased expression of DOCK4 mRNA |
CTD |
PMID:23649840 |
|
NCBI chr 6:60,374,839...60,782,648
Ensembl chr 6:60,566,196...60,782,556
|
|
G |
Dock8 |
dedicator of cytokinesis 8 |
decreases expression |
ISO |
Vincristine results in decreased expression of DOCK8 mRNA |
CTD |
PMID:23649840 |
|
NCBI chr 1:242,934,685...243,153,472
Ensembl chr 1:242,959,488...243,153,465
|
|
G |
Dok4 |
docking protein 4 |
increases expression |
ISO |
Vincristine results in increased expression of DOK4 mRNA |
CTD |
PMID:23649840 |
|
NCBI chr19:10,563,423...10,574,094
Ensembl chr19:10,563,423...10,574,093
|
|
G |
Donson |
DNA replication fork stabilization factor DONSON |
decreases expression |
ISO |
Vincristine results in decreased expression of DONSON mRNA |
CTD |
PMID:23649840 |
|
NCBI chr11:31,834,608...31,847,751
Ensembl chr11:31,837,839...31,847,490
|
|
G |
Dpp4 |
dipeptidylpeptidase 4 |
decreases expression |
ISO |
Vincristine results in decreased expression of DPP4 mRNA |
CTD |
PMID:23649840 |
|
NCBI chr 3:48,291,055...48,372,672
Ensembl chr 3:48,291,055...48,372,672
|
|
G |
Dpyd |
dihydropyrimidine dehydrogenase |
increases response to substance |
ISO |
DPYD gene SNP results in increased susceptibility to Vincristine |
CTD |
PMID:20864405 |
|
NCBI chr 2:221,823,692...222,694,627
Ensembl chr 2:221,823,687...222,694,627
|
|
G |
Dram1 |
DNA-damage regulated autophagy modulator 1 |
increases expression |
ISO |
Vincristine results in increased expression of DRAM1 mRNA |
CTD |
PMID:23649840 |
|
NCBI chr 7:28,898,647...28,932,641
Ensembl chr 7:28,898,649...28,932,641
|
|
G |
Dtl |
denticleless E3 ubiquitin protein ligase homolog |
decreases expression |
ISO |
Vincristine results in decreased expression of DTL mRNA |
CTD |
PMID:23649840 |
|
NCBI chr13:110,219,276...110,257,345
Ensembl chr13:110,220,283...110,257,367
|
|
G |
Dusp1 |
dual specificity phosphatase 1 |
increases expression |
ISO |
Vincristine results in increased expression of DUSP1 mRNA |
CTD |
PMID:23649840 |
|
NCBI chr10:16,970,642...16,973,425
Ensembl chr10:16,970,626...16,973,418
|
|
G |
Dusp10 |
dual specificity phosphatase 10 |
increases expression |
ISO |
Vincristine results in increased expression of DUSP10 mRNA |
CTD |
PMID:23649840 |
|
NCBI chr13:104,284,660...104,321,455
Ensembl chr13:104,284,660...104,321,455
|
|
G |
Dusp16 |
dual specificity phosphatase 16 |
increases expression |
ISO |
Vincristine results in increased expression of DUSP16 mRNA |
CTD |
PMID:23649840 |
|
NCBI chr 4:168,470,141...168,551,346
Ensembl chr 4:168,472,412...168,517,177
|
|
G |
Dusp2 |
dual specificity phosphatase 2 |
increases expression |
ISO |
Vincristine results in increased expression of DUSP2 mRNA |
CTD |
PMID:23649840 |
|
NCBI chr 3:119,776,925...119,779,110
Ensembl chr 3:119,776,925...119,779,099
|
|
G |
Dusp4 |
dual specificity phosphatase 4 |
increases expression |
ISO |
Vincristine results in increased expression of DUSP4 mRNA |
CTD |
PMID:23649840 |
|
NCBI chr16:61,080,767...61,090,973
Ensembl chr16:61,078,175...61,091,169
|
|
G |
Dynlt2 |
dynein light chain Tctex-type 2 |
decreases expression |
ISO |
Vincristine results in decreased expression of DYNLT2 mRNA |
CTD |
PMID:23649840 |
|
NCBI chr 1:56,970,673...56,982,657
Ensembl chr 1:56,970,654...56,982,642
|
|
G |
E2f8 |
E2F transcription factor 8 |
decreases expression |
ISO |
Vincristine results in decreased expression of E2F8 mRNA |
CTD |
PMID:23649840 |
|
NCBI chr 1:104,185,436...104,203,683
Ensembl chr 1:104,187,100...104,202,591
|
|
G |
Ebf1 |
EBF transcription factor 1 |
increases expression |
ISO |
Vincristine results in increased expression of EBF1 mRNA |
CTD |
PMID:23649840 |
|
NCBI chr10:23,654,849...24,051,627
Ensembl chr10:23,661,013...24,050,209
|
|
G |
Ednrb |
endothelin receptor type B |
increases expression |
EXP |
Vincristine results in increased expression of EDNRB mRNA |
CTD |
PMID:20624997 |
|
NCBI chr15:88,004,775...88,036,354
Ensembl chr15:88,006,977...88,036,354
|
|
G |
Efna4 |
ephrin A4 |
decreases expression |
ISO |
Vincristine results in decreased expression of EFNA4 mRNA |
CTD |
PMID:23649840 |
|
NCBI chr 2:188,655,920...188,660,179
Ensembl chr 2:188,655,912...188,660,179
|
|
G |
Egfl6 |
EGF-like-domain, multiple 6 |
decreases response to substance |
ISO |
EGFL6 mRNA results in decreased susceptibility to Vincristine |
CTD |
PMID:25199881 |
|
NCBI chr X:29,430,789...29,488,737
Ensembl chr X:29,430,831...29,488,739
|
|
G |
Egr1 |
early growth response 1 |
increases expression |
ISO |
Vincristine results in increased expression of EGR1 mRNA |
CTD |
PMID:12706485 PMID:23649840 |
|
NCBI chr18:27,657,903...27,660,101
Ensembl chr18:27,657,628...27,661,429
|
|
G |
Egr3 |
early growth response 3 |
increases expression |
ISO |
Vincristine results in increased expression of EGR3 mRNA |
CTD |
PMID:23649840 |
|
NCBI chr15:51,756,683...51,762,080
Ensembl chr15:51,756,736...51,760,722
|
|
G |
Ehbp1l1 |
EH domain binding protein 1-like 1 |
decreases expression |
ISO |
Vincristine results in decreased expression of EHBP1L1 mRNA |
CTD |
PMID:23649840 |
|
NCBI chr 1:221,061,878...221,084,423
Ensembl chr 1:221,062,147...221,084,129
|
|
G |
Eif1 |
eukaryotic translation initiation factor 1 |
decreases expression |
ISO |
Vincristine results in decreased expression of EIF1 mRNA |
CTD |
PMID:23649840 |
|
NCBI chr10:88,227,455...88,229,546
Ensembl chr10:88,227,360...88,229,765
|
|
G |
Eif1ad |
eukaryotic translation initiation factor 1A domain containing |
decreases expression |
ISO |
Vincristine results in decreased expression of EIF1AD mRNA |
CTD |
PMID:23649840 |
|
NCBI chr 1:220,746,387...220,751,687
Ensembl chr 1:220,746,387...220,751,684
|
|
G |
Eif3b |
eukaryotic translation initiation factor 3, subunit B |
decreases expression |
ISO |
Vincristine results in decreased expression of EIF3B mRNA |
CTD |
PMID:23649840 |
|
NCBI chr12:16,285,730...16,310,190
Ensembl chr12:16,285,733...16,310,190
|
|
G |
Eif3m |
eukaryotic translation initiation factor 3, subunit M |
increases expression |
ISO |
Vincristine results in increased expression of EIF3M mRNA |
CTD |
PMID:23649840 |
|
NCBI chr 3:94,990,086...95,007,690
Ensembl chr 3:94,990,068...95,007,712
|
|
G |
Eif4a1 |
eukaryotic translation initiation factor 4A1 |
increases expression |
ISO |
Vincristine results in increased expression of EIF4A1 mRNA |
CTD |
PMID:23649840 |
|
NCBI chr10:56,271,257...56,276,764
Ensembl chr10:56,271,257...56,276,764
|
|
G |
Eif4a2 |
eukaryotic translation initiation factor 4A2 |
decreases expression |
ISO |
Vincristine results in decreased expression of EIF4A2 mRNA |
CTD |
PMID:23649840 |
|
NCBI chr11:81,373,047...81,379,680
Ensembl chr11:81,373,048...81,379,871
|
|
G |
Elf3 |
E74 like ETS transcription factor 3 |
increases expression |
ISO |
Vincristine results in increased expression of ELF3 mRNA |
CTD |
PMID:23649840 |
|
NCBI chr13:52,083,873...52,088,798
Ensembl chr13:52,083,859...52,088,780
|
|
G |
Elk3 |
ETS transcription factor ELK3 |
increases expression |
ISO |
Vincristine results in increased expression of ELK3 mRNA |
CTD |
PMID:23649840 |
|
NCBI chr 7:34,086,213...34,149,601
Ensembl chr 7:34,086,220...34,121,694
|
|
G |
Eme2 |
essential meiotic structure-specific endonuclease subunit 2 |
decreases expression |
ISO |
Vincristine results in decreased expression of EME2 mRNA |
CTD |
PMID:23649840 |
|
NCBI chr10:14,253,552...14,257,017
Ensembl chr10:14,254,252...14,256,930
|
|
G |
Eml6 |
EMAP like 6 |
decreases expression |
ISO |
Vincristine results in decreased expression of EML6 mRNA |
CTD |
PMID:23649840 |
|
NCBI chr14:114,174,282...114,484,663
Ensembl chr14:114,176,051...114,484,127
|
|
G |
Enox1 |
ecto-NOX disulfide-thiol exchanger 1 |
increases expression |
ISO |
Vincristine results in increased expression of ENOX1 mRNA |
CTD |
PMID:23649840 |
|
NCBI chr15:59,331,134...59,884,512
Ensembl chr15:59,678,165...59,884,511
|
|
G |
Enpp2 |
ectonucleotide pyrophosphatase/phosphodiesterase 2 |
increases expression |
ISO |
Vincristine results in increased expression of ENPP2 mRNA |
CTD |
PMID:23649840 |
|
NCBI chr 7:94,479,931...94,563,086
Ensembl chr 7:94,480,396...94,563,001
|
|
G |
Ensa |
endosulfine alpha |
decreases expression |
ISO |
Vincristine results in decreased expression of ENSA mRNA |
CTD |
PMID:23649840 |
|
NCBI chr 2:197,752,544...197,759,882
Ensembl chr 2:197,752,544...197,759,882
|
|
G |
Entpd2 |
ectonucleoside triphosphate diphosphohydrolase 2 |
increases expression |
ISO |
Vincristine results in increased expression of ENTPD2 mRNA |
CTD |
PMID:23649840 |
|
NCBI chr 3:2,617,795...2,623,818
Ensembl chr 3:2,617,805...2,623,445
|
|
G |
Eomes |
eomesodermin |
decreases expression |
ISO |
Vincristine results in decreased expression of EOMES mRNA |
CTD |
PMID:23649840 |
|
NCBI chr 8:127,144,367...127,152,618
Ensembl chr 8:127,144,903...127,151,493
|
|
G |
Epg5 |
ectopic P-granules autophagy protein 5 homolog |
increases expression |
ISO |
Vincristine results in increased expression of EPG5 mRNA |
CTD |
PMID:23649840 |
|
NCBI chr18:74,299,965...74,397,115
Ensembl chr18:74,299,931...74,395,547
|
|
G |
Ephb1 |
Eph receptor B1 |
decreases expression |
ISO |
Vincristine results in decreased expression of EPHB1 mRNA |
CTD |
PMID:23649840 |
|
NCBI chr 8:110,376,954...110,813,193
Ensembl chr 8:110,376,954...110,813,000
|
|
G |
Ephx1 |
epoxide hydrolase 1 |
decreases expression |
ISO |
Vincristine results in decreased expression of EPHX1 mRNA |
CTD |
PMID:21382384 |
|
NCBI chr13:99,271,390...99,300,580
Ensembl chr13:99,271,366...99,300,579
|
|
G |
Epm2aip1 |
EPM2A interacting protein 1 |
decreases expression |
ISO |
Vincristine results in decreased expression of EPM2AIP1 mRNA |
CTD |
PMID:23649840 |
|
NCBI chr 8:119,524,039...119,531,387
Ensembl chr 8:119,524,039...119,531,387
|
|
G |
Epor |
erythropoietin receptor |
decreases expression |
ISO |
Vincristine results in decreased expression of EPOR mRNA |
CTD |
PMID:23649840 |
|
NCBI chr 8:22,969,737...22,974,468
Ensembl chr 8:22,969,745...22,974,321
|
|
G |
Eprs |
glutamyl-prolyl-tRNA synthetase |
increases expression |
EXP |
Vincristine results in increased expression of EPRS mRNA |
CTD |
PMID:20624997 |
|
NCBI chr13:103,300,911...103,371,651
Ensembl chr13:103,300,932...103,371,577
|
|
G |
Epsti1 |
epithelial stromal interaction 1 |
increases expression |
ISO |
Vincristine results in increased expression of EPSTI1 mRNA |
CTD |
PMID:23649840 |
|
NCBI chr15:60,084,966...60,190,360
Ensembl chr15:60,084,918...60,190,363
|
|
G |
Erich3 |
glutamate-rich 3 |
decreases expression |
ISO |
Vincristine results in decreased expression of ERICH3 mRNA |
CTD |
PMID:23649840 |
|
NCBI chr 2:260,947,970...261,049,973
Ensembl chr 2:260,997,497...261,032,821
|
|
G |
Esco2 |
establishment of sister chromatid cohesion N-acetyltransferase 2 |
decreases expression |
ISO |
Vincristine results in decreased expression of ESCO2 mRNA |
CTD |
PMID:23649840 |
|
NCBI chr15:42,500,929...42,519,019
Ensembl chr15:42,500,929...42,518,855
|
|
G |
Esd |
esterase D |
decreases expression |
ISO |
Vincristine results in decreased expression of ESD mRNA |
CTD |
PMID:23649840 |
|
NCBI chr15:56,756,848...56,776,348
Ensembl chr15:56,756,661...56,776,348
|
|
G |
Esm1 |
endothelial cell-specific molecule 1 |
decreases expression |
EXP |
Vincristine results in decreased expression of ESM1 mRNA |
CTD |
PMID:20624997 |
|
NCBI chr 2:45,104,392...45,113,130
Ensembl chr 2:45,104,305...45,113,131
|
|
G |
Esr1 |
estrogen receptor 1 |
multiple interactions |
ISO |
Vincristine binds to and results in decreased activity of ESR1 protein |
CTD |
PMID:25752796 |
|
NCBI chr 1:41,192,029...41,594,799
Ensembl chr 1:41,192,824...41,594,796
|
|
G |
Evc |
EvC ciliary complex subunit 1 |
increases expression |
ISO |
Vincristine results in increased expression of EVC mRNA |
CTD |
PMID:23649840 |
|
NCBI chr14:78,213,601...78,253,266
Ensembl chr14:78,213,635...78,253,266
|
|
G |
Exo1 |
exonuclease 1 |
decreases expression |
ISO |
Vincristine results in decreased expression of EXO1 mRNA |
CTD |
PMID:23649840 |
|
NCBI chr13:93,936,989...93,962,749
Ensembl chr13:93,939,022...93,960,342
|
|
G |
Exog |
exo/endonuclease G |
decreases expression |
ISO |
Vincristine results in decreased expression of EXOG mRNA |
CTD |
PMID:23649840 |
|
NCBI chr 8:128,133,398...128,153,110
Ensembl chr 8:128,133,431...128,153,110
|
|
G |
Ext1 |
exostosin glycosyltransferase 1 |
increases expression |
ISO |
Vincristine results in increased expression of EXT1 mRNA |
CTD |
PMID:23649840 |
|
NCBI chr 7:92,605,008...92,881,392
Ensembl chr 7:92,605,728...92,882,068
|
|
G |
F2 |
coagulation factor II |
affects expression |
ISO |
Vincristine affects the expression of F2 protein |
CTD |
PMID:12542493 |
|
NCBI chr 3:80,529,468...80,542,993
Ensembl chr 3:80,529,428...80,543,031
|
|
G |
F3 |
coagulation factor III, tissue factor |
increases expression |
ISO EXP |
Vincristine results in increased expression of F3 mRNA; Vincristine results in increased expression of F3 protein |
CTD |
PMID:12542493 PMID:20624997 |
|
NCBI chr 2:225,310,686...225,322,281
Ensembl chr 2:225,310,624...225,322,272
|
|
G |
Fam13b |
family with sequence similarity 13, member B |
increases expression |
ISO |
Vincristine results in increased expression of FAM13B mRNA |
CTD |
PMID:23649840 |
|
NCBI chr18:27,223,345...27,304,462
Ensembl chr18:27,223,345...27,289,876
|
|
G |
Fam13c |
family with sequence similarity 13, member C |
increases expression |
ISO |
Vincristine results in increased expression of FAM13C mRNA |
CTD |
PMID:23649840 |
|
NCBI chr20:19,358,869...19,470,212
Ensembl chr20:19,360,230...19,479,325
|
|
G |
Fam171b |
family with sequence similarity 171, member B |
decreases expression |
ISO |
Vincristine results in decreased expression of FAM171B mRNA |
CTD |
PMID:23649840 |
|
NCBI chr 3:71,210,048...71,265,419
Ensembl chr 3:71,210,301...71,262,615
|
|
G |
Fam174a |
family with sequence similarity 174, member A |
increases expression |
ISO |
Vincristine results in increased expression of FAM174A mRNA |
CTD |
PMID:23649840 |
|
NCBI chr 9:102,862,761...102,881,046
Ensembl chr 9:102,862,890...102,881,038
|
|
G |
Fam71f1 |
family with sequence similarity 71, member F1 |
increases expression |
ISO |
Vincristine results in increased expression of FAM71F1 mRNA |
CTD |
PMID:23649840 |
|
NCBI chr 4:56,591,719...56,615,157
Ensembl chr 4:56,591,715...56,615,158
|
|
G |
Fam76b |
family with sequence similarity 76, member B |
decreases expression |
ISO |
Vincristine results in decreased expression of FAM76B mRNA |
CTD |
PMID:23649840 |
|
NCBI chr 8:12,355,767...12,378,040
Ensembl chr 8:12,355,767...12,374,689
|
|
G |
Fam81a |
family with sequence similarity 81, member A |
decreases expression |
ISO |
Vincristine results in decreased expression of FAM81A mRNA |
CTD |
PMID:23649840 |
|
NCBI chr 8:76,521,662...76,579,387
Ensembl chr 8:76,521,657...76,579,387
|
|
G |
Fam83d |
family with sequence similarity 83, member D |
decreases expression |
ISO |
Vincristine results in decreased expression of FAM83D mRNA |
CTD |
PMID:23649840 |
|
NCBI chr 3:155,269,344...155,288,612
Ensembl chr 3:155,269,347...155,288,533
|
|
G |
Fancf |
FA complementation group F |
decreases expression |
ISO |
Vincristine results in decreased expression of FANCF mRNA |
CTD |
PMID:23649840 |
|
NCBI chr 1:107,229,516...107,232,321
Ensembl chr 1:107,231,292...107,232,305
|
|
G |
Fancg |
FA complementation group G |
decreases expression |
ISO |
Vincristine results in decreased expression of FANCG mRNA |
CTD |
PMID:23649840 |
|
NCBI chr 5:58,448,060...58,456,416
Ensembl chr 5:58,448,822...58,455,819
|
|
G |
Fas |
Fas cell surface death receptor |
increases expression |
ISO |
Vincristine results in increased expression of FAS mRNA |
CTD |
PMID:23649840 |
|
NCBI chr 1:252,589,785...252,624,790
Ensembl chr 1:252,589,785...252,624,790
|
|
G |
Faslg |
Fas ligand |
increases expression |
ISO |
Vincristine results in increased expression of FASLG protein |
CTD |
PMID:11716366 |
|
NCBI chr13:79,696,811...79,717,581
Ensembl chr13:79,698,445...79,705,705
|
|
G |
Fastkd2 |
FAST kinase domains 2 |
decreases expression |
ISO |
Vincristine results in decreased expression of FASTKD2 mRNA |
CTD |
PMID:23649840 |
|
NCBI chr 9:70,448,386...70,471,420
Ensembl chr 9:70,450,444...70,470,550
|
|
G |
Fbxl20 |
F-box and leucine-rich repeat protein 20 |
decreases expression |
ISO |
Vincristine results in decreased expression of FBXL20 mRNA |
CTD |
PMID:23649840 |
|
NCBI chr10:86,036,745...86,099,699
Ensembl chr10:86,043,235...86,098,694
|
|
G |
Fbxl4 |
F-box and leucine-rich repeat protein 4 |
decreases expression |
ISO |
Vincristine results in decreased expression of FBXL4 mRNA |
CTD |
PMID:23649840 |
|
NCBI chr 5:36,555,061...36,628,920
Ensembl chr 5:36,555,109...36,629,689
|
|
G |
Fbxo33 |
F-box protein 33 |
decreases expression |
ISO |
Vincristine results in decreased expression of FBXO33 mRNA |
CTD |
PMID:23649840 |
|
NCBI chr 6:80,302,291...80,334,536
Ensembl chr 6:80,302,303...80,334,522
|
|
G |
Fbxo5 |
F-box protein 5 |
decreases expression |
ISO |
Vincristine results in decreased expression of FBXO5 mRNA |
CTD |
PMID:23649840 |
|
NCBI chr 1:42,461,277...42,467,646
Ensembl chr 1:42,461,291...42,467,586
|
|
G |
Fbxo9 |
f-box protein 9 |
decreases expression |
ISO |
Vincristine results in decreased expression of FBXO9 mRNA |
CTD |
PMID:23649840 |
|
NCBI chr 8:85,388,331...85,413,896
Ensembl chr 8:85,388,333...85,413,484
|
|
G |
Fcgr2b |
Fc fragment of IgG receptor IIb |
increases expression |
EXP |
Vincristine results in increased expression of FCGR2B mRNA |
CTD |
PMID:20624997 |
|
NCBI chr13:89,329,298...89,343,916
Ensembl chr13:89,327,794...89,433,815
|
|
G |
Fdft1 |
farnesyl diphosphate farnesyl transferase 1 |
increases expression |
ISO |
Vincristine results in increased expression of FDFT1 mRNA |
CTD |
PMID:23649840 |
|
NCBI chr15:46,339,248...46,367,302
Ensembl chr15:46,339,249...46,367,302
|
|
G |
Fermt2 |
FERM domain containing kindlin 2 |
increases expression |
ISO |
Vincristine results in increased expression of FERMT2 mRNA |
CTD |
PMID:23649840 |
|
NCBI chr15:19,807,806...19,876,557
Ensembl chr15:19,807,808...19,876,408
|
|
G |
Ffar2 |
free fatty acid receptor 2 |
decreases expression |
ISO |
Vincristine results in decreased expression of FFAR2 mRNA |
CTD |
PMID:23649840 |
|
NCBI chr 1:89,268,197...89,271,942
Ensembl chr 1:89,268,938...89,269,930
|
|
G |
Fgr |
FGR proto-oncogene, Src family tyrosine kinase |
decreases expression |
ISO |
Vincristine results in decreased expression of FGR mRNA |
CTD |
PMID:23649840 |
|
NCBI chr 5:151,172,189...151,199,746
Ensembl chr 5:151,172,206...151,199,745
|
|
G |
| |